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Abstract 
 
Endometriosis is a benign gynaecological disorder characterised by the presence of 
endometrial-like glands and stroma occurring outside the uterine cavity. It affects 6-10% 
women of reproductive age and is often associated with chronic pelvic pain which can be 
extremely debilitating. Chronic pain in endometriosis may be of nociceptive, neuropathic 
and/or inflammatory origin. Processes involved in pain generation include neuronal 
development, peripheral sensitisation due to inflammation, signal transduction, conduction 
and pain modulation. A range of genes are known to play important roles in these processes 
and their expression levels are altered in other pain conditions. Dysregulated genes may 
contribute to pain generation in women with endometriosis. Therefore, the aim of this study 
was to investigate the expression of pain related genes in women with endometriosis 
compared to women without the disease by conducting a meta-analysis of available 
microarray gene expression data and associated clinical information. 
 
Suitable studies and data were identified from electronic databases, gene expression 
repositories and within a University Obstetrics and Gynaecology department, by limiting the 
search to peer-reviewed, English language studies. Sixteen published full-text studies and one 
unpublished thesis were included. Included studies were case-control or cross-sectional 
design evaluating gene expression of eutopic endometrium from women with and without 
endometriosis and/or of endometriotic lesions. Study participants were pre-menopausal with 
regular menstrual cycles and surgically proven to have or not have endometriosis. RNA 
hybridisation with whole human genome microarray data were extracted and dysregulated 
gene expression determined through meta-analyses of microarray data.  
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This study has shown that in the eutopic endometrium from women with endometriosis and 
endometriotic lesions, pain related genes were significantly upregulated. Genes involved in 
pain generation were also upregulated in the secretory phase of the menstrual cycle in 
endometriosis. In particular, genes involved in neuronal development, inflammation leading 
to sensitisation, signal transduction, conduction and modulation were upregulated.  
 
Upregulation of genes involved in pain generation likely contributes to pain symptoms in 
women with endometriosis. Increased neuronal development and sensory innervation in the 
eutopic endometrium and endometriotic lesions may contribute to increased neuronal 
sensitisation due to the inflammatory microenvironment. This may lead to enhanced signal 
transduction and conduction of pain signals as well as promotion of pain by pain modulation. 
An improved understanding of the underlying molecular pain mechanisms may aid in 
identifying candidate genes for managing endometriosis-associated pain.   
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Chapter 1 
Endometriosis 
 
1.1 Introduction 
Endometriosis is a benign gynaecological disorder characterised by the presence of 
endometrial-like glands and stroma outside the uterine cavity (Rahmioglu et al., 2012, Fraser, 
2008). It affects approximately 6-10% of women of reproductive age (Fraser, 2008, McLeod 
and Retzloff, 2010, Simoens et al., 2012). The primary symptoms include pain and infertility 
(Giudice and Kao, 2004, Fauconnier et al., 2013). It is highly variable in the age of onset; 
presentation; severity of symptoms; site and extent of pathology; and in the response to 
treatment, such as recurrence of the disease, alleviation of symptoms and restoration of 
fertility (Fraser, 2008, McLeod and Retzloff, 2010, Okeke et al., 2011, Kennedy et al., 2005). 
It is often a debilitating condition, significantly affecting the lives of patients in a variety of 
ways (Mehedintu et al., 2014). 
 
Endometriotic lesions are an important feature of endometriosis. They usually grow on the 
peritoneum lining the pelvic/abdominal cavity; occurring on the pelvic/abdominal wall, 
ovaries, fallopian tubes, outer wall of the uterus and intestines (see Fig. 1.1;  Brosens and 
Benagian, 2011, Koninckx, 1994, Olive and Pritts, 2001). In rare cases, lesions have been 
observed on the pancreas, pleura, thorax, kidneys, vertebrae and sciatic nerve roots (Fraser, 
2008, Olive and Pritts, 2001). Despite extensive research, the aetiology of endometriosis 
remains poorly understood. Abnormalities of the uterine endometrium as well as changes in 
the microenvironment around endometriotic lesions may contribute to the development and 
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maintenance of endometriosis as well as its related symptoms (Ulukus et al., 2006, Jiang and 
Wu, 2012). 
 
 
Fig. 1.1: Common sites of endometriosis (Olive and Pritts, 2001). 
 
1.1.1 Heritability 
Genetic predisposition plays a role in endometriosis (Speroff, 2005). Although it does not 
show a clear Mendelian pattern of inheritance, there is a strong familial component (Treloar 
et al., 1999, Stefansson et al., 2001, Ward et al., 2004, Vigano et al., 2007). There is a six 
times increased risk of developing endometriosis in first-degree relatives of women with the 
disease (Coxhead and Thomas, 1993, Moen and Magnus, 1993, Simpson et al., 1980, 
Kennedy et al., 1995, dos Reis et al., 1999, Augoulea et al., 2012, Simpson and Bischoff, 
2002). Specifically, chromosome alterations in arms 5q, 6q, 9p, 11q and 22q and on 
chromosome 17 have been shown to be associated with endometriosis (Jiang, 1998, Bischoff 
and Simpson, 2004, Bischoff et al., 2002). A number of gene expression microarray studies 
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have also identified a range of candidate genes involved in regulating steroid metabolism, 
neurogenesis, angiogenesis, inflammation and immune response that may be dysregulated in 
endometriosis, contributing to its development and associated symptoms (Bischoff and 
Simpson, 2004, Burney et al., 2007, Crispi et al., 2013, Kao et al., 2003, Zondervan et al., 
2001, Nyholt et al., 2012, Albertsen et al., 2013). 
 
1.2 Symptoms 
The most common symptoms of endometriosis are infertility and pelvic pain. Although a 
proportion of women with endometriosis may be asymptomatic, women with endometriosis 
often present with pain. Pain (thoroughly reviewed in Chapter 2) can manifest non-cyclic 
chronic pelvic pain, dysmenorrhea (menstrual pain), dyspareunia (pain with intercourse) and 
dyschezia (pain with defecation;Kennedy et al., 2005, Mehedintu et al., 2014). Other 
associated symptoms may include dysfunctional uterine bleeding, abdominal bloating, pre-
menstrual spotting, constipation and chronic fatigue (Bellelis et al., 2010). 
 
1.3 Diagnosis 
The complex and highly variable nature of endometriosis makes its diagnosis difficult. A 
delay in diagnosis is very common as endometriosis shows symptomatic commonalities with 
other diseases and its diagnosis is invasive (surgical; Mehedintu et al., 2014). A laparoscopy 
combined with histological confirmation is the gold standard for the diagnosis of 
endometriosis (Kennedy et al., 2005, Fraser, 2008, Mehedintu et al., 2014). Laparoscopy is a 
procedure in which an incision is made in the abdomen and the laparoscope (telescopic 
camera) is inserted, to allow visualisation of the pelvic cavity and biopsies to be taken 
(Jacobson et al., 2010). Trans-vaginal ultrasound and MRI imaging can diagnose deep 
infiltrating endometriosis (Marcal et al., 2010, Holland et al., 2010, Bazot et al., 2004). These 
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techniques are operator-dependent and require both experience and skill to minimise 
diagnostic error (Fraser, 2008, Valle and Sciarra, 2003, Kennedy et al., 2005). There is an 
ongoing need for the development of novel non-invasive tools for diagnosis of endometriosis. 
 
1.4 Theories of pathogenesis 
Various theories have been put forth to explain the development of endometriosis (Linden, 
1996); including, but not limited to, Sampson’s retrograde menstruation theory, theory of 
coelomic metaplasia, theory of lymphatic and vascular induction, and composite theory 
(Sampson, 1940, Meyer, 1919, Sampson, 1927b, Gazvani and Templeton, 2002). However, 
no single theory satisfactorily explains the development of endometriosis. The two most 
popular theories, retrograde menstruation and coelomic metaplasia, are discussed in Sections 
1.4.1 and 1.4.2.  
 
1.4.1 Coelomic metaplasia 
Metaplasia is a process in which one cell type changes into a different form that is abnormal 
for that tissue (Iwanoff, 1989, Vercellini et al., 2004, Cullen, 1896). The theory of coelomic 
metaplasia was proposed by Iwanoff (1989) and then developed by Meyer (1919). It states 
that normal peritoneal cells may develop into ectopic endometrial cells (Iwanoff, 1989, 
Meyer, 1919). Evidence linking metaplasia and endometriosis is lacking, but the 
ultrastructure of pelvic peritoneal tissue from women undergoing surgery suggests that there 
might be a metaplastic change of peritoneal mesothelial cells into endometrial glandular cells 
before the establishment of endometriosis in the peritoneum (Matsuura et al., 1999, Nap et 
al., 2004, Vinatier et al., 2001). An extension to the theory of metaplasia is the induction 
theory which proposes that one or more endogenous, biochemical or immunological factors 
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secreted by menstrual endometrium may promote differentiation of peritoneal cells to 
endometrial-like cells (Nap et al., 2004, Burney and Giudice, 2012). 
 
1.4.2 Retrograde menstruation 
In 1927, Sampson proposed the theory of retrograde menstruation, also known as the 
implantation theory (Sampson, 1927a). According to this theory, endometriosis develops 
through the retrograde flow of viable endometrial fragments into the peritoneal cavity during 
menstruation, which then implant on the peritoneum and form lesions (Sampson, 1940). In 
retrograde menstruation, menstrual fluid flows through the fallopian tubes instead of leaving 
through the vagina (Nap et al., 2004, Halme et al., 1984). 
 
This theory is currently the most widely accepted as clinical findings suggest that 
endometriotic lesions tend to cluster around structures closer to the distal ends of the 
fallopian tubes (Dmowski and Radwanska, 1984, Al-Fozan and Tulandi, 2003). Women with 
anatomical variations or abnormalities obstructing the menstrual outlet, such as cervical 
stenosis and other mullerian anomalies, have a higher risk of developing endometriosis due to 
increased volume of retrograde menstruation (Sanfilippo et al., 1986, Barbieri, 1998, Fallas, 
1956). Furthermore, viable endometrial cells are present in the menstrual and peritoneal fluid 
of women with endometriosis; these cells have the capability to adhere to the peritoneum, 
followed by implantation (Koninckx et al., 1980, Koks et al., 1997, Nisolle et al., 2007). 
However, Sampson’s theory does not explain why endometriosis does not develop in all 
women with retrograde flow, as retrograde menstruation happens in 90% of all women with 
patent fallopian tubes (Vercellini et al., 2004, Nap et al., 2004, Halme et al., 1984). It is 
becoming increasingly evident that other molecular and biochemical factors are involved in 
the pathogenesis of endometriosis. 
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1.5 Eutopic endometrial anomalies 
The eutopic endometrium of women with endometriosis shows differences in physiology and 
biochemistry compared to the endometrium of women without endometriosis (Meresman et 
al., 2000). Increasing evidence indicates that anomalies of the endometrium such as 
decreased apoptosis, evasion of immune surveillance, increased cell adhesion and 
proliferation, increased angiogenesis and neurogenesis and local oestrogen production may 
contribute to lesion establishment, disease progression and associated symptoms (Agic et al., 
2009, Tabibzadeh, 1998, Giudice and Kao, 2004, Sharpe-Timms, 2001, Khoufache et al., 
2012). 
 
1.5.1 Decreased apoptosis 
Apoptosis is a physiological process of programmed cell death whereby excess and 
dysfunctional cells are eliminated by a regulated sequence of molecular events without 
eliciting an inflammatory response (Taniguchi et al., 2011, Kerr et al., 1972, Alison and 
Sarraf, 1992). During menstruation, apoptosis plays a regulatory role by removing senescent 
cells from the lining of the endometrium (Nasu et al., 2011, Taniguchi et al., 2011). In 
women with endometriosis, apoptosis in the endometrium is greatly reduced (Beliard et al., 
2004, Taniguchi et al., 2011, Liu and Lang, 2011). This may be attributed to the increased 
expression of bcl-2, which blocks the apoptotic pathways and decreased expression of bax, 
which promotes apoptosis, in the eutopic endometrium from women with endometriosis 
compared to women without the disease (Jones et al., 1998a, Meresman et al., 2000, Harada 
et al., 2004, Nasu et al., 2011). Moreover, there is dysregulation of genes involved in 
apoptosis in the eutopic endometrium of women with endometriosis which further inhibits 
apoptosis (Zubor et al., 2009). This leads to entry of viable endometrial cells into the 
peritoneal cavity (Beliard et al., 2004, Harada et al., 2004).  
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1.5.2 Ineffective immune response 
Local immune cells facilitate the clearance of endometrial fragments following menstrual 
shedding (Liu and Lang, 2011, Ulukus et al., 2006). Several immune cell populations are 
disturbed both in function and numbers in the eutopic of women with endometriosis (Sharpe-
Timms, 2001, Berbic et al., 2009, Matarese et al., 2003). Cytotoxicity of natural killer (NK) 
cells is decreased and T lymphocyte function is defective (Christodoulakos et al., 2007, 
Giudice et al., 1994, Helvacioglu et al., 1997). Regulatory T lymphocytes (Treg cells) are 
increased during the secretory phase and suppress the action of other immune cell 
populations (Berbic et al., 2010). Increased immature dendritic cell density in the eutopic 
endometrium with decreased presence of mature dendritic cells indicates impaired 
recognition of foreign or displaced cells (Braun and Dmowski, 1998, Matarese et al., 2003). 
Moreover, macrophage numbers are decreased during menstruation (Sharpe-Timms, 2001, 
Sharpe-Timms et al., 2002). In endometriosis, the endometrial immune system appears 
unable to contain shed endometrial fragments, indicating that more viable shed endometrial 
cells reach the peritoneal cavity subsequently leading to establishment of the lesions (Sharpe-
Timms et al., 2002, Christodoulakos et al., 2007, Ulukus et al., 2006). The resident immune 
cell populations of the eutopic endometrium also produce pro-inflammatory 
cytokines/chemokines (Sinaii et al., 2002, Herington et al., 2011). Furthermore, the mRNA 
levels of genes encoding for immune cells as well as inflammatory cytokines are increased in 
the eutopic endometrium of women with endometriosis (Chand et al., 2007, Kyama et al., 
2008, Akoum et al., 1995). This may trigger an intense inflammatory response and contribute 
to pain in endometriosis (Berkley et al., 2005).  
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1.5.3 Increased cell adhesion and proliferation 
In the eutopic endometrium of women with endometriosis, both protein and mRNA 
expression levels of cell adhesion molecules such as integrin-αvβ3, cadherins, intracellular 
adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), CD166, 
annexin A2, interlukin-11 (IL-11) and leukaemia-inhibiting factor (LIF) are increased 
(Sundqvist et al., 2012, Dimitriadis et al., 2006, Fowler et al., 2007, Al Jefout et al., 2009, 
Somigliana et al., 1996, Abu-Asab et al., 2011, Burney et al., 2007). This is thought to lead to 
the attachment of refluxed endometrial tissue on to the peritoneal surface and promote lesion 
establishment (Ulukus et al., 2006, Al Jefout et al., 2009, Witz et al., 1999). 
 
Increased cell proliferation has also been observed in the eutopic endometrium of women 
with endometriosis (Johnson et al., 2005, von Rango et al., 1998, Jones et al., 1998b). For 
example, there is an increased number of endothelial, epithelial and stromal cells in the 
eutopic endometrium of women with endometriosis when compared to women without 
endometriosis (Wingfield et al., 1995, Jones et al., 1998b, Jiang and Wu, 2012). Increased 
proliferation in the eutopic endometrium likely contributes to endometrial cell survival, 
implantation and growth in ectopic locations (Lawson et al., 2008, Lessey et al., 1994, 
Wingfield et al., 1995, Johnson et al., 2005, Kyama et al., 2008).  
 
1.5.4 Angiogenesis 
Angiogenesis is the process of formation of new blood vessels from pre-existing blood 
vessels (Xu et al., 2013). It is an important process for the progression of endometriosis as the 
lodged endometrial fragments on the peritoneum require blood supply for survival (Liu and 
Lang, 2011). The eutopic endometrium of women with endometriosis is highly angiogenic 
compared to the endometrium from women without endometriosis (Laschke and Menger, 
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2007, Torry and Torry, 1997, Groothuis et al., 2005, Hur et al., 2006). In the eutopic 
endometrium of women with endometriosis, there is a higher protein and gene expression of 
angiogenic factors, such as vascular endothelial growth factor-A (VEGF-A), interlukin-8 (IL-
8), fibroblast growth factor (FGF), hepatocyte growth factor (HGF) and epidermal growth 
factor (EGF) compared to endometrium from women without endometriosis (Bourlev et al., 
2006, Nisolle et al., 1993, Mihalich et al., 2003, Sugawara et al., 1997, Fukaya et al., 1999, 
Jiang and Wu, 2012, Mueller et al., 2000, Takehara et al., 2004, Huang and Yeh, 1994). 
These findings indicate that increased angiogenic capacity of the eutopic endometrium may 
facilitate establishment of a blood supply for ectopically implanted endometrial fragments 
and therefore initiation and progression of endometriosis. 
 
1.5.5 Local oestrogen production 
In the eutopic endometrium of women with endometriosis, there is evidence of excessive 
oestrogen production (Dassen et al., 2007, Bukulmez et al., 2008, Aghajanova et al., 2009, 
Kitawaki et al., 1997). Aromatase, an essential enzyme for oestrogen production, not 
expressed in normal endometrium, is highly expressed in the eutopic endometrium of women 
with endometriosis (Kitawaki et al., 1997, Kyama et al., 2008). There are increased levels of 
17β-hydroxysteroid dehydrogenase-1 (17β-HSD-1) and decreased levels of 17β-HSD-2 
which catalyse the activation and inactivation of oestradiol, respectively (Zeitoun et al., 1998, 
Andersson and Moghrabi, 1997, Dassen et al., 2007). Aberrant aromatase gene and protein 
expressions along with defective oestradiol metabolism may increase local oestrogen levels, 
which correspond with elevated oestradiol concentrations in the menstrual blood of women 
with endometriosis (Lessey et al., 1988, Nisolle and Donnez, 1997, Attia et al., 2000, Al-
Sabbagh et al., 2012, Ulukus et al., 2006, Kyama et al., 2008). Excessive oestrogen 
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production favours the inflammatory characteristics of endometriosis and lesion growth and 
persistence (Tsai et al., 2001, Bulun et al., 2001).  
 
1.5.6 Neurogenesis 
Neurogenesis is the formation of nervous tissue occurring under the control of neurotrophic 
factors and their receptors (Asante and Taylor, 2011). In eutopic endometrium from women 
with endometriosis, there is increased protein and gene expression of neurotrophic factors, 
such as nerve growth factor (NGF), neurotrophin-3 and neurotrophin-4/5 (NT-3, NT-4/5), 
and brain-derived neurotrophic factor (BDNF) compared to women without endometriosis 
(Browne et al., 2012, Tokushige et al., 2008). Increased density of neuroendocrine cells has 
also been identified in the eutopic endometrium of women with endometriosis, which 
produce neuromodulatory substances in response to chemical stimulation (Tischler, 1989, 
Wang et al., 2010). In addition, in the eutopic endometrium of women with endometriosis, 
nerve fibres have been identified in the functional layers of endometrium and myometrium of 
women with endometriosis, not found otherwise in the endometrium from women without 
endometriosis (Tokushige et al., 2007, Tokushige et al., 2006a, Zhang et al., 2009, Aghaey 
Meibody et al., 2011). These nerve fibres are sensory C, adrenergic and cholinergic, 
responsible for transmitting dull, throbbing and diffuse pain (Al-Jefout et al., 2009, Al Jefout 
et al., 2009). Increased neurogenesis as well as the presence of nerve fibres in the eutopic 
endometrium of women with endometriosis may be responsible for increased peripheral 
sensitisation contributing to the pain-related symptoms of endometriosis (Bloski and Pierson, 
2008, Tokushige et al., 2006a). 
 
Endometriosis remains an enigmatic gynaecological disorder. It is becoming increasingly 
evident that fundamental changes in the eutopic endometrium of women with endometriosis 
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may contribute to development of the disease. The presence of aberrantly expressed 
apoptotic, immuno-modulatory, adhesive, proliferative, hormonal, angiogenic and neurogenic 
factors within the eutopic endometrium may contribute to the development of the 
endometriosis and its associated symptoms. The pro-inflammatory microenvironment of the 
eutopic endometrium along with the presence of small unmyelinated sensory nerve fibres 
may also contribute to the associated pain symptoms. However, it should be noted that exact 
mechanisms of pain generation remain unknown and require in-depth study of the involved 
molecular mechanisms (discussed further in Chapter 2). 
 
1.6 Endometriotic lesions 
There are three broad types of endometriotic lesions: superficial peritoneal endometriosis, 
ovarian endometriomas and deep infiltrating endometriosis (DIE; described in more detail in 
Table 1.1). Typical endometriotic lesions show histological features similar to the 
endometrium, with stroma and glandular epithelium that respond to hormonal stimuli and 
exhibit characteristics of cyclic growth (Weitzman and Buttram, 1989). However, there are 
many differences between the cells of endometriotic lesions and those of the 
surrounding/normal peritoneum or the eutopic endometrium, including differences related to 
angiogenesis, hormone production and responsiveness, immune environment and 
neurogenesis.  
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Table 1.1: Types of endometriotic lesions. 
Lesion type Appearance Characteristics Location 
Peritoneal endometriotic lesions
1
 Clear Papules that resemble 
normal endometrium 
Around the 
peritoneum, 
fallopian tubes 
and bowel 
 Red flare Considered the most 
“active”; highly 
vascularised 
 
 Blue-black Puckered; presence of 
pigmented 
haemosiderin deposits 
from “old blood”; 
older, more advanced 
than red flare and 
considered less active  
 
 White Surrounded by dense 
collagen and 
connective tissue 
deposits; thought to be 
older and the least 
active 
 
Ovarian endometriomas
2
 Brown tar-
like filled 
cysts 
Contain shed 
menstrual debris; arise 
after endometrial 
ectopic implantation 
On the ovaries 
 
Deep-infiltrating endometriosis
3
 Nodular in 
appearance  
 
Firm, solid, tumour-
like mass that extends 
more than 5 mm from 
peritoneal surface into 
adjacent structures 
Posterior cul-
de-sac, 
uterosacral 
ligaments, 
bowel, bladder 
and the 
rectovaginal 
septum  
1(Brosens et al., 2012, Nisolle et al., 1997, Donnez et al., 2003)
 
2(Nisolle et al., 1997) 
3(Nisolle et al., 1997) 
 
 
1.6.1 Angiogenesis 
Angiogenesis is essential for the growth and persistence of endometriotic lesions, as lesions 
derive their blood supply from the surrounding vasculature (Xu et al., 2013). A number of 
angiogenic factors are synthesised by endometriotic lesions, the most potent and strongly 
expressed being VEGF-A (Donnez et al., 1998, Machado et al., 2008, Tan et al., 2002, 
13 
 
Takehara et al., 2004). VEGF-A gene and protein expression has been observed to be higher 
in endometriotic lesions compared to eutopic endometrium (Di Carlo et al., 2009, Donnez et 
al., 1998, Bourlev et al., 2006, Tan et al., 2002). Angiogenic properties also tend to differ 
between lesion types, for example, active, early-developing, red flare lesions show greater 
vascularisation compared to less active black or white scarred lesions (Matsuzaki et al., 
2001). In general, peritoneal lesions have greater expression of VEGF-A compared to ovarian 
(Tan et al., 2002, Takehara et al., 2004). Furthermore, deep infiltrating lesions show higher 
expression of VEGF-A and greater blood vessel density compared to peritoneal or ovarian 
lesions (Machado et al., 2008).  
 
1.6.2 Hormone production and responsiveness 
Oestrogen is the key hormone that regulates growth and development of endometriotic 
lesions (Jones et al., 1995). Oestradiol, biologically active oestrogen, is locally produced 
within lesions (Bulun et al., 2012), attributable to increased aromatase at both transcriptional 
and protein levels (Kitawaki et al., 1997, Zeitoun et al., 1998, Vinatier et al., 2000, Kyama et 
al., 2008, Bukulmez et al., 2008). In lesions, cyclo-oxygenase-2 (COX-2) which stimulates 
oestrogen production (and vice versa) is also upregulated, creating a positive feedback loop 
favouring continuous oestrogen production (Attar and Bulun, 2006, Tsai et al., 2001). 
Increased expression of enzymes such as 17β-HSD-1 in endometriotic lesions also 
contributes to local oestrogen production (Huhtinen et al., 2012, Rižner, 2009, Smuc et al., 
2007, Cheng et al., 2008, Borghese et al., 2010).  
 
The actions of oestrogen and progesterone are mediated through their receptors, oestrogen 
receptor (ER-α and -β) and progesterone receptor (PR) (Bulun et al., 2012, Bukulmez et al., 
2008, Bulun et al., 2010). Significantly lower transcriptional and protein levels of 
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progesterone receptors and ER-α have been observed in endometriotic lesions compared to 
the eutopic endometrium from women with endometriosis (Attia et al., 2000, Bulun et al., 
2006, Bukulmez et al., 2008). These changes may contribute to the loss of control of 
oestrogen production and resistance to progesterone observed in women with endometriosis, 
thought to facilitate development and progression of the disease (Bulun et al., 2010, Xue et 
al., 2007, Attia et al., 2000). 
 
1.6.3 Immune alterations  
Macrophages, immature dendritic cells, natural killer cells and T cells are recruited directly to 
the site of endometriotic lesions, possibly in an attempt to clear the lesion (Tran et al., 2009, 
Jones et al., 2002, Schulke et al., 2009, Berbic and Fraser, 2011). However, the local immune 
environment is dysfunctional and lesions persist (Herington et al., 2011, Berbic and Fraser, 
2011). These immune cells produce cytokines, chemokines, growth factors and potent 
angiogenic factors which actually contribute to the survival and ectopic growth of 
endometrial tissue fragments (Lebovic et al., 2001). An inflammatory response is initiated 
and mediators are released which stimulate blood flow and extravasation of leukocytes 
(neutrophils and monocytes) from blood vessels into the tissue, further favouring lesion 
persistence (Berbic and Fraser, 2011, Christodoulakos et al., 2007, Sidell et al., 2002).  
 
1.6.4 Neurogenesis 
Neuronal growth has been observed in endometriotic lesions (Wang et al., 2009, Guo and 
Wang, 2006, Mechsner et al., 2007). The protein and mRNA expressions of NGF and other 
neurotrophins; such as NT-3, NT-4 and BDNF; and their receptors are increased in 
endometriotic lesions (Tokushige et al., 2010, Tokushige et al., 2006a, Anaf et al., 2002, 
Abu-Asab et al., 2011). Increased angiogenesis and immune cell populations produce 
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neuroattractant cytokines which promote nerve fibre growth into lesions (Tokushige et al., 
2006a, Tlandi et al., 2001, Tamburro et al., 2003, Anaf et al., 2006, Asante and Taylor, 2011, 
Berbic et al., 2009). Moreover, abnormal hormonal environment promotes higher expression 
of neurotrophic factors and neuronal growth (Anaf et al., 2002, Tokushige et al., 2006b).  
 
Furthermore, nerve fibres have been observed in all types of endometriotic lesions 
(Tokushige et al., 2006b, Tokushige et al., 2010, Herington et al., 2011, Mechsner et al., 
2007, Anaf et al., 2002). These nerve fibres are a mixture of sensory Aδ, sensory C, 
adrenergic and cholinergic (Tokushige et al., 2006b, Mechsner et al., 2007). Presence of 
sensory nerve fibres in the endometriotic lesions may contribute to the pain symptoms 
associated with endometriosis (Tokushige et al., 2006a, Morotti et al., 2014b). Interestingly, 
higher densities of nerve fibres and neurotrophins have been observed in DIE lesions 
compared to peritoneal or ovarian lesions, which correlates with increased pain in women 
with DIE (Herington et al., 2011, Vercellini et al., 2007, Stratton and Berkley, 2011, Gruppo 
Italiano per lo Studio, 2001). A recent study also suggests that women who complain of 
moderate to severe pain have higher densities of endometriosis-associated nerve fibres 
(Mechsner et al., 2009). 
 
Overall, it appears that abnormal eutopic endometrium predisposes susceptible women to 
develop endometriosis. In addition, it is likely the presence of endometriotic lesions further 
regulates the eutopic endometrium. Ongoing processes in endometriotic lesions not only 
contribute to disease progression, but apparently also to the development of associated 
symptoms such as pain. However, mechanisms of pain generation in women with 
endometriosis are not well understood (further explored in Chapter 2).  
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Chapter 2 
Pain in Endometriosis 
 
2.1 Introduction 
The most common symptom of endometriosis is pain, however pain mechanisms in 
endometriosis remain poorly understood (Taylor et al., 1999, Ozkan et al., 2008, Martinez-
Roman et al., 1997, Kao et al., 2003, Triolo et al., 2013, Kobayashi et al., 2013, Morotti et al., 
2014b). As introduced in Chapter 1, pain associated with endometriosis can be broadly 
described as the common triad of dysmenorrhoea (painful menses), dyspareunia (painful 
sexual intercourse) and dyschezia (pain with defecation; Nasir and Bope, 2004, Fraser, 2008). 
Pain intensity does not correspond with the anatomical severity or other parameters of 
endometriosis (Mathias et al., 1996 , Fraser, 2008). It has been linked to the presence of 
unmyelinated sensory nerve fibres in the eutopic endometrium and endometriotic lesions; 
interaction between peripheral nerves, the peritoneal environment and the central nervous 
system; as well as to altered hormonal, immune and inflammatory environments in the pelvis 
(Evans et al., 2007, Tokushige et al., 2006a, Reis et al., 2013, Morotti et al., 2014b, Stratton 
and Berkley, 2011, Asante and Taylor, 2011). 
 
2.2 Nervous system  
The nervous system is divided into the central nervous system (CNS) and peripheral nervous 
system (PNS). The CNS consists of the brain and spinal cord; the PNS of sensory neurons, 
ganglia and nerves, which connect to the CNS (Amann and Constantinescu, 1990, Barker, 
1901). The divisions and functions of the CNS and PNS are summarised in Fig. 2.1.  
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Human Nervous System 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.1: Organisation of the nervous system (adapted from Barker, 1901). 
 
Neurons are the basic units of the nervous system, connecting to form neural networks (Luse, 
1956, DeFelipe, 1997). Each neuron consists of dendrites (projections that receive electric 
stimuli), a cell body and axons (Bohler et al., 2007). Axons are specialised structures that 
conduct and transmit action potentials to adjacent neurons via synapses (Liu and Bahu, 
1975). Once the signal reaches the axon terminal a neurotransmitter is released which rapidly 
crosses over to the receptor site of the next neuron (DeFelipe, 1997).  
 
Specialised neurons are triggered by specific stimuli (Dubin and Patapoutian, 2010). Sensory 
neurons, also known as afferent neurons, respond to stimuli such as sound, touch, light and 
changes in the pH. The Aδ and C afferent sensory neurons that respond to painful stimuli are 
known as nociceptors (Barker, 1901, Dubin and Patapoutian, 2010). Nociceptors have high 
Central nervous system Peripheral nervous system 
Spinal cord 
allows for 
communication 
between the brain 
and the PNS 
Brain is the centre 
for processing 
information 
Autonomic 
nervous system 
controls internal 
organs and glands 
Somatic nervous 
system controls 
the sensory and 
motor nerves 
Sympathetic 
nervous system 
mobilises body 
systems 
Parasympathetic 
nervous system 
conserves energy and 
promotes house-
keeping functions 
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sensitivity and are sensitised by mechanical, thermal or chemical stimuli leading to pain 
generation (Dubin and Patapoutian, 2010, Basbaum et al., 2009, Millan, 1999). 
 
2.2.1 Female pelvic innervation  
The female pelvis is a complex structure and any dysfunction within it can lead to pelvic pain 
(Wasnik et al., 2011). The female pelvis has both sympathetic and parasympathetic nerve 
supplies (Ferner, 1964, Keast, 2006). Furthermore, the pelvic viscera are innervated with both 
sensory and motor fibres. The motor nerve fibres extend from the spinal cord or the brain to 
the organ and sensory fibres bring information back to the spinal cord or brain (Frank and 
Netter, 2006). The complex innervation of the pelvis comes from the superior hypogastric 
plexus, sympathetic chain (L1–L5), parasympathetic fibres (S2–S4) and sacral plexus (sacral 
splanchnic nerves, S1–S5; see Fig. 2.2; Cervero, 1994, Keast, 2006). Visceral sensory nerve 
fibres respond to noxious stimuli and can evoke the sensation of pain which is generally 
poorly localised (Cervero, 2010, Cervero, 1991). Most visceral sensory nerve fibres are Aδ 
and C unmyelinated fibres, as observed in the eutopic endometrium and endometriotic lesions 
of women with endometriosis (Cervero and Laird, 2004, Tokushige et al., 2006a, Tokushige 
et al., 2007, Wang et al., 2009). These fibres are responsible for transmitting dull, throbbing 
pain (Bielefeldt et al., 2006). 
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Fig 2.2.: Female pelvic innervation (Frank and Netter, 2006). 
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2.3 Pain 
According to the International Association for the Study of Pain, pain is defined as an 
unpleasant emotional and sensory experience due to noxious stimuli associated with actual or 
potential tissue damage (Merskey and Bogduk, 1994, Anand and Craig, 1996, Schaible, 2007, 
Howard, 2009). Pain can be acute or chronic. Acute pain is the normal processing that warns 
the body against noxious stimuli. In contrast, chronic pain is caused by disease or when 
noxious stimuli persist for longer periods (six months or more; Schaible, 2007, Calvino and 
Grilo, 2006, Russo and Brose, 1998). Pain is also influenced by social and psychological 
factors (Merskey, 1994, Chapman and Gavrin, 1999, Kendall, 1999) and can promote a stress 
response leading to fatigue, impaired mental and physical function (Chapman and Gavrin, 
1999, Kendall, 1999).  
 
Pain is generated when potentially noxious stimuli sensitise the surrounding specialised 
sensory neurons known as nociceptors responsible for transmitting painful signals, thus 
generating an action potential which is conducted along the nerve axons to the spinal cord 
and the CNS (Latremoliere and Woolf, 2009, Schaible, 2007, Ji and Woolf, 2001). The CNS 
then processes the received information and generates responses of pain recognition such as 
discrimination and localization, arousal and aversive reactions due to the noxious event 
(Schaible, 2007, Cervero, 1995, Cervero and Laird, 2004). Application of noxious stimuli can 
either lead to spontaneous pain (pain in the absence of any intentional stimulation), 
hyperalgesia (extreme pain from a stimulus that evokes pain) and/or allodynia (pain due to a 
stimulus that does not usually provoke pain; Jensen and Finnerup, 2014). 
 
Pain can be further classified into nociceptive, neuropathic and inflammatory. Nociceptive 
pain typically originates from the peripheral tissue to warn of potentially noxious stimuli  
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(Asante and Taylor, 2011, Cervero, 1988, Fraser, 2010, Grimm et al., 2011, Howard, 2009). 
It includes four basic processes: transduction, transmission, modulation and perception 
(described in detail in Section 2.4; Howard, 2009). It may be somatic or visceral in origin. 
Somatic pain is localised and is often recognised as sharp pain, whereas visceral pain is 
diffuse and often difficult to assess (Vercellini et al., 2009, Gebhart, 2000). Neuropathic pain 
is caused by damage to the central or peripheral nervous system (Latremoliere and Woolf, 
2009, Campbell and Meyer, 2006). It generally does not trigger an acute event but leads to a 
state of chronic pain (Howard, 2009, Sivilotti and Woolf, 1994). Following nerve injury, 
persistent axonal discharges set up abnormal neural circuits via the spinal cord resulting in 
persistent, prolonged or intermittent signals to the brain and even after the original stimulus 
has been removed (Wu et al., 2001, Djouhri et al., 2006, Obata et al., 2003). In inflammatory 
pain, sensitisation lowers the threshold of polymodal nociceptors as well as recruits 
insensitive nociceptor which evokes an intense response and renders non-painful stimuli to be 
painful (Schaible, 2007, Voscopoulos and Lema, 2010, Staud, 2011). However, pain may not 
strictly be nociceptive, neuropathic or inflammatory as all three may contribute to one 
another (Schaible, 2007).  
 
2.3.1 The pain matrix 
The pathways and processes in the body associated with pain perception are complex and 
may collectively be referred to as the pain matrix (Tracey and Mantyh, 2007). The processes 
involved in pain generation include neuronal development, peripheral sensitisation due to 
inflammation, transduction, conduction via synaptic transmission and modulation (see Fig. 
2.3; Foulkes and Wood, 2008). These processes are described in more detail below in 
Sections 2.3.1.1-2.3.1.5. 
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Fig. 2.3: Figure illustrating pain pathways and processes from the site of injury through 
the spinal cord to the brain; as well as the genes involved in the transduction, 
conduction, transmission and modulation of pain (adapted from Foulkes and Wood, 
2008). 
 
Briefly, in the periphery, enhanced neuronal remodelling and development may lead to 
increased peripheral sensitisation due to pro-inflammatory mediators produced following a 
noxious event (Schaible, 2007). This activates the nociceptors on the peripheral nerves to 
create action potentials, causing depolarisation of the local membranes and transmission 
along the axons (Foulkes and Wood, 2008, Cervero and Laird, 2004). Synaptic transmission 
takes place in the spinal cord. Cytokines, released in response to injury, alter the excitability 
of sensory neurons leading to pain modulation (Cervero and Laird, 2004, Sivilotti and Woolf, 
1994). From the spinal cord, information is transmitted to the brain and processed (Foulkes 
23 
 
and Wood, 2008, Apkarian et al., 2005, Gangadharan and Kuner, 2013, Kuner, 2010, 
Kitahata, 1993, Willis, 1985, Millan, 1999, Derbyshire, 2000). 
 
Pathways and processes in chronic pain are more complex. Chronic pain persists even after 
the original injury heals, and is influenced by an individual’s genetically determined pain 
sensitivity combined with changes in the neuroplasticity of the CNS (Phillips and Clauw, 
2011, Sarzi-Puttini et al., 2011, Staud, 2011). Individuals with chronic pain have enhanced 
sensitisation to stimuli and increased levels of pro-inflammatory mediators involved in pain 
modulation (Vincent et al., 2011, Kaya et al., 2013). 
 
2.3.1.1 Neuronal development 
Neurotrophic factors such as NGF and BDNF are responsible for the development, survival 
and maintenance of sensory neurons in the periphery (Lindsay, 1996, Huang and Reichardt, 
2001). Both protein and mRNA expressions of these growth factors are known to be 
increased during pain generation, which may contribute to increased neuronal development in 
the periphery (Cho et al., 1997b, Zhu et al., 2001, Hinsby et al., 2004, Lin et al., 2011, 
McKelvey et al., 2013). The sensitisation of the peripheral sensory neurons by pro-
inflammatory mediators contributes to pain generation (Cervero, 1995, Voscopoulos and 
Lema, 2010, Gangadharan and Kuner, 2013).  
 
Persistent noxious stimulation leads to remodelling of the neurons as well as neuronal 
synapses which intensify signal transmission (Voscopoulos and Lema, 2010, Treede, 1999). 
This leads to the sensory neurons becoming more sensitive to noxious stimulation and 
evoking a stronger response to even non-painful stimuli (Russo and Brose, 1998, Schachner, 
1997, Voscopoulos and Lema, 2010). Moreover, the remodelled neurons tend to develop 
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more connections with the neurons in the dorsal root ganglion (DRG) of the spinal cord and 
CNS in order to transmit more painful signals contributing to the development of chronic 
pain (Ji and Woolf, 2001, Woolf and Salter, 2000).  
 
2.3.1.2 Sensitisation due to inflammation 
Peripheral sensitisation leads to lowering of threshold of peripheral sensory neurons and 
activating the nociceptors at the peripheral nerve ends (Gangadharan and Kuner, 2013, 
Kitahata, 1993, Staud, 2011, Schaible, 2007). This generates an action potential which is 
transferred from the nerves to the spinal cord and the brain (Schaible, 2007, Voscopoulos and 
Lema, 2010). Following a noxious event, the pro-inflammatory mediators such as cytokines 
and growth factors, released by the damaged cells directly sensitise the nociceptors (Sommer 
and Kress, 2004, Kawasaki et al., 2008, Pezet and McMahon, 2006). Furthermore, 
inflammatory mediators such as prostaglandins, serotonin and bradykinin alter the sensitivity 
of the sensory neurons to mechanical and thermal stimuli (Dray and Perkins, 1993, Bardin, 
2011, Voscopoulos and Lema, 2010).  
 
Due to persistent sensitisation due to inflammation, the threshold of the peripheral sensory 
neurons lowers to an extent that innocuous stimuli can activate the nociceptors (Schaible, 
2007). Moreover, mechano-insensitive nerve fibres become mechano-sensitive fibres leading 
to a much more pronounced input to the spinal cord (Schaible, 2007, Russo and Brose, 1998, 
Voscopoulos and Lema, 2010). Following injury, both protein and gene levels of 
inflammatory mediators upregulate contributing to increased peripheral sensitisation thereby 
leading to pain generation (Banner and Patterson, 1994, Gadient and Patterson, 1999, Page et 
al., 2005, Homma et al., 2013).   
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2.3.1.3 Transduction 
Transduction is the conversion of noxious stimuli to electrical impulses. It takes place when 
nerve endings of nociceptors (C and Aδ fibres) respond to noxious stimuli (Foulkes and 
Wood, 2008, Xu et al., 2008, Cervero and Laird, 2004, Treede, 1999). Nociceptors are 
distributed in the skin, muscles, connective tissue, bones, joints and viscera. Their 
characteristics and functions are detailed in Table 2.1 (Millan, 1999, Binshtok, 2011). Once a 
noxious stimulus is received by the nociceptor, an action potential is generated due to the 
opening of ion channels and a flux of ions across cell membranes within the afferent sensory 
neurons (Foulkes and Wood, 2008). Information regarding the intensity and site of injury is 
sent to the CNS via these action potentials (Gangadharan and Kuner, 2013, Dussor et al., 
2009).  
Table 2.1: Types of nociceptors 
Type of 
nociceptor 
Type of stimuli Receptors Acute or 
chronic pain 
Type of nerve 
fibre 
Thermal
1 Noxious heat (~40-
45°C); cold (10-15°C) 
TRPV1, TRPM8 Acute pain Small 
diameter, 
myelinated Aδ  
fibres 
Mechanical
2 Change in pressure; 
distension; cuts; blows  
TRPV4, Vesicular 
glutamate transporter  
Acute pain Small 
diameter, 
myelinated Aδ 
fibres 
Chemical
3 Changes in pH; 
inflammatory mediators; 
capsaicin 
Acid sensing ion 
channels (ASIC),  
Chronic pain Small 
diameter, 
unmyelinated 
C fibres 
Polymodal
4 Change in temperature, 
pressure and pH; 
inflammatory mediators 
TRPA1, tachykinin 
NK1 receptor 
Chronic pain Small 
diameter, 
unmyelinated 
C fibres 
1 (Dubin and Patapoutian, 2010, Foulkes and Wood, 2008, Lee et al., 2005b, Levine and Alessandri-Haber, 2007, Liu et al., 2013) 
2 (Dubin and Patapoutian, 2010, Lee et al., 2005b) 
3 (Dubin and Patapoutian, 2010, Lee et al., 2005b, DeFelipe, 1997) 
4 (Dubin and Patapoutian, 2010, Lee et al., 2005b, Treede, 1999) 
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Genes involved in transduction are expressed in the primary sensory neurons (Treede, 1999, 
Foulkes and Wood, 2008, Zakir et al., 2012, Urano et al., 2012). Some genes are specifically 
expressed following tissue damage, mediate the release of soluble mediators following 
sensitisation and increase the excitability of sensory neurons (Trang et al., 2006, Chessell et 
al., 2005, Binshtok, 2011, Lee et al., 2005b). 
 
2.3.1.4 Conduction and transmission  
Pain impulses are conducted from the site of transduction along sensory nerve fibres and 
transmitted to the dorsal horn neurons of the spinal cord via synapses, and then to the brain 
(see Fig. 2.4; Schaible, 2007, Foulkes and Wood, 2008, Argoff, 2011, Gangadharan and 
Kuner, 2013, Lee et al., 2005b). 
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Fig. 2.4: Schematic presentation of conduction and transmission of pain impulses from 
the site of injury to the brain. 
 
Voltage-gated sodium ion channels conduct action potentials along the axons to the spinal 
cord (Waxman et al., 1999, Lee et al., 2005b, Wood, 2004, Foulkes and Wood, 2008). In 
response to depolarisation of local membranes, sodium channels open and allow an influx of 
sodium ions generating a potential in the terminal ends of the sensory neurons and conducting 
them along the axons (Dib-Hajj et al., 2010, Binshtok, 2011, Waxman, 2010, Waxman et al., 
1999, Lee et al., 2005b).  
Pain impulse generated at the site 
of injury 
Reaches the dorsal horn neurons 
of the spinal cord 
Reaches multiple areas of the 
brain for processing 
Conducted along terminal ends of 
the sensory nerve fibres 
Post-synaptic potentials due to 
binding of the neurotransmitters 
Neurotransmitter released at the 
synapse by Ca
2+
 influx  
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The action potential is transmitted from the peripheral nerve fibres to the DRG of the spinal 
cord (Foulkes and Wood, 2008, Kitahata, 1993, Argoff, 2011), which is mediated by the 
influx of calcium ions (Ca 
2+
) through the voltage dependent calcium ion channels (Rahman 
and Dickenson, 2013). This leads to the release of neurotransmitters from the presynaptic 
membrane of the neuron transmitting the action potential by interacting with the receptors of 
postsynaptic membrane of the receiving neuron (Kitahata, 1993, Cervero and Laird, 2004, 
Schaible, 2007). Synaptic transmission is modulated by neurotransmitters and may either 
inhibit or enhance the signal transmission (Schaible, 2007).  
 
The genes involved in conduction of action potentials include gated sodium-ion channel 
genes (SCN10A, SCN9A, SCN3, and SCN11A) and gated potassium ion genes (KCNQ). Their 
expressions have been shown to be altered during pain (Dib-Hajj et al., 2013, Black et al., 
2004, Wang et al., 2011, Rahman and Dickenson, 2013, Yoshimura and de Groat, 1999, 
Waxman, 2010, Lee et al., 2005b). Moreover, inflammatory mediators such as cytokines, 
NGF, tumor necrosis factor-α (TNF-α) and prostaglandins can increase the expression of 
sodium ion channels (Gould et al., 2000, Black et al., 2004) and may contribute to increased 
action potential generation and conduction.  
 
2.3.1.5 Pain modulation 
Pain modulation is the alteration of the excitability of sensory neurons, leading to promotion 
or inhibition of ascending or descending pain impulses (Gangadharan and Kuner, 2013, 
Yarnitsky, 2010, Schaible, 2007, Millan, 1999, Kitahata, 1993). Changes in neuronal function 
following persistent nociceptive activity can contribute to the enhancement of signal 
transmission as well as increased neuronal excitation, leading to persistent pain (Ossipov et 
al., 2010, Millan, 2002, Tracey and Mantyh, 2007).  
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Receptors involved in determining enhancement and inhibition of signal transmission include 
ligand gated ion channels, G-protein coupled receptors and receptor tyrosine kinases, 
serotonin (5-HT) receptors 1A and 5A, norepinephirine receptors, gamma-aminobutyric acid 
(GABA) receptors and adrenergic receptors (Ahmad and Dray, 2004, Bolay and Moskowitz, 
2002, Pan et al., 2008, Yarnitsky, 2010, Ossipov, 2012, Ossipov et al., 2010, Lindstedt et al., 
2011, Treister et al., 2011, Lambe et al., 2011). Genes encoding for these receptors may have 
both enhancing and inhibitory effects on the ongoing pain pathways. For example, genes 
encoding for serotonin receptor 1A and 5A, inhibit pain, whereas genes encoding for 
serotonin receptors 2A and 7A promote pain (Treister et al., 2011, Foulkes and Wood, 2008, 
Lambe et al., 2011). Moreover, inhibitory receptors may become excitatory in cases of 
intense activation, such as following axonal injury and contribute to chronic pain (Staley et 
al., 1995, Owens et al., 1996, Cho et al., 1997a).  
 
The pain modulating receptors are activated by a number of neurotransmitters which are 
released by sensory nerve fibres following persistent noxious stimulation (Woolf and Salter, 
2000). An upregulation in the expression of excitatory receptors may contribute to 
maintenance of pain. Neurotransmitters involved in excitatory pain modulation include brain 
derived neurotrophic factor (BDNF), nerve growth factor (NGF), cytokines such as 
interleukin-1 (IL-1), prostaglandins and substance P (Foulkes and Wood, 2008, Kitahata, 
1993). These factors not only sensitise the sensory neurons directly but also modulate them to 
respond to low-intensity stimuli (Foulkes and Wood, 2008, Millan, 1999, Schaible, 2007). 
Gene expression of excitatory neurotransmitters upregulates in chronic pain conditions (di 
Mola et al., 2000, Obata et al., 2003, Lin et al., 2011, Browne et al., 2012).  
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2.4 Current understanding of pain in endometriosis 
Pain symptoms often debilitate women with endometriosis for years (see Table 2.2). The 
compression of the nerve fibres by endometriotic lesions and/or sensitisation of the 
infiltrating nerve fibres in the lesion may contribute to endometriosis pain (Triolo et al., 2013, 
Morotti et al., 2014b, Neziri et al., 2014, McKinnon et al., 2015). Peripheral sensitisation in 
endometriosis may be promoted due to increased production of pro-inflammatory mediators 
by eutopic endometrium and endometriotic lesions, enhancing signal transduction, 
conduction and modulation which may contribute to the associated pain symptoms (Stratton 
and Berkley, 2011, Triolo et al., 2013). Moreover, pain in endometriosis may be due to 
nociceptive, inflammatory and/or neuropathic mechanisms (Howard, 2009, Fraser, 2010, 
Grimm et al., 2011).  
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Table 2.2: Pain symptoms associated with endometriosis. 
Symptoms Description and characteristics Prevalence 
Chronic pelvic 
pain 
 Non-cyclic pain lasting more than six months (34-90%)
1
 
Dysmenorrhoea  
 
 Uterine pain during menstruation 
 Sharp pelvic cramps at the start of menstrual flow 
radiating to the lower back or thighs or deep, dull 
aches 
(40-90%)
2
 
Dyspareunia 
 
 Pain during sexual intercourse 
 May be at the vaginal canal, at the level of the 
cervix or in the pelvic/uterine/abdominal region or 
the vulvar region and/or the vaginal introitus 
(24-80%)
3
 
Dyschezia 
 
 Pain in defecating 
 Can worsen with menstruation 
(7-51%)
4
 
Dysuria 
 
 Pain and burning sensation during urination in the 
absence of urinary tract infection 
(5-27%)
5
 
1(De Graaff et al., 2013, Fauconnier et al., 2002, Mahmood et al., 1991, Porpora et al., 1999, Milingos et al., 2006, Leng et al., 2007, Ling, 
1999) 
2(De Graaff et al., 2013, Fauconnier et al., 2002, Mahmood et al., 1991, Porpora et al., 1999, Chapron et al., 2003, Milingos et al., 2006) 
3(Bernuit et al., 2011, Denny and Mann, 2007, Ferrero et al., 2005, De Graaff et al., 2013, Fauconnier et al., 2002, Mahmood et al., 1991, 
Porpora et al., 1999) 
4(Fauconnier et al., 2002, Roman et al., 2012, Hao et al., 2009, Leng et al., 2007, Dai et al., 2012, MacDonald et al., 1999) 
5(Gabriel et al., 2011, Camanni et al., 2009, MacDonald et al., 1999) 
6(Preciado Ruiz et al., 2005, Schrager et al., 2013, Meuleman et al., 2009, Khawaja et al., 2009, Holoch and Lessey, 2010, Ozkan et al., 
2008) 
 
2.4.1 Nociceptive pain in endometriosis
 
Pain in endometriosis involves the pelvic viscera, evidence for which includes high density of 
unmyelinated C fibres in the eutopic endometrium and endometriotic lesions (Tokushige et 
al., 2006a, Tokushige et al., 2010, Wang et al., 2009). Also, chemical mediators, such as 
cytokines, released by local immune cell populations may contribute to the activation of 
nociceptors (Fraser, 2010, Cervero and Laird, 2004, Cervero, 1995, Simone and Kajander, 
1997, Perl, 2007, Basbaum et al., 2009, Giudice and Kao, 2004, Schmidt et al., 1995). 
Typical nociceptive pain ceases when noxious stimuli are removed. Studies have shown 
significant improvement in pain symptoms after surgical removal of endometriotic lesions 
(Grimm et al., 2011, Howard, 2009, Sutton et al., 1994, Abbott et al., 2004). However, in 
some cases total pain relief is not achieved and some degree of pelvic pain persists, indicating 
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that pain in endometriosis is not only nociceptive but may also be of inflammatory and/or 
neuropathic origin (Howard, 2009). 
 
2.4.2 Inflammatory pain 
Inflammatory pain occurs due to tissue injury and is a major cause of visceral pain. Many 
processes in endometriosis increase the production of pro-inflammatory mediators (Costigan 
et al., 2002, Cakmak et al., 2009, Hirata et al., 2008, Anaf et al., 2002, Noble et al., 1997). 
For example, macrophage migration inhibitory factor, TNF-α, IL-1β, IL-6, IL-8, regulated on 
activation normal T expressed and secreted (RANTES) and monocyte chemotactic protein-1 
have increased levels in the eutopic endometrium and peritoneal fluid of women with 
endometriosis compared to women without endometriosis (Hille, 1992, Mannion et al., 1999, 
Bedaiwy et al., 2007, Bersinger et al., 2006, Velasco et al., 2010, Arici, 2002, Akoum et al., 
2001, Morin et al., 2005). These may contribute to sensitisation of peripheral sensory neurons 
leading to pain generation. 
 
Pro-inflammatory factors released by the eutopic endometrium as well as endometriotic 
lesions may contribute to inflammatory pain (Longhurst and Dittman 1987; Bulmer, Lunny et 
al. 1988; Bennett 2001; Malcangio and Lessmann 2003; Antsiferova, Sotnikova et al. 2005; 
Tegeder, Costigan et al. 2006; Merighi, Salio et al. 2008;  Borghese, Vaiman et al. 2010; 
Tremblay and Hamet 2010; Browne, Yu et al. 2012). For example, NGF contributes to 
inflammatory pain by inducing the expression of neuropeptides and modulating central pain 
transmission (Gould et al., 2000, Pezet and McMahon, 2006). Excessive oestrogen 
production leads to production of prostaglandins, which can directly activate nerve endings 
thereby aiding in inflammatory pain generation (Kauppila et al., 1979, Koike et al., 1992). 
Although the number of studies indicating that pain in endometriosis is inflammatory is 
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increasing, it remains to be determined whether the inflammatory microenvironment is causal 
or a consequence of endometriosis. 
 
2.4.3 Neuropathic pain 
The presence of nerve fibres both in the eutopic endometrium and endometriotic lesions as 
well as their association with endometriosis-associated pain has been reported (Anaf et al., 
2002, Tokushige et al., 2007, Berkley et al., 2005). Direct evidence for neuropathic pain in 
endometriosis is lacking; however, there are studies to support this (McAllister et al., 2012, 
Bajaj et al., 2003, Pacchiarotti et al., 2013). For example, Anaf et al. (2000) reported that pain 
in endometriosis may be due to the physical interaction between nerve fibres and 
endometriotic lesions. However, these findings have been limited to only DIE lesions (Anaf 
et al., 2002). Moreover, women with peritoneal lesions associated with high nerve fibre 
densities reported more pain than women with peritoneal lesions not associated with nerve 
fibres (McKinnon et al., 2012).  
 
In peritoneal lesions, there is an increased expression of markers for sensory, sympathetic and 
parasympathetic nerves compared to normal peritoneum (Tokushige et al., 2006b). Studies 
have confirmed the innervation of endometriotic lesions by slow unmyelinated sensory C and 
the faster myelinated Aδ nerve fibres which are responsible for mediating painful stimuli 
(Berkley et al., 2004, Tokushige et al., 2006b). Research by Mechsner et al. (2007) has shown 
growth associated protein (GAP) 43, a marker for neural outgrowth and regeneration, to be 
strongly expressed in nerve fibres associated with endometriotic lesions. All these suggest 
that endometriosis may have neuropathic properties that can lead to changes in the nervous 
system, however the exact mechanisms remain unclear (Howard, 2009, McKinnon et al., 
2015).  
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2.4.4 Central pain processing in endometriosis 
It has been observed that in chronic pelvic pain conditions such as endometriosis, women 
exhibit enhanced pain processing by the CNS (Bajaj et al., 2003, Weiwei He et al., 2010, 
Laursen et al., 2005, As-Sanie et al., 2012, Neziri et al., 2014). Chronic pain, as experienced 
by many women with endometriosis, is a consequence of deficits in conditioned pain 
modulation, which inhibits pain by the descending pathways, and increased sensitivity to 
noxious stimulation (Calvino and Grilo, 2006, Fornasari, 2012). 
 
In endometriosis, the pro-inflammatory microenvironment together with hyper sensory 
innervation in the pelvic viscera may lead to intense nociception, which contributes to 
increased sensitisation of the neurons in the DRG and CNS, also known as central hyper-
excitability (Triolo et al., 2013, Evans et al., 2007, Kobayashi et al., 2013). The central hyper-
excitability involves loss of inhibitory mechanisms, contributing to increased pain and 
enlarged referred areas, which is pain perceived at a site distant from the site of painful 
stimulus (Dubner, 1991, Dubner, 1994, Bajaj et al., 2003). Central hyper-excitability is 
further aggravated during menstruation due to abrupt changes in hormonal production and 
increased production of pro-inflammatory neuropeptides such as prostaglandins, leading to 
decreased threshold of the neurons to pressure and heat (Bajaj et al., 2003, Bajaj et al., 2002, 
Brawn et al., 2014). The aggravated central hyper-excitability may lead to persisting pain 
even after the surgical removal of endometriotic lesions (Bajaj et al., 2003). Furthermore, 
women with endometriosis-associated pain demonstrate increased sensitivity to noxious 
stimulation due to inflammation than women without endometriosis (Bajaj et al., 2003, 
Brawn et al., 2014, Neziri et al., 2010).  
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In addition to central hyper-excitability, women with endometriosis show changes in the 
brain that relate to pain processing. Morphological changes in the brain such as reduced grey 
matter volume have been observed in chronic pain (Rodriguez-Raecke et al., 2009, Baliki et 
al., 2011). In a recent study by As-Sanie et al. (2012), a reduction in the volume of brain grey 
matter was demonstrated in women with endometriosis-associated pain compared to women 
with endometriosis but no pain. Reduced volume of grey matter, which processes the sensory 
signals from the viscera, means that noxious stimulation is no longer required for pain 
generation and the constant pain experience is being driven by the brain itself (Rodriguez-
Raecke et al., 2009, As-Sanie et al., 2012, Baliki et al., 2011). Longer duration of noxious 
stimulation and neuronal remodelling of the pain network contributes to reduced grey matter 
volume and transition to a chronic pain state (As-Sanie et al., 2012). 
 
In summary, pain in endometriosis ranges from mild to severe with some women being 
asymptomatic. Complex mechanisms, along with genetic and environmental factors and prior 
experiences may contribute to variability in pain experiences by women with endometriosis. 
Pain in endometriosis may be of nociceptive, inflammatory or neuropathic origin. However, 
pain mechanisms in endometriosis remain poorly understood due to lack of research as well 
as the multifaceted nature of the disease and associated molecular mechanisms. Studies 
focusing on elucidating pain mechanisms have generally been hampered by factors such as 
insufficient sample size, loss to follow up and improper study designs. 
 
2.5 Impact of pain on women’s lives  
Endometriosis pain has a negative impact on women’s professional and personal lives 
(Mathias et al., 1996 , Huntington and Gilmour, 2005, Oehmke et al., 2009, Culley et al., 
2013). It is entwined with a wide range of other symptoms such as bowel problems, being 
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generally unwell, fatigue and depression (Huntington and Gilmour, 2005). Delay in diagnosis 
as well as uncertainty of response to treatment impacts the duration and severity of the pain 
experienced by these women (Denny, 2004, Oehmke et al., 2009). Absenteeism from work, 
reduced productivity, financial hardship due to lost work hours, cost of treatment and lack of 
understanding by employers and colleagues often hampers professional lives of women with 
endometriosis (Denny, 2004, Culley et al., 2013, Huntington and Gilmour, 2005).  
 
In terms of their personal lives, many women are embarrassed to talk about endometriosis 
pain due to the taboos surrounding menstruation, sexual problems and pelvic pain, leading to 
social isolation (Huntington and Gilmour, 2005, Gilmour et al., 2008, Jones et al., 2004, 
Denny, 2004). Women may not be able to participate in daily chores due to pain associated 
with endometriosis (Oehmke et al., 2009). Endometriosis pain impacts not only women with 
the disease but also those who surround them, and society as a whole. The combined annual 
costs of healthcare and loss of productivity associated with pain due to endometriosis have 
been estimated at AUD 12,094.25 (approximately €9579) per patient (Simoens et al., 2012).  
 
2.6 Pain management 
The complex and highly variable nature of endometriosis pain makes its successful 
management difficult. Conservative surgery for treating pain in endometriosis provides relief 
in 60-80% patients (Abbott et al., 2004). This type of surgery includes endometriotic lesion 
excision and ablation, with both providing same level of pain relief (Healey et al., 2010). In 
women with ovarian endometriosis, excision of the endometrioma cyst wall results in 
reduced pain rates compared to ablation (Hart et al., 2008). Complete removal of lesions may 
provide relief from pain symptoms, however pain symptoms can recur after surgery. Almost 
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half of women relapse within five years of the surgery and almost half of these patients 
require further surgery (Sutton et al., 1997, Fauconnier and Chapron, 2005, Medicine, 2006).  
 
Disruption of neural pathways serving the pelvis may also provide relief from pain due to 
endometriosis (Hansen et al., 2010, The Practice Committee of the American Society for 
Reproductive, 2014, Lee and Yang, 2008, Yuan, 2006). These include laparoscopic 
uterosacral nerve ablation, the disruption of efferent nerve fibres in the uterosacral ligaments 
and presacral neurectomy, interruption of sympathetic innervations at the level of superior 
hypogastric plexus (Howe et al., 2010, Medicine, 2006, Valle and Sciarra, 2003, Kennedy et 
al., 2005). Laparoscopic uterosacral nerve ablation provides no significant pain relief when 
compared to conservative surgery (The Practice Committee of the American Society for 
Reproductive, 2014, Davis, 1996). On the other hand, presacral neurectomy has been 
proposed for treating midline pain, however it is a technically challenging procedure and 
involves significant risk of bleeding from the adjacent venous plexus so is unpopular (Valle 
and Sciarra, 2003, Howe et al., 2010, Kennedy et al., 2005, Hansen et al., 2010). 
 
Radical surgery may be offered to women who do not wish to conceive or for whom all other 
therapies for relieving pain have failed (Hansen et al., 2010, The Practice Committee of the 
American Society for Reproductive, 2014). This includes hysterectomy, bilateral 
oophorectomy and removal of all endometriotic implants. Radical surgery is generally 
thought to provide definitive pain relief, however if ovaries are not removed at the time of 
surgery pain may recur (Hansen et al., 2010).  
 
Currently available medical management approaches for endometriosis pain include 
analgesics and hormonal suppression (Bruner-Tran et al., 2013, Huang, 2008). When 
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investigations reveal no definite diagnosis, analgesics and non-steroidal anti-inflammatory 
drugs (NSAIDs), available over the counter or through prescription, are offered for 
controlling pain symptoms (Kennedy et al., 2005). Analgesics such as Paracetamol, the daily 
dose for which is 4000 mg or 1000 mg four hourly, reduce pain by blocking existing pain 
however do not alter any disease mechanism in the body (Huang, 2008, Bruner-Tran et al., 
2013, Nasir and Bope, 2004, Kennedy et al., 2005). In cases where these are not able to 
alleviate endometriosis pain, stronger pain killers such as co-analgesics, dihydrocodeine or 
opioids may be prescribed (Kennedy et al., 2005). However, these cannot be used for long 
term as they have side effects such as dependency (Medicine, 2014, Kennedy et al., 2005). 
NSAIDS such as ibuprofen, naproxen sodium, ketoprofen and mefenamic acid alleviate pain 
symptoms by blocking cyclooxygenase and therefore the production of prostaglandins 
(Lethaby et al., 2007). They must be taken 24 hours before the expected pain experience as 
well as six-hourly in order to be effective (Lethaby et al., 2007). Although effective, they can 
have serious side effects such as nausea, vomiting, diarrhoea, irritation of the stomach and 
stomach ulcers (Medicine, 2014).  
 
Hormonal treatment involves providing a steady hormonal environment that suppresses 
eutopic endometrium and endometriotic lesions to provide relief from the associated pain. It 
is used as primary medical therapy as well as in conjunction with surgical resection for 
managing endometriosis pain (Surrey, 2006, Brown et al., 2012, Zito et al., 2014, Angioni et 
al., 2014, Schweppe, 2001). Hormonal treatment includes the combined oral contraceptive 
(OCs); progestins taken as tablet, injection once in three months or continuously as a rod 
inserted under the skin or released from an intrauterine system (levonorgestrel-releasing 
intrauterine system; LNG-IUD); and gonadotropin-releasing hormone (GnRH) analogues 
(Prentice et al., 2004, Moore et al., 2004, Kennedy et al., 2005). Combined oral contraceptive 
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pills alleviate pain symptoms by suppressing endometriotic lesion growth as well as reducing 
production of prostaglandins thereby decreasing inflammation (Moore et al., 2004, Moore et 
al., 2000). Both traditional OCs containing androgenic progestogens (19-nortestosterone 
derivatives) as well as new generation OCs containing progestogen and desogestrel provide 
relief from endometriosis pain symptoms in up to 75% patients (Moore et al., 2004, Hansen 
et al., 2010, Proctor et al., 2001, Harada et al., 2008). Continuous low dose OCs are more 
effective in controlling pain symptoms than cyclic doses (Zorbas et al., 2015, Vercellini et al., 
2003, Seracchioli et al., 2010). 
 
Progestins relieve endometriosis pain symptoms by creating a state of pseudopregnancy and 
atrophy of endometriotic lesions (Schweppe, 2001). The variety of available agents have 
varying pros and cons (see Table 2.3), however no single agent can be considered more 
efficacious than another (Schweppe, 2001, Zito et al., 2014, Surrey, 2006, Bahamondes et al., 
2007, Fedele and Berlanda, 2004). This may be due to lack of appropriate randomised 
controlled trials and standardised evaluation of pain in women with endometriosis (Surrey, 
2006, Fedele and Berlanda, 2004). All available progestins have similar side effects such as 
weight gain, acne, increased hair growth, breast tenderness, cramps and mood swings 
(Schweppe, 2001). 
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Table 2.3: Types of available progestins 
Name Form Dosage Advantages 
Dienogest
1
 Tablet 2 mg/day  Fewer side effects than 
Danazol and GnRH 
analogues  
 Safe 
Dydrogesterone
2
 Tablet 10-30 mg/day  Compatible with 
conception 
 Reduces bleeding 
Medroxyprogesterone 
acetate
3
 
Tablet 30-60 mg/day  Fewer side effects than 
Danzol and GnRH 
analogues  
Norethisterone
4
 Tablet 2.5-5 mg/day  Controls uterine bleeding 
 Positive effect on calcium 
metabolism  
 No negative effects on 
lipoprotein metabolism at 
low dosages 
Depot 
medroxyprogesterone 
acetate
5
 
Long-
acting 
injection 
50 mg injection/week 
or 100 mg injection/2 
weeks or 150 mg 
injection/2-3 months 
 Fewer side effects than 
Danzol and GnRH 
analogues  
 Compliance with long-
term administration 
Levonorgestrel 
intrauterine system
6
 
T-shaped 
intrauterine 
device 
52 mg levonorgestrel 
released into the uterus 
over a period of 5 years  
 Avoidance of repeated 
administrations  
 Increase of compliance in 
long-term administration 
 Greater efficacy compared 
to GnRH analogues 
1 (Harada and Taniguchi, 2010, Morotti et al., 2014a, Strowitzki et al., 2010) 
2 (Brown et al., 2012, Fedele and Berlanda, 2004, Zito et al., 2014, Schweppe, 2001) 
3 (Schlaff et al., 2006, Fedele and Berlanda, 2004) 
4 (Morotti et al., 2014a, Schweppe, 2001) 
5 (Schlaff et al., 2006) 
6 (Bahamondes et al., 2007, Petta et al., 2005, Vercellini et al., 2005, Lockhat et al., 2005) 
 
GnRH analogues provide pain relief by inducing amenorrhea and progressive endometrial 
atrophy (Huang, 2008, Medicine, 2006, Zito et al., 2014). They are administered either by a 
calibrated nasal spray of nafarelin acetate two times a day, or by injection of a short-acting 
formulation daily or a longer acting formulation every 1-3 months (Brown et al., 2010, 
Sagsveen et al., 2003). They are as effective as progestins or OCs in providing relief from 
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endometriosis pain symptoms and they are particularly effective in providing relief from 
dysmenorrhea since they cause amenorrhea (Medicine, 2014, Vercellini et al., 1993). Side 
effects of GNRH analogues include hot flushes, vaginal dryness, decreased libido, mood 
swings, headache and bone mineral depletion, hence they are not widely recommended 
(Sagsveen et al., 2003, Zito et al., 2014). Although hormonal treatment can be effective in 
providing relief, pain relapses at suspension of treatment as the endometriotic lesions become 
active again (Vercellini et al., 2008, Minjarez and Schlaff, 2000, Medicine, 2006).  
 
Pain symptoms in some patients persist even after medical and/or surgical treatment. Overall, 
there is 10-50% recurrence rate of endometriosis pain symptoms and up to 20% of women do 
not respond to any treatment (Davis and McMillan, 2003, Abbott et al., 2004, Lindsay et al., 
2015). Therefore, individualised and multidisciplinary approaches may be required in the 
treatment of endometriosis pain (Kennedy et al., 2005). For example, since the efficacy of 
available pain treatments is similar, women need to be informed regarding the expense, side-
effects and invasiveness of therapy to make an informed decision regarding the approach 
most appropriate for them (The Practice Committee of the American Society for 
Reproductive, 2014, Kennedy et al., 2005, Dunselman et al., 2014).  
 
Problematic pain due to endometriosis can call for a multidisciplinary treatment approach 
(Rocha et al., 2012, Greco, 2003, Metzger, 1997). This may combine medical therapy, 
counselling and alternative therapies in order to improve women’s responses to treatment 
(Greco, 2003, Kames et al., 1990, Ortiz, 2008). Counselling should be offered to certain 
patients so they can return to their routine social and family lives (Greco, 2003, Townsend et 
al., 2006, Gilmour et al., 2008). Alternative therapies such as acupuncture, herbal medicines, 
dietary changes and yoga have also been successful in reducing endometriosis-associated 
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pain (Medicine, 2014, Kennedy et al., 2005). The complexities and inadequacies of pain 
management in endometriosis indicate the importance of understanding molecular 
mechanisms underlying pain generation in women with the disease. Improved understanding 
of mechanisms will facilitate development of better pain management techniques. 
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Aims and Hypotheses 
 
Aims  
The overall aim of this thesis was to investigate the expression of pain related genes in 
women with endometriosis compared to women without the disease.  
 
This thesis also aimed to investigate the relationship between endometrial and endometriotic 
lesion gene expression and menstrual cycle phase.  
 
Hypotheses 
1. Pain related genes are dysregulated in eutopic endometrium from women with 
endometriosis and in endometriotic lesions.  
2. The endometrial and endometriotic lesion expression levels of pain related genes vary 
during different phases of the menstrual cycle. 
3. The expression levels of different pain related genes correlate with each other in the 
eutopic endometrium from women with endometriosis and in endometriotic lesions. 
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Chapter 3 
Methodology 
 
3.1 Introduction 
In order to gain insights into the mechanisms involved in pain generation in women with 
endometriosis, a meta-analysis of microarray gene expression was conducted between 
eutopic endometrium from women with and without endometriosis; and endometriotic 
lesions. Microarray technology is a powerful tool for analysing expression of numerous genes 
simultaneously in a single tissue specimen in a highly efficient manner (Ramasamy et al., 
2008). A number of studies have used this technology to understand the underlying biological 
mechanisms in endometriosis (Burney et al., 2007, Hurst et al., 2014, Kao et al., 2003, Khan 
et al., 2012). Through a meta-analysis, the statistical power for obtaining a more precise 
estimate of differential gene expression increases (Ramasamy et al., 2008, Taminau et al., 
2014). This may aid in developing a more accurate picture of the biological pathways 
underlying pain generation in women with endometriosis.  
 
This meta-analysis will utilise the primary two types of microarray gene expression data: 
 individual participant raw or normalised data which represent measurement of expression 
for every gene in a sample (Ioannidis et al., 2002, Stewart and Parmar, 1993); and 
 lists of dysregulated genes published in the studies (Miller and Stamatoyannopoulos, 
2010, Cahan et al., 2007, Griffith et al., 2006).   
 
Figure 3.1 provides an overview of the present meta-analyses highlighting the type of data 
used, number of included studies, tissue types being compared, primary outcomes of the 
meta-analyses and results convergence. This meta-analysis was conducted by separately 
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analysing individual participant gene expression data and published gene lists. For both data 
types, comparisons were made between eutopic endometrium from women with and without 
endometriosis as well as between eutopic endometrium and endometriotic lesions from 
women with endometriosis. Individual participant gene expression data were adjusted for 
menstrual cycle phase. However, this could not be done for the published gene list data as 
lists of genes dysregulaed in different menstrual cycle phases were not available. The primary 
outcome measure for all the analyses was dysregulated genes involved in pain generation. In 
order to find genes that are consistently dysregulated throughout the datasets, results 
comparing gene expression of eutopic endometrium from women and without endometriosis 
as well as of eutopic endometrium from women with endometriosis and endometriotic lesions 
from both the individual participant gene expression data and published gene lists were 
converged.
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Individual participant gene 
expression data 
Eutopic 
endometrium 
endo vs. control 
(n = 3) 
Endo eutopic vs. 
lesions 
(n = 5) 
Irrespective 
of menstrual 
cycle phase 
Adjusted for 
menstrual 
cycle phase  
Irrespective 
of lesion site 
or menstrual 
cycle phase 
Lesions 
adjusted for 
menstrual 
cycle phase  
Published gene lists 
Eutopic 
endometrium 
endo vs. control 
(n = 3) 
Endo eutopic 
vs. lesions 
(n = 7) 
Irrespective 
of menstrual 
cycle phase 
Irrespective 
of lesion site 
or menstrual 
cycle phase 
Fig 3.1: Flow-chart illustrating an overview of the present meta-analyses highlighting the data type used, the no. of suitable 
studies (n), the tissue type being compared, the groups being compared to get the outcomes and result convergence.  Data for 
published gene lists could not be adjusted for menstrual cycle phase since related information and data were not available. 
Endo = endometriosis 
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3.2 Criteria for considering studies for the review 
Inclusion and exclusion criteria for study selection are summarised in Table 3.1. Further 
details regarding criteria for study design, participant characteristics, study methods and 
outcome measures are provided below. 
 
Table 3.1: Study inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
 Studies investigating gene expression 
profiles in endometrium and 
endometriotic lesions 
 Participants: premenopausal with 
normal menstrual cycles  
 Presence or absence of endometriosis 
confirmed laparoscopically 
 Eutopic endometrial and endometriotic 
lesion specimens obtained through 
endometrial biopsy/curetting/excision 
 Use of whole human genome 
microarray chips 
 Availability of individual participant 
gene expression data or published gene 
lists 
 Peer-reviewed studies 
 Participants on hormonal treatment 
 Individual participant gene 
expression data or published gene 
lists unavailable  
 
 
 
48 
 
Study design 
Studies included in the meta-analysis were one of two designs: (1) case-control type studies 
that recruited women with a confirmed diagnosis of endometriosis and women without 
endometriosis, and compared gene expression of eutopic endometrial tissue samples; or (2) 
cross-sectional type studies that either recruited women with a confirmed diagnosis of 
endometriosis and compared gene expression of endometriotic lesions and eutopic 
endometrial samples, or recruited women without endometriosis and profiled gene expression 
of the endometrium.  
 
Participant characteristics 
Within the studies, premenopausal women with regular menstrual cycles and laparoscopic 
evidence of being with or without endometriosis were suitable for inclusion. Women taking 
hormonal treatment were excluded.  
 
Types of interventions (study methods) 
In the included studies, endometrial samples of the participants with or without endometriosis 
were obtained by biopsy or curettage. Samples for endometriotic lesions from women with 
endometriosis were obtained by surgical excision. Tissues were processed for ribonucleic 
acid (RNA) extraction and hybridisation with whole human genome microarray chips. 
 
Outcome measures 
The primary outcome measure for the included studies was dysregulated gene expression 
along with availability of either individual participant gene expression data or published lists 
of genes declared to be dysregulated in the eutopic endometrium from women with and 
without endometriosis as well as in endometriotic lesions. 
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Secondary outcome measures from included studies of particular interest were  
 expression of genes involved in pain generation;  
 gene expression in different menstrual cycle phases; and 
 dysregulated biological pathways revealed by gene ontology analyses. 
 
Adverse outcomes  
Adverse outcomes were not applicable in this meta-analysis since treatment effects were not 
being considered. 
 
3.3 Search methods 
Literature and gene database searches were conducted from 1/8/2013 to 30/11/2013 and 
4/9/2014 to 6/10/2014. Searches were limited to studies in peer-reviewed scientific journals 
published in English. Of the 116 studies found, 24 studies analysing microarray gene 
expression of whole eutopic endometrium from women with and without endometriosis as 
well as endometriotic lesions were further reviewed. Out of these, 16 were suitable as per the 
inclusion criteria (see Fig. 3.2 and Table 3.1). The excluded studies were either not peer 
reviewed, had insufficient data or had compared data from single cell types.  
 
An in-house departmental search was also conducted in order to look for suitable studies that 
could be included in this meta-analysis. The search revealed one study by Zevallos (2012) 
which compared the expression of neurotrophins in the eutopic endometrium of women with 
and without endometriosis. The study was suitable for inclusion as per the inclusion criteria 
(Table 3.1) and had individual participant gene expression data available.
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Fig. 3.2: Summary of search results. 
  
Studies searched from electronic 
databases and microarray 
repositories 
 
PubMed: n = 100;  
Medline: n = 116;  
Endometrial Database: n = 15; 
Google Scholar: n = 107;  
Array Express: n = 8;  
Gene Expression Omnibus: n = 8 
Analysing microarray gene expression 
of endometrium from women with and 
without endometriosis; and 
endometriotic lesions. 
n = 24  
Included: N = 17;  
16 published studies; 1 unpublished 
thesis from The Department of 
Obstetrics and Gynaecology, 
University of Sydney 
 
Excluded: n = 8 
Reasons: 2 with inadequate 
data/information; 6 compared 
single cell types 
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Electronic searches 
The following electronic databases were searched for eligible studies using the search terms 
endometriosis, endometrium, eutopic, ectopic, endometriotic lesion, microarray and gene 
expression.  
 Medline via Ovid (http://www.nlm.nih.gov/pubs/factsheets/medline.html) 
 Pubmed (www.ncbi.nlm.nih.gov/pubmed/) 
 Google Scholar (http://scholar.google.com.au/) 
 Endometrium Database Resource 
(http://edr.research.bcm.edu/edr/ui_home.seam?cid=76228)  
 
Other resources 
Reference lists of relevant publications and included studies were also explored to ensure all 
relevant manuscripts were identified. In addition, a search for microarray gene expression 
data was performed; using the terms endometriosis, endometrium, eutopic, ectopic and 
endometriotic lesion, and limiting the search to species Homo sapiens; in the following 
repositories: 
 Array express (available from http://www.ebi.ac.uk/arrayexpress/) 
 Gene expression omnibus (GEO; available from http://www.ncbi.nlm.nih.gov/geo/). 
 
3.4 Study selection and data assessment 
3.4.1 Selection of studies 
A single reviewer (MS) scanned all 116 article titles and abstracts retrieved from the 
searches. Studies that did not conduct a microarray analysis were removed. Full text 
manuscripts of 24 studies were retrieved out of which those that did not analyse gene 
expression of whole tissue samples or had inadequate information available were removed. 
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The reviewer assessing the relevance was not blinded to the information about the articles, 
such as the publishing journal, names of authors, institution and results. Studies that did not 
meet the inclusion criteria (criteria summarised previously in Table 3.1) were discarded. See 
Table 3.2 and Appendix 1 for characteristics of included studies and Appendix 2 for those of 
excluded studies.  
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Table 3.2: Studies included in meta-analysis. 
Citation Tissue Data type (available from/accession no.) Type of 
microarray 
used 
Sample 
# 
Age-
group 
(years) 
Study 
type 
Hull et al. 
(2008) 
Eutopic 
endometrium; 
peritoneal lesions 
Individual participant gene expression data 
(Pubmed accession no.: GSE11691) 
HG U133A  EU = 9; 
EL = 9 
20-46 Cross-
sectional  
Hever et al. 
(2007) 
Eutopic 
endometrium; 
ovarian lesions 
Individual participant gene expression data 
(Pubmed accession no.: GSE7305) 
HG U133A plus 
2.0  
EU =10; 
EL = 10 
Not given Cross-
sectional  
Burney et al. 
(2007) 
Eutopic 
endometrium 
Individual participant gene expression data 
(Pubmed accession no.: GDS2737) 
HG U133A plus 
2.0 
EU = 21; 
EL = 16 
22-44 Case-
control  
Khan et al. 
(2012) 
Eutopic 
endometrium; 
ovarian lesions 
Individual participant gene expression data 
(Pubmed accession no.: GSE 37837) 
Agilent Whole 
Human Genome 
60-mer 4X44K 
EU = 18; EL 
= 18 
24-45 Cross-
sectional  
Talbi et al. 
(2006) 
Eutopic 
endometrium 
Individual participant gene expression data 
(Pubmed accession no.: GDS2052) 
HG U133A plus 
2.0 
EU = 27 22-50 Cross-
sectional  
Zevallos 
(2012) 
 
Eutopic 
endometrium 
Individual participant gene expression data 
(http://pwbc.garvan.unsw.edu.au/caarray) 
HuGene 1.0 ST 
array 
EU = 12 
NE = 18 
25-43 Case-
control  
Crispi et al. 
(2013) 
Eutopic 
endometrium; 
peritoneal lesions 
Individual participant gene expression data 
(Pubmed accession no.: GSE25628) 
HG U133A plus 
2.0 
EU = 8 
EC = 8 
NE = 6 
22-46 Case-
control  
Sohler et al. 
(2013) 
Eutopic 
endometrium; 
peritoneal lesions 
Individual participant gene expression data 
(Array Express accession no.: E-MTAB-
694) 
HG U133A plus 
2.0 
EU = 27 
EC =27 
21-52 Cross-
sectional  
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Citation Tissue Data type (available from/accession no.) Type of 
microarray 
used 
Sample 
# 
Age-
group 
(years) 
Study 
type 
Sherwin et 
al. (2008) 
Eutopic 
endometrium 
Prioritised gene list (Pubmed accession 
no.: 18353903) 
Custom made 
(containing 
oligonucleotides 
specific for 
22000 human 
transcripts) 
EU = 10 
NE = 6  
Not given Case-
control  
Kao et al. 
(2003) 
Eutopic 
endometrium 
Prioritised gene list (Pubmed accession 
no.: 12810542) 
Affymetrix 
Genechip 
Hu95A 
EU = 8 
NE = 7 
28-39 Case-
control  
Hurst et al. 
(2014) 
Eutopic 
endometrium 
Prioritised gene list (Pubmed accession 
no.: 24292148) 
Affymetrix 
8500 array 
EU = 10 
NE = 5 
18-40 Case-
control  
Zafrakas et 
al. (2008) 
Eutopic 
endometrium; 
ovarian lesions 
Prioritised gene list (Pubmed accession 
no.: 18288381) 
Affymetrix 
Gene Chip HG-
U133 
EU = 4 
EC = 4 
Not given Case-
control  
Gaetje et al. 
(2007) 
Eutopic 
endometrium; 
peritoneal lesions 
Prioritised gene list (Pubmed accession 
no.: 17952761) 
HG U133A EU = 3 
EC = 3 
Not given Case-
control  
Eyster et al. 
(2007) 
Eutopic 
endometrium; 
ovarian & 
peritoneal lesions  
Prioritised gene list (Pubmed accession 
no.: 17462640) 
CodeLink 
Whole Human 
Genome 
Bioarrays 
EU = 11 
EC = 11 
28-45 Cross-
sectional  
Borghese et 
al. (2008) 
Eutopic 
endometrium; 
ovarian lesions 
Prioritised gene list (Pubmed accession 
no.: 18818281) 
Institut Cochin 
HG18 60mer 
expression array 
47K 
EU = 12 
EC = 12 
Not given Cross-
sectional  
Mettler et al. 
(2007) 
Eutopic 
endometrium; 
ovarian lesions 
Prioritised gene list (Pubmed accession 
no.: 17333364) 
Atlas Human 
1,2 array 
EU = 5 
EC = 5 
22-40 Cross-
sectional  
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Citation Tissue Data type (available from/accession no.) Type of 
microarray 
used 
Sample 
# 
Age-
group 
(years) 
Study 
type 
Sun et al. 
(2014) 
Eutopic 
endometrium; 
ovarian lesions  
Prioritised gene list (Pubmed accession 
no.: 24502888) 
SurePrint G3 
Human Gene 
Expression 
8x60K v2 
EU = 4 
EC = 4 
24-45 Cross-
sectional  
Vouk et al. 
(2011) 
Eutopic 
endometrium; 
Ovarian lesions 
Prioritised gene list (Pubmed accession 
no.: 21397694) 
TaqMan low-
density array 
EU = 9 
EC = 11 
24-50 Cross-
sectional  
*EU= Eutopic endometrium from women with endometriosis; EC= Endometriotic lesions; NE= No endometriosis 
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3.4.2 Data extraction 
According to the type of available data, information from the included studies was extracted.  
Individual participant gene expression data were downloaded from public repositories - GEO and 
Array Express. Data for individual participants were extracted from eligible studies, including 
(where available) participant identification code, age, menstrual cycle phase, surgically confirmed 
diagnosis/exclusion of endometriosis and whether the participant was taking any hormonal 
treatment. Appendix 3 shows participant characteristics from studies with individual participant 
gene expression data. 
 
Published gene lists were collected from the included studies for which individual participant gene 
expression data were not available. Information extracted for gene lists included information 
regarding the groups being compared for gene expression, gene symbols, unique identifiers 
(Accession ID, Affymetrix probe ID, UniGene ID, etc.), fold change and significance values. All 
data extraction was conducted by a single person (MS).  
 
3.4.3 Assessment of risk bias in included studies 
Bias is a systematic error which can over- or under-estimate the results of a study. In order to 
anticipate the validity of the included studies in this meta-analysis, the methodology of each study 
was critically assessed. Factors that were assessed to evaluate potential sources of bias in the 
studies included: sample size of the studies, blind histological assessment of tissue samples to 
determine stage of endometriosis, established criteria for assessing menstrual cycle phase, quality 
of RNA sample used for microarray hybridisation, validation of microarray results and 
unavailable participant information.  
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All these factors were evaluated for every individual study by a single reviewer (MS). The sample 
size of the studies was considered to be adequate if the number of participants in each group was 
more than 20, as this is thought of as acceptable for small qualitative research projects (Mason, 
2010, Guest et al., 2006, Hedges and Bliss-Holtz, 2006). The histological assessment of the 
endometrial samples was required to be conducted by a histopathologist who was not aware of the 
participant’s history and other details. The criteria for assessing the menstrual cycle phase of the 
endometrial samples were published such as the Noyes criteria. The quality of RNA used for 
hybridisation with the microarray chips should have been assessed by either gel electrophoresis or 
Agilent’s Bioanalyzer. The results obtained by microarray analysis should have been further 
validated by RT-PCR. The clinical characteristics of the individual participants should have been 
available.  
 
After assessing the methodology of every individual study included in this meta-analysis for the 
above-mentioned factors it was found that all the studies had potential risk of bias. However, the 
potential for risk was low for the studies; hence all the studies were included in the meta-analysis.   
 
3.4.4 Measures of effect 
In this meta-analysis of gene expression data comparing eutopic endometrium from women with 
and without endometriosis and endometriotic lesions, the fold-change values of genes were 
considered to be the measures of effect. Gene expression and dysregulation data were continuous. 
For individual participant gene expression data, the results were expressed as mean difference ± 
standard error (SE). For published gene lists, the results were continuous and expressed as ranks 
given to the genes (Kolde et al., 2012).   
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3.4.5 Dealing with unavailable data 
Information regarding menstrual cycle phase was unavailable for Hull et al. (2008). Individual 
participant data describing menstrual cycle phase was required for sub-group analyses to 
determine dysregulated genes in different menstrual cycle phases in women with and without 
endometriosis. Corresponding author was contacted in an attempt to obtain the unavailable 
participant data, but unfortunately no replies were received. Therefore, Hull et al. (2008) was 
excluded from menstrual cycle sub-group analyses.  
 
3.4.6 Assessment of heterogeneity 
Participant characteristics from different studies were reviewed for heterogeneity to explore their 
influence on the results of the meta-analysis. The characteristics for which information was 
available, such as severity or stage of endometriosis and parity, are not known to impact pain and 
so were not formally assessed for heterogeneity (Vercellini et al., 2007, Gruppo Italiano per lo 
Studio, 2001, Fauconnier and Chapron, 2005). Moreover, participant characteristics were not 
available for all of the included studies; therefore, were not assessed for heterogeneity.  
 
3.4.7 Assessment of reporting bias 
Reporting bias may arise when dissemination of studies gets influenced by the nature of the 
results. Positive and significant results increase the likelihood of such studies to be published 
quicker, in English, in significant journals and occasionally more than once. In order to reduce the 
chances of reporting bias, a comprehensive literature review, including searching of microarray 
data repositories, for eligible studies was conducted to minimise any potential reporting bias. Care 
was taken not to include data that have been published more than once.  
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3.5 Data analysis 
Analyses of data are detailed below. Briefly, analyses were conducted by grouping the studies 
according to the type of data available, i.e. individual participant gene expression data or 
published gene lists, analysing for dysregulated genes and pathways, and then converging the 
results from both the analyses to determine consistently dysregulated genes. Figure 3.2 provides 
an overview of the steps undertaken in this meta-analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3.3: Flow-chart illustrating an overview of the steps undertaken in the present meta-
analysis. 
Individual dataset pre-processing  
Quality assessment of individual 
datasets 
Datasets combined  
Analysed for gene interaction by 
hierarchical clustering  
Extraction of individual 
participant gene expression data 
Extraction of prioritised gene lists 
Standardisation 
Convergence of results from the two 
analyses   
Analysed for gene dysregulation Analysed for gene dysregulation 
Gene lists combined  
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For both the individual participant gene expression data and published gene lists, gene expression 
was compared between eutopic endometrium from women and without endometriosis as well as 
endometriotic lesions and eutopic endometrium from women with endometriosis. For individual 
participant gene expression data, the groups were further analysed after adjusting for menstrual 
cycle phases. This could not be done for published gene lists as the required information and data 
were not available.  
 
For every study, the individual participant gene expression data were extracted from their 
respective accession sites, pre-processed and assessed for quality. All the datasets were then 
integrated into one global dataset and analysed for dysregulated genes and pathways. The 
dysregulated genes were further analysed to determine the correlation amongst their expression 
levels.  
 
The published gene lists were extracted from their respective studies, standardised and integrated 
for analysis of dysregulated genes. The dysregulated gene were further analysed to determine the 
pathways most affected by them. Lists of dysregulated genes obtained from both the analyses of 
individual participant gene expression data and published gene lists were then converged to 
determine gene that are consistently dysregulated across the datasets. 
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3.5.1 Meta-analysis of individual participant gene expression data 
In conducting a gene expression meta-analysis, individual participant gene expression data are 
preferable as this allows for consistent handling of all the datasets by standardised preprocessing 
(Ioannidis et al., 2002, Stewart and Parmar, 1993). Another advantage of using individual 
participant gene expression data is that along with published data, unpublished data can be also 
included (for example, the Zevallos 2012 dataset included in this meta-analysis). Array quality can 
also be evaluated and the poorer quality ones subsequently removed from further analyses 
(Ramasamy et al., 2008).   
 
3.5.1.1 Data pre-processing and normalisation 
Pre-processing of all individual datasets was performed using GeneSpring version 12.6.2. This is 
an essential step in microarray analyses as it allows the assessment of data quality and conversion 
of microarray data to gene expression values which can be further analysed. It also minimises any 
differences that might occur due to technical reasons, also known as noise, and ensures that results 
attained are of highest quality (Zhang et al., 2006, Lu et al., 2012, Agilent, 2013).  
 
Data uploaded to GeneSpring, were automatically pre-processed depending on the type of 
microarray used (see Appendix 4).  Pre-processing consists of the following steps:  
 background correction to ensure accurate measures of intensity for each spot on the 
microarray chip by reducing affects arising due to non-specific sources;  
 normalisation to ensure that any differences that exist between samples are due to biological 
rather than technical variations;  
 correction for non-specific binding to ensure that all the miss-matched spots are removed; and 
 summarisation of the data into an expression value for the gene in question (Agilent, 2013, 
Wu, 2009). 
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For Affymetrix platform data, pre-processing was performed using robust multi-array analysis 
(RMA) algorithm. RMA algorithm converts probe-level data to measures of gene expression using 
positive signal intensities for probe-level normalisation, and reduces noise in the data (Irizarry et 
al., 2003). The probe intensities are corrected using a global model for probe intensity distribution. 
Observed probes are modelled as the sum of a normal noise component N (normal with mean µ 
and variance σ2) and an exponential signal component s (exponential with mean α). To avoid any 
possibilities of getting any negative values the normal is truncated at zero. Given there are O 
observed intensities, the following adjustment is applied: 
𝐸 (𝑠 𝑂 = 0) = 𝑎 + 𝑏
φ (
𝑎
𝑏
) − φ (
0−𝑎
𝑏
)
Φ (
𝑎
𝑏
) + φ (
0−𝑎
𝑏
) − 1
⁄  
where a = s−µ−σ2α and b = σ. Note that φ and Φ are the standard normal distribution density and 
distribution functions, respectively. The log2 transformed value of each background corrected, 
perfect-matched probe is obtained and these values are normalised using quantiles normalisation 
method which makes the array comparable against each other and gives an expression measure for 
each probe (Irizarry et al., 2003). RMA is then carried out on the expression measures obtained. 
RMA16 was used for Affymetrix Exon Expression platform data - this involves the addition 16 to 
expression values prior to log-transformation to stabilise the data (provides the required 
stabilisation effect without changing or suppressing true signal values as values smaller than 16 
are due to noise; Agilent, 2013).  
 
Pre-processing for Agilent single colour platform data was by percentile shift. Percentile shift 
adjusts the locations of all spot intensities in an array. Each column in an experiment is taken 
independently and the nth percentile (where n = 0 to 100) of the expression values for an array is 
computed across all spots. This value is then subtracted from the expression value of each entity. 
The percentile is subtracted from the expression value to give the normalised intensity value. A 
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default value of 75 was chosen for normalisation as this value is more robust and makes sure that 
only genes that are expressed are reported (Agilent, 2013). 
 
3.5.1.2 Quality assessment of datasets 
Box plots obtained after pre-processing of individual datasets were assessed in order to evaluate 
the dataset quality. Box plots were constructed using log2 transformed probe intensity values. 
Each boxplot from a dataset represents the distribution of probe intensity values for an individual 
sample, with the middle line representing the median, the whiskers indicating the variability 
outside the upper and lower quantiles, and the outliers represented by the individual points outside 
the whiskers (as shown in Fig. 3.4).  
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Figs. 3.4 a-h: Box plots illustrating sample-wise log-2 transformed probe intensity values of 
normalised data from individual participant gene expression studies: (a) Crispi et al. 2013; 
(b) Sohler et al. 2013; (c) Zevallos 2008; (d) Khan et al. 2012; (e) Burney et al. 2007; (f) 
Hever et al. 2007; (g) Hull et al. 2008; (h) Talbi et al. 2006. Each boxplot represents the 
distribution of probe intensity values for an individual sample, the middle line representing 
the median, the whiskers indicating the variability outside the upper and lower quantiles, 
and individual points outside the whiskers, the outliers. Encircled box plots in (d) represent 
problematic array which may be discarded from further analysis. 
 
The box plots with a uniform spread of probe intensity values for individual samples across 
dataset in each study indicate ideal sample quality. However, Figure 3.4 (d) does not have a 
uniform spread of normalised log2-transformed intensity values, especially for samples 5, 6, 10, 
12, 16 and 18. This indicates that these samples may be of poor quality and should be removed 
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from further analysis. However, te box plot created after convergence of all the individual 
participant gene expression datasets shows a uniform spread of probe intensity values for all the 
samples; therefore all the samples were retained for further analysis (Fig. 3.5). 
 
 
Fig. 3.5: Box plot illustrating uniform probe intensity values for individual participant gene 
expression data of all datasets obtained after convergence. Each boxplot represents the 
distribution of probe intensity values for an individual sample, the middle line representing 
the median, the whiskers indicating the variability outside the upper and lower quantiles, 
and individual points outside the whiskers, the outliers. 
 
3.5.1.3 Cross-platform integration of datasets  
ArrayMining was chosen to conduct individual participant gene expression data meta-analysis as 
it offers cross-platform integration of data (Glaab et al., 2009). ArrayMining conducts statistical 
microarray analyses and generates output webpages with downloadable results in the form of plots 
and tables. Pre-processed data obtained from GeneSpring (in tab-delimited text-file format) were 
uploaded to ArrayMining as per the programme’s instructions (Glaab et al., 2009). ENTREZ gene 
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IDs were selected as common identifiers across datasets as they are stable and regularly updated 
(Maglott et al., 2011). Each sample of the dataset was labelled according to the group it belonged 
to, with ‘0’ for endometrium from women without endometriosis, ‘1’ for endometrium from 
women with endometriosis, ‘2’ for endometriotic lesions, ‘P’ for proliferative phase and ‘S’ for 
secretory phase. Any missing values in the data files were labelled as ‘NA’. Two data files at a 
time were uploaded in compressed zip formats and integrated by XPN method. 
 
The XPN method for cross-platform integration, devised by Shabalin et al. (2008), integrates gene 
expression data from different studies by clustering together samples and genes with similar 
expression characteristics to produce a unified dataset which can be statistically analysed. This is 
done in two steps. The first step is to find clusters of similar genes and samples across datasets by 
k-means clustering. In the second step, with in each of these clusters, a combination of weighted 
averages of the platform parameters is applied to normalise the data across platforms (Deshwar 
and Morris, 2014, Sirbu et al., 2010, Tsiliki et al., 2011). This procedure runs multiple times in 
order to account for all possible clustering patterns. The output generated is a unified dataset 
containing genes/probes that are common across all datasets (Tsiliki et al., 2011, Deshwar and 
Morris, 2014).  
 
Before starting the method three parameters are required to be set: number of gene clusters, 
numbers of sample clusters and number of iterations. Although the method is robust to these 
parameters, however it is recommended that the number of genes clusters should be between 10 
and 30, number of sample clusters should be between 5 and 8, and number of iteration should be 
between 10 and 30. Choosing values that are too low or too high can degrade the performance of 
the method (Shabalin et al., 2008). In the present meta-analysis, default values of the parameters 
were chosen.  
68 
 
 
3.5.1.4 Clustering of samples 
After all the individual datasets were integrated into a single dataset, samples were clustered into 
discrete groups according to their disease status (with or without endometriosis) or menstrual 
cycle phase (proliferative or secretory phase). This helps in visualising how the samples are 
grouped together based on similarity of gene expression and provides an integrated understanding 
of the association between the condition (endometriosis) and the gene expression (Makretsov et 
al., 2004, Eisen et al., 1998, Alberts et al., 2002). For this, Hierarchical Clustering method (HCL) 
in ArrayMining was chosen. It joins together the most similar pair of samples, and then identifies 
and pairs the next most similar samples, repeating the procedure till all the samples in the dataset 
are merged into one cluster (Makretsov et al., 2004, Alberts et al., 2002). It calculates the 
similarity between samples by assigning each sample its own cluster and averaging the distance 
between all the members of the two closest clusters (Eisen et al., 1998). It also increases the 
robustness and reliability of the statistical tests applied to the dataset (Glaab et al., 2009).  
 
The gene expression values for each sample in the integrated dataset were standardised by 
choosing the Robust Median Absolute Deviation from the drop down menu (MAD; Gentleman et 
al., 2005) in order to better distinguish samples into separate groups based on gene expression 
pattern (Glaab et al., 2009). For each row, Robust MAD subtracts the median gene expression 
value from the expression value of the particular gene and divides it by the median absolute 
deviation (Gentleman et al., 2005). A variance filter was also applied to standardised data to retain 
2000 genes with the highest variance across samples. This removes all irrelevant genes with low 
variance across samples as well as improves the interpretability of the results (Tritchler et al., 
2009). 
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3.5.1.5 Detection of dysregulated genes 
Gene expression output from the hierarchical clustering of samples was analysed within 
ArrayMining to identify dysregulated genes in endometriosis. To evaluate gene dysregulation 
following comparisons were made: 
 Eutopic endometrium from women with and without endometriosis 
o overall  
o proliferative phase of menstrual cycle 
o secretory phase of the menstrual cycle 
o proliferative phase vs. secretory phase of the menstrual cycle in eutopic 
endometrium from women with endometriosis    
 Eutopic endometrium and endometriotic lesions from women with endometriosis 
o overall  
o proliferative phase of menstrual cycle 
o secretory phase of the menstrual cycle 
o proliferative phase vs. secretory phase of the menstrual cycle in endometriotic 
lesions  
 
This was conducted using moderated t-statistics, which has the same interpretation as an ordinary 
t-test but is more likely to have a moderate value based on a more reliable variance estimate with 
higher number of degrees of freedom. This often gives a more significant p-value which is 
adjusted by controlling the false discovery rate (FDR; Smyth, 2004).  
 
The Benjamini and Hochberg (1995) method, which tests thousands of hypotheses 
simultaneously, was applied for the strong control of false discovery rate (FDR) . The resulting 
outcome was a list of genes with known gene identifiers (ENTREZ gene IDs). Genes with an 
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FDR-based significance score (P score) < 0.05 and fold-change in expression >1.5 were 
considered as significant. 
 
3.5.1.6. Interactions amongst dysregulated genes  
The expression values of pain related genes obtained from analysing individual participant gene 
expression data for all the sub-groups were uploaded to Cluster 3.0. The data were imported as a 
tab-delimited text file with rows representing the genes and columns representing their expression 
values. This was done in order to determine if the genes involved in neuronal development, 
sensitisation due to inflammation, signal transduction, conduction and modulation influence 
expression levels of one another, which may contribute to the enhanced pain generation observed 
in women with endometriosis. To compute these interactions, Pearson’s correlation coefficient 
was calculated. The correlation coefficient provides a measure of the linear association between 
two continuous variables, ranging from -1 to +1. A negative value indicates that the expression of 
one gene decreases with an increase in expression of the other gene. A positive value indicates that 
the expression of one gene increases with an increase in expression of the other. A value of zero 
indicates no association. 
 
The most correlated genes were then clustered together by hierarchical clustering. In hierarchical 
clustering, the distance matrix between gene expression data is calculated. To compute the 
distance matrix, average linkage clustering was applied in which each gene is assigned its own 
cluster. Then, the distance between two clusters x and y is the mean of all pair wise distances 
between all the items contained in x and y. The genes closest to each other are clustered together 
and this process continues until all the genes have been incorporated in a single cluster. The 
output, a dendogram showing clustered genes (see Fig. 3.6) was visualised using Tree View 
software (©1998-2000, Stanford University, written by Michael Eisen).  
71 
 
 
 
 
Fig. 3.6. Figure illustrating clustering of genes by hierarchical clustering method with gene 
clusters on the left and gene names on the right. The smaller the dendograms the more 
correlated are the genes. 
 
3.5.1.7 Detection of dysregulated pathways 
The dysregulated genes were aggregated into functionally related genes to form gene sets using 
ArrayMining. Within the program, dysregulated pathways were annotated using the Gene 
Ontology database, which identifies functionally related genes in a dataset. The parametric 
analysis of gene set enrichment method was chosen to detect dysregulated pathways. It is a robust 
method which requires less computation and detects dysregulated gene sets across different 
platforms. It uses a parametric statistical model to define significantly expressed gene sets and 
employs a fold change between the groups and calculates a z-score, the measure of dysregulation 
and a significance score (P value), respectively for a gene set  (Kim and Volsky, 2005). Pathways 
with a P value < 0.05 were considered significant. 
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3.5.2 Meta-analysis of published gene lists 
Individual participant gene expression data was unavailable for some gene expression studies. 
Using published analyses of datasets and integrating the available gene lists provides an 
alternative approach for meta-analysis of gene expression data (Kolde et al., 2012, Miller and 
Stamatoyannopoulos, 2010, Cahan et al., 2007, Al-Ejeh et al., 2014, Peri et al., 2013). However, 
gene expression data usually contains a significant proportion of technical variation, hence a 
robust method is required to find accurate ranking even if the lists contain only top-most 
dysregulated genes (Kolde et al., 2012). Rank aggregation based on ordered statistics is a meta-
analysis method for published gene lists (Stuart et al., 2003, Aerts et al., 2006).  
 
3.5.2.1 Extraction and standardisation of published gene lists 
Published gene lists consist of up or downregulated genes with a measure of significance and fold 
change showing the difference of expression between disease and control groups (Vosa et al., 
2013). For the present meta-analysis, published gene lists from all relevant studies (see Table 3.2) 
were extracted, and up and downregulated genes listed separately. Gene names across different 
lists were standardised with the gene annotation tool Database for Annotation, Visualization and 
Integrated Discovery (DAVID) which systematically combines functionally descriptive data with 
graphical displays (Huang da et al., 2009). Each gene list was uploaded into DAVID, the type of 
identifier selected and submitted for mapping to obtain standardised gene names.   
 
3.5.2.2 Gene list integration and detection of dysregulated genes  
The robust rank aggregation, proposed by Kolde et al. (2012) integrates published gene lists into a 
single list of commonly dysregulated genes. It can even be used in cases where the datasets are 
from different platforms and cover different sets of genes (Ma et al., 2013b). This method assumes 
that the number of genes in the lists is known and the ranks of the genes are according to their 
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dysregulation in the disease (endometriosis). Then, the corresponding rank vectors for every gene 
rank are calculated and assigned a significance score under a null mode. The null model assumes 
that all the studies produce uncorrelated, irrelevant lists of genes. Since the gene ranks are solely 
based on the expression measurements, the null model becomes equivalent to a permutation test 
(Kolde et al., 2012). The significance scores provide a rigorous way of keeping only statistically 
relevant genes in the final list. This method is implemented as a GNU R package 
ROBUSTRANKAGGREG (step wise description of the procedure is given in Appendix 5). 
 
3.5.2.3 Detection of dysregulated pathways  
The dysregulated genes detected in the published gene lists meta-analysis were further analysed 
for detection of pathways most affected by them. This was conducted by the Gene Ontology (GO) 
enrichment analysis tool of the GO consortium (available from http://geneontology.org/). For a 
group of genes, the enrichment analysis tool finds GO terms that are over- or under-represented. 
The gene names were pasted, one per row, in the designated area. Then, the name of the species 
(H. sapiens) and the ontology (biological processes) where the enrichment is required to be 
calculated were chosen from the drop-down menu. The results were displayed as a list of 
significant GO terms, background frequency (the number of genes annotated to a GO term in the 
entire background), sample frequency (the number of genes annotated to that GO term in the input 
list) and the corresponding p values. In addition, the criteria used and any unresolved gene names 
in the analysis were also listed on the top of the table.   
 
\3.6 Convergence of results 
The dysregulated genes detected in the meta-analyses of individual participant gene expression as 
well as the published gene lists comparing gene expression of eutopic endometrium from women 
with and without endometriosis as well as endometriotic lesions were converged by using Venn 
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diagrams. Venn diagrams provide multiple circles with overlapping regions which illustrate 
relations among datasets. This is conducted by calculating all possible logical relations between 
the given datasets and representing them in the same diagram (Li and Ghosh, 2014, Michael et al., 
2011, Granlund et al., 2013). 
 
NetVenn software was applied to converge the results of analysing individual participant gene 
expression data and published gene lists for this meta-analysis (Wang et al., 2014; freely available 
from http://probes.pw.usda.gov/NetVenn or http://wheat.pw.usda.gov/NetVenn). It compares and 
analyses gene expression datasets and provides information regarding the biological function of 
the genes by interactively annotating each element with their potential biological networks 
annotation databases such as Gene Ontology (Wang et al., 2014). The lists to be converged were 
pasted on to the designated columns and submitted for analysis. An output with interactive graphs 
is the generated which illustrates overlapping circles showing overlapping genes from the 
provided lists. 
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Chapter 4 
Results 
 
4.1 Individual participant gene expression data 
4.1.1 Eutopic endometrium from women with and without endometriosis 
Overall, 32 genes involved in neuronal development, sensitisation due to inflammation, signal 
transduction, conduction and modulation (the pain matrix) were significantly upregulated in the 
eutopic endometrium of women with endometriosis compared to women without the disease 
(Table 4.1). The downregulated genes in the eutopic endometrium from women with 
endometriosis were involved in processes such as, embryogenesis, tumorogenesis, general cell 
development and cell cycle regulation. A list of the 35 most significantly upregulated and 
downregulated genes in the eutopic endometrium of women with endometriosis (overall) are 
provided in Appendices 6 and 7, respectively.  
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Table 4.1: Upregulated pain related genes in the eutopic endometrium of women with 
endometriosis compared to endometrium from women without endometriosis.  
Entrez Id Gene symbol Gene name 
Fold 
change P value 
Neuronal development  
1942 EFNA1  Ephrin-A1 2.64 0.4 X 10
-22
 
1808 DPYSL2  Dihydropyrimidinase-like 2 1.91 0.1 X 10
-14
 
10397 NDRG1 N-myc downstream regulated 1 2.11 0.1 X 10
-14
 
8495 PPFIBP2  PTPRF interacting protein, binding protein 2  1.8 0.1 X 10
-13
 
604 BCL6  B-cell CLL/lymphoma 6 2.86 0.3 X 10
-13
 
91 ACVR1B  Activin A receptor, type IB 1.69 0.4 X 10
-13
 
81631 MAP1LC3B  
Microtubule-associated protein 1 light chain 
3 beta 
1.52 0.1 X 10
-12
 
10677 AVIL Advillin 1.95 0.1 X 10
-12
 
Sensitisation due to inflammation 
  1052 CEBPD CCAAT/enhancer binding protein 3.14 0.2 X 10
-18
 
3600 IL15  Interleukin 15 2.98 0.2 X 10
-16
 
1438 CSF2RA  
Colony stimulating factor 2 receptor, alpha, 
low-affinity 
2.02 0.2 X 10
-16
 
7132 TNFRSF1A  
Tumor necrosis factor receptor superfamily, 
member 1A 
1.55 0.2 X 10
-15
 
26253 CLEC4E  C-type lectin domain family 4, member E 1.7 0.3 X 10
-14
 
718 C3 Complement component 3 2.93 0.2 X 10
-13
 
9252 RPS6KA5 
Ribosomal protein S6 kinase, 90kDa, 
polypeptide 5 
2.13 0.2 X 10
-13
 
7099 TLR4  Toll-like receptor 4 1.75 0.1 X 10
-12
 
3601 IL15RA  Interleukin 15 receptor, alpha 1.49 0.2 X 10
-12
 
Signal transduction 
   4217 MAP3K5 Mitogen-activated protein kinase kinase 5 3.15 0.3 X 10
-17
 
347902 AMIGO2  Adhesion molecule with Ig-like domain 2 3.09 0.3 X 10
-15
 
5597 MAPK6 Mitogen-activated protein kinase 6 1.95 0.8 X 10
-13
 
6774 STAT3 
Signal transducer and activator of 
transcription 3 
1.42 0.2 X 10
-12
 
Conduction 
   2040 STOM Stomatin 1.73 0.3 X 10
-13
 
3752 KCND3 
Potassium voltage-gated channel, Shal-
related subfamily, member 3 
1.76 0.2 X 10
-12
 
Modulation 
   6505 SLC1A1  Solute carrier family 1 member 1 4.71 0.5 X 10
-21
 
6539 SLC6A12  Solute carrier family 6 member 12 2.53 0.6 X 10
-20
 
54463 FAM134B 
Family with sequence similarity 134, 
member B 
1.98 0.3 X 10
-16
 
3976 LIF  Leukemia inhibitory factor 2.74 0.1 X 10
-14
 
9846 GAB2  GRB2-associated binding protein 2 1.99 0.3 X 10
-14
 
5533 PPP3CC 
Protein phosphatase 3, catalytic subunit, 
gamma isozyme 
1.49 0.9 X 10
-14
 
3572 IL6ST  Interleukin 6 signal transducer  2.41 0.4 X 10
-13
 
80736 SLC44A4  Solute carrier family 44, member 4 2.35 0.5 X 10-
13
 
81539 SLC38A1  Solute carrier family 38, member 1 2.09 0.2 X 10
-12
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Dysregulated pathways. Overall, the most significantly dysregulated pathways were related to 
inflammatory and immune responses (top-20 most dysregulated pathways in Appendix 8). 
 
Interactions amongst genes. Formation of clusters amongst genes involved in sensitisation due to 
inflammation, neuronal development and pain generation is illustrated in the figure (see Fig. 4.1). 
In the figure, the dendograms on the left represent correlations between the gene expression 
values. The smaller the dendogram, the more correlated are the expression values of the genes. 
This implies that these genes are functionally related and may regulate each other’s expression, 
thereby contributing to increased pain generation observed in women with endometriosis. 
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Fig. 4.1: Interactions among upregulated pain related genes in the eutopic endometrium of 
women with endometriosis. The dendograms on the left illustrate correlation amongst genes 
expression values. The shorter the dendograms, the more correlated are the genes.  
 
4.1.1.1 Proliferative phase 
Twenty genes involved in the pain matrix were significantly upregulated in the eutopic 
endometrium of women with compared to women without endometriosis (see Table 4.2). The 
downregulated genes were mostly involved in cell cycle regulation, tumorogenesis, apoptosis and 
transcription. A list of top-35 upregulated and downregulated genes in the proliferative phase is 
provided in Appendices 9 and 10, respectively.  
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Table 4.2: Upregulated pain related genes in the proliferative phase of the eutopic 
endometrium of women with endometriosis compared to women without endometriosis. 
Entrez 
ID 
Gene 
symbol 
Gene name 
Fold 
Change 
P value 
Neuronal development 
1942 EFNA1  Ephrin-A1 1.95 0.0006 
604 BCL6  B-cell CLL/lymphoma 6 2.15 0.004 
10397 NDRG1 N-myc downstream regulated 1 1.71 0.011 
2026 ENO2  Enolase 2 (gamma, neuronal) 1.4 0.023 
Sensitisation due to inflammation 
9510 ADAMTS1 
ADAM metallopeptidase with thrombospondin 
type 1 motif, 1 
1.92 0.009 
6347 CCL2  Chemokine (C-C motif) ligand 2 1.63 0.021 
1051 CEBPB  CCAAT/enhancer binding protein (C/EBP), beta 1.37 0.004 
1052 CEBPD CCAAT/enhancer binding protein (C/EBP), delta 2.17 0.005 
1999 ELF3  
E74-like factor 3 (ets domain transcription factor, 
epithelial-specific ) 
1.83 0.007 
5732 PTGER2 Prostaglandin E receptor 2 (subtype EP2), 53kDa 1.45 0.02 
54210 TREM1 Triggering receptor expressed on myeloid cells 1 1.85 0.01 
Signal transduction 
4217 MAP3K5 Mitogen-activated protein kinase kinase kinase 5 1.79 0.02 
1326 MAP3K8 Mitogen-activated protein kinase kinase kinase 8 1.45 0.02 
2872 MKNK2  MAP kinase interacting serine/threonine kinase 2 1.29 0.004 
9961 MVP  Major vault protein 1.43 0.02 
Conduction 
6533 SLC6A6  
Solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 
1.47 0.004 
Modulation 
23529 CLCF1  Cardiotrophin-like cytokine factor 1 1.36 0.008 
3659 IRF1  Interferon regulatory factor 1 1.38 0.02 
3976 LIF  
Leukemia inhibitory factor (cholinergic 
differentiation factor) 
1.87 0.02 
80736 SLC44A4  Solute carrier family 44, member 4 1.71 0.02 
 
Dysregulated pathways. Processes involved in immune and inflammatory responses were among 
the top dysregulated pathways in the proliferative phase of the eutopic endometrium from women 
with endometriosis (see Appendix 8 for 20-top most dysregulated pathways). 
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4.1.1.2 Secretory phase 
Seventeen genes involved in neuronal development, sensitisation due to inflammation, signal 
transduction and modulation in the secretory phase eutopic endometrium of women with 
endometriosis were significantly upregulated when compared to women without endometriosis 
(see Table 4.3). The downregulated genes in the secretory phase were those involved in 
embryogenesis, apoptosis, cell growth and differentiation as well as muscle contraction. A list of 
top-35 upregulated and downregulated genes in the secretory phase is provided in Appendices 11 
and 12, respectively.  
 
Table 4.3: Upregulated pain related genes in the secretory phase of the eutopic endometrium 
of women with endometriosis compared to women without endometriosis.  
Entrez 
ID 
Gene 
Symbol 
Gene name 
Fold 
Change 
P value 
Neuronal development 
1942 EFNA1  Ephrin-A1 2.4 0.6 X10
-14
 
10397 NDRG1 N-myc downstream regulated 1 1.9 0.4 X10
-12
 
8495 PPFIBP2  
PTPRF interacting protein, binding protein 2 
(liprin beta 2) 
2 0.3 X10
-11
 
604 BCL6  B-cell CLL/lymphoma 6 2.1 0.7 X10
-10
 
Sensitisation due to inflammation 
145741 C2CD4A C2 calcium-dependent domain containing 4A 7.1 0.1 X10
-14
 
9547 CXCL14  Chemokine (C-X-C motif) ligand 14 9 0.3 X10
-11
 
718 C3 Complement component 3 3.3 0.1 X10
-10
 
1052 CEBPD CCAAT/enhancer binding protein (C/EBP), delta 2.4 0.1 X10
-9
 
Signal transduction 
4217 MAP3K5 Mitogen-activated protein kinase kinase kinase 5 3.3 0.9 X10
-14
 
347902 AMIGO2  Adhesion molecule with Ig-like domain 2 2.8 0.7 X10
-13
 
Conduction 
No. of genes : 0 
Modulation 
6505 SLC1A1  
Solute carrier family 1 (neuronal/epithelial high 
affinity glutamate transporter, system Xag), 
member 1 
7.4 0.1 X10
-14
 
54463 FAM134B Family with sequence similarity 134, member B 2.2 0.4 X10
-11
 
9180 OSMR Oncostatin M receptor 2.2 0.1 X10
-10
 
3976 LIF  Leukemia inhibitory factor  2.6 0.2 X10
-10
 
80736 SLC44A4  Solute carrier family 44, member 4 2.1 0.3X10
-10
 
81539 SLC38A1  Solute carrier family 38, member 1 2.5 0.1 X10
-9
 
3572 IL6ST  Interleukin 6 signal transducer 2.1 0.2 X10
-9
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Dysregulated pathways. The top dysregulated pathways involved processes such as immune and 
inflammatory responses (see Appendix 8 for 20-top most dysregulated pathways). 
 
4.1.1.3 Eutopic endometrium from women with endometriosis: Secretory vs. proliferative 
phase  
In the eutopic endometrium from women with endometriosis, 30 genes involved in the pain matrix 
were significantly upregulated in the secretory phase when compared to the proliferative phase of 
the menstrual cycle (see Table 4.4). Genes involved in processes, such as cellular proliferation and 
cell cycle regulation were downregulated. A list of top-35 upregulated and downregulated genes in 
the secretory phase is provided in Appendices 13 and 14, respectively.  
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Table 4.4: Upregulated pain related genes in the secretory phase of eutopic endometrium of 
women with endometriosis. 
Entrez 
ID 
Gene 
symbol 
Gene name 
Fold 
change 
P value 
Neuronal development 
4684 NCAM1 Neural cell adhesion molecule 1 2.79 0.7 X10
-12
 
10397 NDRG1 N-myc downstream regulated 1 2.76 0.2 X10
-8
 
1808 DPYSL2  Dihydropyrimidinase-like 2 2.17 0.1 X10
-7
 
Sensitisation due to inflammation 
5578 PRKCA Protein kinase C, alpha 1.8 0.4 X10
-9
 
10855 HPSE Heparanase 3.07 0.8 X10
-9
 
1116 CHI3L1  Chitinase 3-like 1 (cartilage glycoprotein-39) 3.46 0.2 X10
-8
 
2532 DARC  Duffy blood group, chemokine receptor 2.85 0.4 X10
-8
 
1435 CSF1 Colony stimulating factor 1 (macrophage) 2.35 0.6 X10
-8
 
2268 FGR  
Gardner-Rasheed feline sarcoma viral (v-fgr) 
oncogene homolog 
2.77 0.3 X10
-7
 
Signal transduction 
5791 PTPRE Protein tyrosine phosphatase, receptor type, E 3.01 0.1 X10
-10
 
7223 TRPC4 
Transient receptor potential cation channel, 
subfamily C, member 4 
3.38 0.4 X10
-9
 
916 CD3E CD3e molecule, epsilon (CD3-TCR complex) 2.41 0.5 X10
-8
 
79054 TRPM8 
Transient receptor potential cation channel, 
subfamily M, member 8 
2.71 0.7 X10
-7
 
3718 JAK3 Janus kinase 3 1.72 0.1 X10
-6
 
6777 STAT5B  Signal transducer and activator of transcription 5B 1.56 0.1 X10
-6
 
Conduction 
3777 KCNK3 Potassium channel, subfamily K, member 3 2.64 0.3 X10
-8
 
3749 KCNC4 
Potassium voltage-gated channel, Shaw-related 
subfamily, member 4 
1.83 0.3 X10
-7
 
6548 SLC9A1  
Solute carrier family 9 (sodium/hydrogen 
exchanger), member 1 
1.92 0.9 X10
-7
 
3756 KCNH1 
Potassium voltage-gated channel, subfamily H 
(eag-related), member 1 
1.76 0.1 X10
-6
 
55117 SLC6A15  
Solute carrier family 6 (neutral amino acid 
transporter), member 15 
2.11 0.1 X10
-6
 
Modulation 
6539 SLC6A12  
Solute carrier family 6 (neurotransmitter 
transporter, betaine/GABA), member 12 
3.02 0.3 X10
-8
 
6812 STXBP1 Syntaxin binding protein 1 2.53 0.9 X10
-8
 
9180 OSMR Oncostatin M receptor 2.36 0.1 X10
-7
 
6505 SLC1A1  
Solute carrier family 1 (neuronal/epithelial high 
affinity glutamate transporter, system Xag), 
member 1 
4.23 0.4 X10
-7
 
27092 CACNG4 
Calcium channel, voltage-dependent, gamma 
subunit 4 
2.28 0.1 X10
-6
 
3352 HTR1D 5-Hydroxytryptamine (serotonin) receptor 1D 1.95 0.1 X10
-6
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Dysregulated pathways. Pathways involved in cytokine activity as well as potassium ion channel 
activity were amongst the most upregulated (see Appendix 8 for a list of top-20 dysregulated 
pathways). 
 
4.1.2 Endometriotic lesions compared to eutopic endometrium from women with 
endometriosis 
Thirty genes involved in the pain matrix were significantly upregulated in the endometriotic 
lesions when compared to eutopic endometrium from women with endometriosis, overall (see 
Table 4.5). The downregulated genes were involved in proton conductance, embryonic 
development, DNA repair and cancer-related processes. A list of top-35 up and downregulated 
genes is given in Appendices 15 and 16, respectively.  
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Table 4.5: Upregulated pain related genes in the endometriotic lesions compared to eutopic 
endometrium from women with endometriosis. 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
Change 
P value 
Neuronal development 
1942 EFNA1  Ephrin-A1 1.83 0.4 X10
-14
 
10397 NDRG1 N-myc downstream regulated 1 1.79 0.9 X10
-9
 
10677 AVIL Advillin 1.63 0.5 X10
-8
 
91 ACVR1B  Activin A receptor, type IB 1.5 0.1 X10
-6
 
Sensitisation to inflammation 
9547 CXCL14  Chemokine (C-X-C motif) ligand 14 4.03 0.9 X10
-10
 
7099 TLR4  Toll-like receptor 4 1.6 0.9 X10
-9
 
3600 IL15  Interleukin 15 2.11 0.1 X10
-8
 
9180 OSMR Oncostatin M receptor 1.86 0.2 X10
-8
 
4982 TNFRSF11B  
Tumor necrosis factor receptor superfamily, 
member 11b 
1.76 0.3 X10
-7
 
10855 HPSE Heparanase 1.91 0.3 X10
-7
 
9252 RPS6KA5 
Ribosomal protein S6 kinase, 90kDa, 
polypeptide 5 
1.65 0.4 X10
-7
 
2150 F2RL1  Coagulation factor II (thrombin) receptor-like 1 1.83 0.4 X10
-7
 
1116 CHI3L1  Chitinase 3-like 1 (cartilage glycoprotein-39) 2.68 0.5 X10
-7
 
7127 TNFAIP2  Tumor necrosis factor, alpha-induced protein 2 1.55 0.6 X10
-7
 
9173 IL1RL1  Interleukin 1 receptor-like 1 1.75 0.1 X10
-6
 
Signal transduction 
55890 GPRC5C 
G protein-coupled receptor, family C, group 5, 
member C 
1.56 0.2 X10
-9
 
266977 GPR110 G protein-coupled receptor 110 2.02 0.9 X10
-9
 
4217 MAP3K5 Mitogen-activated protein kinase kinase kinase 5 1.99 0.3 X10
-8
 
302 ANXA2  Annexin A2 1.56 0.1 X10
-6
 
6775 STAT4 Signal transducer and activator of transcription 4 1.54 0.2 X10
-6
 
Conduction 
6505 SLC1A1  
Solute carrier family 1 (neuronal/epithelial high 
affinity glutamate transporter, system Xag), 
member 1 
3.81 0.1 X10
-17
 
6533 SLC6A6  
Solute carrier family 6 (neurotransmitter 
transporter, taurine), member 6 
1.76 0.4 X10
-8
 
3775 KCNK1 Potassium channel, subfamily K, member 1 1.5 0.4 X10
-6
 
Modulation 
6564 SLC15A1  
Solute carrier family 15 (oligopeptide 
transporter), member 1 
2.79 0.2 X10
-12
 
6539 SLC6A12  
Solute carrier family 6 (neurotransmitter 
transporter, betaine/GABA), member 12 
2.05 0.3 X10
-12
 
3976 LIF  Leukemia inhibitory factor 2.28 0.1 X10
-8
 
80736 SLC44A4  Solute carrier family 44, member 4 2.11 0.4 X10
-8
 
2643 GCH1 GTP cyclohydrolase 1 1.71 0.8 X10
-7
 
6571 SLC18A2  
Solute carrier family 18 (vesicular monoamine), 
member 2 
2.47 0.1 X10
-6
 
2555 GABRA2  
Gamma-aminobutyric acid (GABA) A receptor, 
alpha 2 
2.15 0.3 X10
-6
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Dysregulated pathways. The pathways involved in both neuron development and pain modulation 
were found to be significantly upregulated compared to the eutopic endometrium from women 
with endometriosis (see Appendix A17 for a list of top-20 dysregulated pathways). 
 
Interaction amongst genes. It can be seen from the figure that genes involved in the pain matrix 
are functionally related and may regulate the expression of one another (see Fig. 4.2). The 
clustering amongst the genes illustrates that the expression values of the genes are positively 
correlated with each other. The dendograms on the left show clustering amongst correlated genes. 
The shorter the dendograms, the more correlated are the expression values of the genes.  
 
 
Fig. 4.2: Interactions among upregulated pain related genes in endometriotic lesions. The 
dendograms on the left illustrate correlation amongst genes expression values. The shorter 
the dendograms, the more correlated are the genes.   
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4.1.2.1 Proliferative phase 
In the proliferative phase, 28 genes involved in the pain matrix were found to be significantly 
upregulated in endometriotic lesions compared to the eutopic endometrium from women with 
endometriosis (Table 4.6). The significantly downregulated genes were involved in immune 
responses, embryogenesis, tumorogenesis and in encoding proteins for various metabolic 
processes. For a list of top-35 up and downregulated genes, see Appendices 18 and 19, 
respectively.  
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Table 4.6: Upregulated pain related genes in the proliferative phase of the endometriotic 
lesions compared to eutopic endometrium of women with endometriosis. 
Entrez 
ID 
Gene symbol Gene name 
Fold 
Change 
P value 
Neuronal development 
1729 DIAPH1 Diaphanous homolog 1 (Drosophila) 1.2 0.6 X10
-4
 
1906 EDN1  Endothelin 1 1.5 0.3 X10
-3
 
10677 AVIL Advillin 1.3 0.5 X10
-3
 
Sensitisation due to inflammation 
728 C5AR1 Complement component 5a receptor 1 2.2 0.1 X10
-4
 
1051 CEBPB  
CCAAT/enhancer binding protein (C/EBP), 
beta 
1.5 0.1 X10
-4
 
3553 IL1B Interleukin 1, beta 2.3 0.2 X10
-4
 
3576 IL8  Interleukin 8 3.9 0.2 X10
-4
 
1116 CHI3L1  Chitinase 3-like 1 (cartilage glycoprotein-39) 2.9 0.1 X10
-3
 
9173 IL1RL1 Interleukin 1 receptor-like 1 1.6 0.2 X10
-3
 
6696 SPP1 Secreted phosphoprotein 1 2.9 0.2 X10
-3
 
2921 CXCL3  Chemokine (C-X-C motif) ligand 3 2.2 0.3 X10
-3
 
3569 IL6 Interleukin 6 (interferon, beta 2) 1.9 0.3 X10
-3
 
3269 HRH1 Histamine receptor H1 1.4 0.3 X10
-3
 
3659 IRF1 Interferon regulatory factor 1 1.4 0.3 X10
-3
 
4067 LYN  
v-yes-1 Yamaguchi sarcoma viral related 
oncogene homolog 
1.3 0.3 X10
-3
 
9516 LITAF Lipopolysaccharide-induced TNF factor 1.3 0.3 X10
-3
 
10859 LILRB1 
Leukocyte immunoglobulin-like receptor, 
subfamily B (with TM and ITIM domains), 
member 1 
1.2 0.3 X10
-3
 
834 CASP1 
Caspase 1, apoptosis-related cysteine 
peptidase (interleukin 1, beta, convertase) 
1.3 0.4 X10
-3
 
30817 EMR2 
egf-like module containing, mucin-like, 
hormone receptor-like 2 
1.6 0.4 X10
-3
 
4982 TNFRSF11B 
Tumor necrosis factor receptor superfamily, 
member 11b 
1.5 0.6 X10
-3
 
Signal transduction 
5791 PTPRE Protein tyrosine phosphatase, receptor type, E 1.5 0.2 X10
-4
 
1326 MAP3K8 
Mitogen-activated protein kinase kinase 
kinase 8 
1.6 0.3 X10
-4
 
1366 CLDN7  Claudin 7 1.4 0.3 X10
-3
 
5873 RAB27A  RAB27A, member RAS oncogene family 1.3 0.3 X10
-3
 
80232 WDR26 WD repeat domain 26 1.2 0.5 X10
-3
 
Conduction 
3775 KCNK1 Potassium channel, subfamily K, member 1 1.5 0.9 X10
-6
 
Modulation 
3976 LIF Leukemia inhibitory factor  2.4 0.4 X10
-5
 
6539 SLC6A12 
Solute carrier family 6 (neurotransmitter 
transporter, betaine/GABA), member 12 
1.7 0.5 X10
-4
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Dysregulated pathways. In endometriotic lesions, pathways involved in inflammatory and 
immune responses were among the top upregulated pathways (see Appendix 17 for a list of top-20 
dysregulated pathways). 
 
4.1.2.2 Secretory phase 
In the secretory phase, none of the significantly upregulated genes were involved in the pain 
matrix , however genes involved in cell adhesion, proliferation and anti-apoptosis were found to 
be significantly upregulated. A progesterone receptor gene unc-45 homolog A (C. elegans) 
(UNC45A) was significantly downregulated. For a list of top-35 up and down-regulated genes, see 
Appendix 20, respectively.  
 
Dysregulated pathways. There were no significantly upregulated pathways during the secretory 
phase in endometriotic lesions. 
 
4.1.2.3 Endometriotic lesions from women with endometriosis: Secretory vs. proliferative 
phase 
Twenty-five genes involved in neuronal development, signal transduction, conduction and pain 
modulation were significantly upregulated in the secretory phase endometriotic lesions when 
proliferative and secretory phases of the menstrual cycle were compared (Table 4.7). The 
dowregulated genes were mostly involved in cytokinesis, antigen presentation, cancer 
development, apoptosis and immune responses. For a list of top-35 up and downregulated genes, 
see Appendices 21 and 22, respectively.  
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Table 4.7: Upregulated pain related genes in the secretory phase of endometriotic lesions. 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
Change 
P value 
Neuronal development 
4684 NCAM1 Neural cell adhesion molecule 1 4.8 0.00046 
5098 PCDHGA8 Protocadherin gamma subfamily A, 8 2.7 0.00067 
157922 CAMSAP1 Calmodulin regulated spectrin-associated protein 1 2.5 0.00069 
5354 PLP1 Proteolipid protein 1 4.3 0.00081 
4133 MAP2 Microtubule-associated protein 2 2.6 0.00084 
2047 EPHB1  EPH receptor B1 3.7 0.00086 
9752 PCDHA9 Protocadherin alpha 9 2.7 0.00089 
5365 PLXNB3  Plexin B3 2.7 0.00106 
63974 NEUROD6  Neurogenic differentiation 6 2.5 0.00107 
Sensitisation due to inflammation 
No genes 
Signal transduction 
51208 CLDN18  Claudin 18 2.6 0.00081 
607 BCL9  B-cell CLL/lymphoma 9 2.4 0.00082 
7275 TUB Tubby homolog (mouse) 2.3 0.00086 
1432 MAPK14 Mitogen-activated protein kinase 14 2.3 0.00089 
10178 ODZ1  odz, odd Oz/ten-m homolog 1(Drosophila) 3 0.00102 
5567 PRKACB Protein kinase, cAMP-dependent, catalytic, beta 2.1 0.00106 
Conduction 
10479 SLC9A6  
Solute carrier family 9 (sodium/hydrogen 
exchanger), member 6 
3.1 0.0008 
3778 KCNMA1 
Potassium large conductance calcium-activated 
channel, subfamily M, alpha member 1 
2.7 0.00082 
6543 SLC8A2  
Solute carrier family 8 (sodium/calcium 
exchanger), member 2 
4.3 0.00086 
57419 SLC24A3  
Solute carrier family 24 
(sodium/potassium/calcium exchanger), member 3 
3.9 0.00092 
3750 KCND1 
Potassium voltage-gated channel, Shal-related 
subfamily, member 1 
3.3 0.00098 
Modulation 
7166 TPH1 Tryptophan hydroxylase 1 4.3 0.00046 
6581 SLC22A3  
Solute carrier family 22 (extraneuronal monoamine 
transporter), member 3 
3.4 0.00086 
2897 GRIK1  Glutamate receptor, ionotropic, kainate 1 2.3 0.00103 
2550 GABBR1  
Gamma-aminobutyric acid type B receptor subunit 
1 
2.7 0.00106 
79664 NARG2 NMDA receptor regulated 2 2.2 0.00106 
 
Dysregulated pathways. In the secretory phase endometriotic lesions compared to proliferative 
phase lesions, pathways involved in ion and neurotransmitter transport were among the top 10 
upregulated pathways (see Appendix 17 for a list of top-20 dysregulated pathways). 
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4. 2 Published gene lists  
4.2.1 Eutopic endometrium from women with and without endometriosis 
There were 16 significantly upregulated genes involved in the pain matrix (see Table 4.8). In total, 
there were 45 upregulated genes and 37 downregulated genes across the three datasets (see 
Appendices 23 and 24).  
 
Table 4.8: Significantly upregulated genes in the eutopic endometrium of women with 
endometriosis. 
Gene Symbol Gene name P value 
Neuronal development 
JUNB Jun B proto-oncogene 0.0009 
ASCL1 Achaete-scute complex homolog 1 (Drosophila) 0.0018 
efnb1 Ephrin B1 0.009213 
POU3F4 Brain 4 mRNA 0.013459 
Sensitisation due to inflammation 
CPE Carboxypeptidase E 0.002699 
CCL21 Chemokine (C–C motif) ligand 21 0.005846 
Signal transduction 
PTPRR Protein tyrosine phosphatase, receptor type, R 0.00045 
CASP5 Cysteine protease (ICErel-III) 0.000709 
SNCG Synuclein, gamma 0.002249 
PDE9A Phosphodiesterase 9A 0.002249 
TSPAN15 Tetraspanin 15 0.003599 
FOS V-fos FBJ murine osteosarcoma viral oncogene homolog 0.004947 
Conduction 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide 0.00045 
Modulation 
IL6ST Interleukin-6 signal transducer 0.003599 
GPR56 G-Protein coupled receptor  0.004498 
MAP3K1 Mitogen activate protein kinase kinase 1 0.009921 
 
Dysregulated pathways. Pathways related to signal transduction, response to stimuli were 
significantly upregulated which may contribute to increased signal transduction in the eutopic 
endometrium from women with endometriosis (for a list of top-20 dysregulated pathways see 
Appendix 25). 
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4.2.2 Eutopic endometrium and endometriotic lesions from women with endometriosis      
In endometriotic lesions compared to eutopic endometrium from women with endometriosis, there 
was one gene involved in conduction and two genes involved in inflammation (see Table 4.9). The 
meta-analysis of published gene lists from seven studies revealed 43 down-regulated and 37 
upregulated genes in the endometriotic lesions when compared to the eutopic endometrium from 
women with endometriosis (see Appendices 26 and 27). 
 
Table 4.9: Significantly upregulated genes in endometriotic lesions 
Gene Symbol Gene Name P value 
Neuronal development  
No genes  
Sensitisation due to inflammation 
 PLA2G5 Phospholipase A2, group V 0.000068 
CPVL Carboxypeptidase, vitellogenic-like 0.001065 
Signal transduction  
No genes  
Conduction 
 SCN7A Sodium channel, voltage-gated, type VII, alpha subunit 0.0000268 
Pain modulation 
No genes 
 
Differentially regulated pathways. No pathways involved in pain generation were significantly 
dysregulated in endometriotic lesions compared to eutopic endometrium from women with 
endometriosis. Pathways involved in reproduction and cellular organisation were amongst the top 
dysregulated pathways in endometriotic lesions compared to eutopic endometrium from women 
with endometriosis (for a list of top-20 dysregulated pathways see Appendix 25). 
 
4.3 Convergence of gene list results 
The converged list of upregulated genes involved in pain generation from both meta-analyses of 
individual participant gene expression data and published genes lists, comparing eutopic 
endometrium from women with and without endometriosis revealed only one gene, interleukin 6 
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signal transducer, IL6ST (see Fig. 4.3). No genes involved in pain generation were revealed to be 
common in the lists comparing gene expression in endometriotic lesions with eutopic 
endometrium from women with endometriosis. 
 
 
Fig. 4.3: Venn diagram illustrating one upregulated pain related gene common across gene 
list results obtained from meta-analyses of individual patient gene expression data and 
published gene list, comparing eutopic endometrium from women with and without 
endometriosis. A: List of upregulated pain related genes from the meta-analysis of 
individual participant gene expression data; B: List of upregulated pain genes from meta-
analysis of published gene lists. The overlap of the two lists resulted in one common gene: 
Interleukin 6 signal transducer gene (IL6ST). 
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Chapter 5 
Discussion 
 
5.1 Introduction 
This study has demonstrated an upregulation of pain related genes and pathways in both the 
eutopic endometrium and lesions as well as in the secretory compared to proliferative menstrual 
cycle phase in women with endometriosis. Genes involved in neuronal development, 
inflammation and sensitisation, signal transduction, signal conduction and pain modulation were 
all implicated in endometriosis. An upregulation of pain related genes may enhance peripheral 
sensitisation thereby leading to increased pain generation observed in women with endometriosis. 
 
5.2 Neuronal development in endometriosis 
In both the individual gene expression and published gene list meta-analyses, genes involved in 
neuronal development were upregulated in the eutopic endometrium from women with 
endometriosis as well as in endometriotic lesions. Neurogenesis is a well-known phenomenon in 
endometriosis and has been implicated in the progression of the disease as well as its related pain 
symptoms (Bokor et al., 2009, Anaf et al., 2002, Arnold et al., 2012, Greaves et al., 2014, Asante 
and Taylor, 2011, Abu-Asab et al., 2011, Chen et al., 2014, McKinnon et al., 2015, Eyster et al., 
2007, Hull et al., 2008). 
 
As an example, in the eutopic endometrium from women with endometriosis, Jun B proto-
oncogene (JUNB) was significantly upregulated. JUNB is a member of a family of transcription 
factors (Jun) and is promoted by growth factors and cytokines such as NGF and IL6 (Ransone and 
Verma, 1990, Angel and Karin, 1991, Dutta et al., 2011, Lord et al., 1993), which are also found 
to be at increased levels in the eutopic endometrium, peritoneal fluid and endometriotic lesions of 
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women with endometriosis (Anaf et al., 2002, Akoum et al., 1996, Barcena de Arellano et al., 
2011). JUNB functions by decreasing neuronal apoptosis in conjunction with NGF to promote 
neuronal survival (Lee et al., 2005a). Its mRNA and protein expression levels are high in 
cancerous cells (Lee et al., 2005a). JUNB expression is also known to be increased in neurons 
which respond to noxious stimuli and contribute to pain (Morgan and Curran, 1991, Naranjo et al., 
1991). Recently, Hurst et al. (2014) have demonstrated increased JUNB gene expression in the 
eutopic endometrium of women with endometriosis compared to women without the disease. 
Furthermore, there is an increase in NGF mRNA and protein expression in the eutopic 
endometrium (Browne et al., 2012, Tokushige et al., 2007) which may increase JUNB expression 
in the eutopic endometrium. Together, they may increase sensory innervation in the eutopic 
endometrium of women with endometriosis (Aghaey Meibody et al., 2011, Kobayashi et al., 2013, 
Cervero, 1994, Triolo et al., 2013, Tokushige et al., 2007). 
 
In endometriotic lesions, gene encoding for adivilin (AVIL) was upregulated compared to the 
eutopic endometrium. This gene is a member of the Gelsolin superfamily of actin binding proteins 
and is predominantly expressed in the peripheral somatosensory neurons which innervate 
peripheral organs and transmit pro-nociceptive painful signals (Hasegawa et al., 2007, Marks et 
al., 1998, Ravenall et al., 2002). Advillin is involved in axonal remodelling, regrowth of the 
peripheral sensory neurons and responding to cellular stress (Hasegawa et al., 2007, Zurborg et al., 
2011, Marks et al., 1998, Shibata et al., 2004). In endometriotic lesions, upregulation of this gene 
may lead to the hyper-innervation of the endometriotic lesions and also to increased pro-
nociceptive signalling, thereby contributing to increased pain generation in women with 
endometriosis (Wang et al., 2009, Kobayashi et al., 2013, Anaf et al., 2002, Triolo et al., 2013). 
Furthermore, in endometriotic lesions, neuronal development pathways such as those involved in 
the development of synapses between neurons as well as those involved in formation of the post-
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synaptic membrane were also upregulated compared to the eutopic endometrium from women 
with endometriosis. Upregulation of these genes and the related pathways in endometriotic lesions 
may contribute to pain by increased lesion innervation which may lead to increased peripheral 
sensitisation (Asante and Taylor, 2011, Wang et al., 2009, Anaf et al., 2002, Arnold et al., 2012, 
Stratton and Berkley, 2011).     
 
There was an upregulation of neuronal development genes in the secretory compared to the 
proliferative phase in both the eutopic endometrium and lesions from women with endometriosis. 
For example, in the secretory phase compared to the proliferative phases, in both the eutopic 
endometrium and endometriotic lesions from women with endometriosis, neural cell adhesion 
molecule (NCAM) gene NCAM-1 was significantly upregulated. NCAM-1 encodes for a 
glycoprotein which is involved in intercellular adhesions (Francavilla et al., 2007, Hinsby et al., 
2004, Rønn et al., 1998) and mediates neuronal migration, proliferation and survival, as well as 
synapse formation and plasticity (Delling et al., 2002, Murase and Schuman, 1999, Schachner, 
1997). It is also known to be involved in perineural invasion which damages the nerve cells and 
generates pain (Ben et al., 2010, Bapat et al., 2011). Odagiri et al. (2008) and Yu et al. (2009) have 
also demonstrated increased NCAM-1 gene expression in both eutopic endometrium and 
endometriotic lesions. An upregulation of NCAM-1 may increase innervation of the eutopic 
endometrium and endometriotic lesions, and may also generate pain by promoting nerve cell 
damage. Upregulation of neuronal development genes in the secretory phase in endometriosis 
correlates with increased pain in women during the late secretory phase of the menstrual cycle 
(Barbosa Mde et al., 2013, de Tommaso, 2011, Hellstrom and Anderberg, 2003). 
 
During chronic pain conditions, there is an upregulation of genes involved in neuronal 
development (Costigan et al., 2009, Costigan et al., 2002). In endometriosis, upregulation of genes 
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involved in neuronal development in the eutopic endometrium and endometriotic lesions may 
contribute to the high density of sensory nerve fibres observed in women with endometriosis and 
to pain in the disease (Tokushige et al., 2006a, Wang et al., 2009, Tokushige et al., 2007). The 
importance of this for pain in endometriosis is supported by a correlation between nerve fibre 
density in lesions with pain intensity in endometriosis (Stratton and Berkley, 2011).  
 
5.3 Sensitisation due to inflammation in endometriosis 
Genes involved in inflammation leading to peripheral sensitisation were upregulated in the eutopic 
endometrium from women with endometriosis as well as in endometriotic lesions in both meta-
analyses. Increased expression of these genes is known to be linked to pain (Black et al., 2004, Di 
Sebastiano et al., 2003, Homma et al., 2013, Yukhananov and Kissin, 2008). Inflammatory 
mediators sensitise peripheral sensory neurons, lowering their threshold for generating an action 
potential (Chen et al., 2009, Schaible, 2007, Voscopoulos and Lema, 2010).  
 
Increased expression of genes involved in inflammation in both the eutopic endometrium of 
women with endometriosis and endometriotic lesions is supported by the included studies (Vouk 
et al., 2011, Burney et al., 2007, Eyster et al., 2007) as well as the broader literature (Kyama et al., 
2006, Chand et al., 2007, Bertschi et al., 2013, Tseng et al., 1996, Abu-Asab et al., 2011, Nikoo et 
al., 2014, Lin et al., 2014, Li et al., 2013). Genes involved in inflammation have been implicated 
in the pathogenesis of endometriosis and in related pain symptoms (Scholl et al., 2009). Moreover, 
this study has found that the most highly dsyregulated pathways in the eutopic endometrium and 
lesions from women with endometriosis were those involved in inflammatory and immune 
responses such as acute inflammatory response, activation of cytokines and chemokines as well as 
promoting a response to stimulus. This correlates with findings of immune dysfunction and an 
inflammatory microenvironment in endometriosis, leading to disease progression and 
97 
 
 
development of associated pain symptoms (Braun and Dmowski, 1998, Matarese et al., 2003, 
Bloski and Pierson, 2008, Herington et al., 2011, Ahn et al., 2015. In press). 
 
In the eutopic endometrium from women with endometriosis compared to endometriotic lesions, 
upregulated genes involved in inflammation included interleukin 6 signal transducer (IL6ST). 
IL6ST, also known as glycoprotein 130 (gp130), was the only gene found to be common amongst 
the converged results of the two meta-analyses. This gene may play an important role in 
endometriosis-related pain. It is expressed by peripheral sensory neurons and has been implicated 
in pathological pain (Andratsch et al., 2009, Langeslag et al., 2011). IL6ST leads to the 
sensitisation of peripheral sensory neurons by activating MAPK pathways as well as through the 
activation of thermal nociceptive receptor transient receptor potential vallinoid (TRPV1; 
Langeslag et al., 2011, Andratsch et al., 2009, Dominguez et al., 2008). A variety of pro-
inflammatory cytokines, such as IL-6, IL-11, leukemia inhibitory factor (LIF), and oncostatin M 
(OSM) are known to bind to IL6ST for activation as well as for signalling the production of mast 
cells, macrophages and other immune cells (Andratsch et al., 2009). Of these, IL6 is the most 
notable as it is extremely elevated in chronic inflammatory conditions such as in the peritoneal 
fluid and eutopic endometrium of women with endometriosis (Tseng et al., 1996, Akoum et al., 
1996, Kyama et al., 2006, Velasco et al., 2010, Slater et al., 2006) and causes peripheral 
sensitisation due to thermal and mechanical stimuli, contributing to pain (Langeslag et al., 2011, 
Malsch et al., 2014, Punnonen et al., 1996). Increased expression levels of IL6ST may increase the 
cytokine levels secreted by the immune cells which in turn are excessively produced by the 
eutopic endometrium of women with endometriosis (Schulke et al., 2009, Anaf et al., 2006) and 
ultimately to sensitisation of peripheral neurons (Howard, 2009, Scholl et al., 2009, Neziri et al., 
2014, Cakmak et al., 2009, Bloski and Pierson, 2008).  
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In both the eutopic endometrium and endometriotic lesions, interleukin-15 (IL-15) was 
significantly upregulated. IL-15 is a pro-inflammatory cytokine which is important for protective 
immune responses (Perera et al., 2012, Perera, 2000, Liew and McInnes, 2002). Its levels 
positively correlate with the severity of pain in chronic pain conditions (Scanzello et al., 2009, Sun 
et al., 2013). High concentration of IL-15 favours the production of other pro-inflammatory 
cytokines such as IL-1, IL-6, IL-8 and TNF-α as well as the recruitment of immune cells, thereby 
amplifying the inflammatory reaction (Alleva et al., 1997, Cassatella and McDonald, 2000, Ren 
and Dubner, 2010, Sun et al., 2013). In women with endometriosis, IL-15 levels are elevated in 
endometriotic lesions and peritoneal fluid compared to women without the disease and have been 
implicated in mediating an early immune response (Arici et al., 2003, Chegini et al., 2003). 
Upregulation of IL-15 in both the eutopic endometrium and endometriotic lesions may contribute 
to peripheral sensitisation by increasing local cytokine production and immune cell recruitment 
(Gomez-Nicola et al., 2008, Chegini et al., 2003).     
 
Genes involved in inflammation were also upregulated in the secretory compared to the 
proliferative phase in the eutopic endometrium in endometriosis, for example heparanase (HPSE). 
It encodes for a degradation enzyme leading to extracellular matrix remodelling and release of 
pro-inflammatory mediators such as VEGF and cytokines (Lerner et al., 2011). HPSE is 
upregulated in inflammation and controls many inflammatory and immune responses (Meirovitz 
et al., 2013, Goldberg et al., 2013). HPSE stimulates macrophage activation which in turn induces 
heparanase production (Lerner et al., 2011, Vlodavsky et al., 2012, Edovitsky et al., 2006). The 
modulation of macrophage activation and pro-inflammatory cytokine and growth factor 
production leads to inflammation which may lead to the sensitisation of the peripheral neurons 
(Vlodavsky et al., 2012, Kidd and Urban, 2001, Meirovitz et al., 2013, Goldberg et al., 2013). 
Upregulation of HPSE expression may promote macrophage recruitment and pro-inflammatory 
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cytokine production observed in women with endometriosis (Hassa et al., 2009, Scholl et al., 
2009, Berbic et al., 2009), thus contributing to peripheral sensitisation and pain generation (Liew 
and McInnes, 2002, Sun et al., 2013). Significant upregulation of genes involved in inflammation 
in secretory phase eutopic endometrium from women with endometriosis indicates increased 
peripheral sensitisation within the uterus in the lead up to menstrual pain (Hellstrom and 
Anderberg, 2003, de Tommaso, 2011, Tousignant-Laflamme and Marchand, 2009).  
 
5.4 Signal transduction and conduction in endometriosis 
Genes involved in signal transduction and conduction were significantly upregulated in both the 
eutopic endometrium and lesions from women with endometriosis. Studies included in this meta-
analysis (Khan et al., 2012, Eyster et al., 2007, Sohler et al., 2013, Hurst et al., 2014) as well as 
those from the broader literature have reported increased expression of genes involved in signal 
transduction and conduction in both eutopic endometrium and lesions in women with 
endometriosis (Liu et al., 2012, Greaves et al., 2014, Abu-Asab et al., 2011, Makker et al., 2012, 
Poli-Neto et al., 2009, Pelch et al., 2010, Wren et al., 2007). Enhanced expression of these genes 
increases the excitability of sensory neurons and signal conduction, leading to increased pain 
signal transfer (Ossipov, 2012, Basbaum et al., 2009, Foulkes and Wood, 2008).   
 
As an example from the current study, in both eutopic endometrium of women with endometriosis 
and endometriotic lesions, genes encoding for members of the mitogen activated protein kinases 
(MAPK; involved in signal transduction) family such as mitogen-activated protein kinase 5 
(MAP3K5), mitogen-activated protein kinase 6 (MAPK6) and mitogen-activated protein kinase 8 
(MAP3K8) were significantly upregulated. MAPK are a family of intracellular signalling 
molecules expressed by peripheral nociceptive neurons (Ji et al., 2009, Ji and Woolf, 2001). They 
are activated following intense noxious stimulation (Ji et al., 2009, Adwanikar et al., 2004, 
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Voscopoulos and Lema, 2010, Imbe et al., 2011, Impey et al., 1999, Gao and Ji, 2008, Kumar et 
al., 2003, Ji and Woolf, 2001). Their activation leads to impulse generation contributing to pain (Ji 
et al., 2009). In endometriosis, increased MAPK expression may contribute to increased signal 
transduction by getting activated following noxious stimuli and generating action potential leading 
to initiation of painful nerve impulses  (Tarek et al., 2001, Bukulmez et al., 2008, Yoshino et al., 
2004).  
 
In both the eutopic endometrium of women with endometriosis and endometriotic lesions genes 
involved in signal transduction were upregulated in the secretory phase of the menstrual cycle 
when compared to the proliferative phase. In the endometriotic lesions, MAPK family genes were 
upregulated whereas in the eutopic endometrium, transient receptor potential M8 (TRPM8) was 
one of the significantly upregulated genes. TRPM8 is a member of the transient receptor potential 
channel family that responds to noxious stimuli by initiating transient elevations of intracellular 
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ion concentration (Gees et al., 2010, Nilius and Owsianik, 2011). Its expression levels increase 
following injury and lower the threshold of peripheral sensory neurons leading to generation of 
impulses (Proudfoot et al., 2006, McKemy et al., 2002, Levine and Alessandri-Haber, 2007). 
TRPM8 is activated by noxious cold or chemical agents as well as modulated by cell stress 
(Morgan et al., 2014). Increased secretion of pro-inflammatory mediators such as cytokines, 
during the secretory phase in the eutopic endometrium (Ma et al., 2013a, Wolff et al., 2000) may 
increase the expression of TRPM8 leading to enhanced signal transduction thereby contributing to 
dysmenorrhea. 
 
In both the eutopic endometrium and endometriotic lesions, signal conducting genes encoding for 
potassium ion gated channels such as potassium voltage-gated channel, Shal-related subfamily, 
member 3 (KCND3) and potassium voltage-gated channel, Shaw-related subfamily, member 1 
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(KCNC1) were upregulated. Electrical impulses generated in excited neurons are conducted along 
the axons via potential gradients (Schaible, 2007). Potassium ion gated channels generate potential 
gradient by allowing selective flow of potassium ions across cell membranes (Moldovan et al., 
2013, Wulff et al., 2009, Takeda et al., 2011, Hayashi et al., 2014). They conduct currents in order 
to regulate the sensitisation of the sensory neurons, for example KCND3 encodes for a channel 
conducting fast-inactivating currents and KCNK1 encodes for a channel conducting slow-
inactivating current (Tsantoulas and McMahon, 2014, Takeda et al., 2011). In case of intense 
noxious stimulation, potassium ion channels contribute to enhanced signal conduction by 
increasing the frequency of impulse firing (Takeda et al., 2011). The intense inflammatory 
microenvironment in endometriosis (Bloski and Pierson, 2008, Bruner-Tran et al., 2013, Scholl et 
al., 2009, Neziri et al., 2014) may lead to increased impulse conduction via potassium ion gated 
channels contributing to pain generation (Sommer and Kress, 2004).  
 
Pathways related to signal transduction and conduction, such as MAPK cascades, activity of 
ligand gated ion channels and calcium ion homeostasis were among the top upregulated pathways 
in both eutopic endometrium and endometriotic lesions. The upregulation of genes and pathways 
involved in signal transduction and conduction in both the eutopic endometrium and endometriotic 
lesions may be linked to increased sensory innervation and peripheral sensitisation as a result of 
increased production of pro-inflammatory mediators in the pelvic viscera. Neuronal sensitisation 
modulates activation of voltage-gated ion channels and thereby excitability, generation and 
conduction of action potentials (Schaible, 2007, Kitahata, 1993, Binshtok, 2011). Information is 
then sent from the pelvic viscera to the brain, contributing to perception of pain (Morotti et al., 
2014b).  
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5.5 Pain modulation in endometriosis 
In both tissue types included in the meta-analyses, genes involved in pain modulation were 
upregulated. Certain pain modulating genes are known to be upregulated during chronic pain 
conditions (Gangadharan and Kuner, 2013, Schaible, 2007, Foulkes and Wood, 2008, Millan, 
2002). Pain modulating genes may enhance or inhibit pain generation pathways. They contribute 
to pain by enhancing the release of neurotransmitters which increase the excitability of sensory 
neurons and facilitate the transfer of painful signals from the periphery to the CNS (Foulkes and 
Wood, 2008, Mogil et al., 2000). Included as well as other studies have also shown expression of 
genes involved in pain modulation is increased in women with endometriosis.  
 
In both the eutopic endometrium of women with endometriosis and endometriotic lesions, LIF 
was one of the significantly upregulated genes involved in pain modulation. LIF is a cytokine, the 
expression levels of which are known to increase following injury (Banner and Patterson, 1994, 
Banner et al., 1998, Curtis et al., 1994, Oshima et al., 2007, Knight, 2001). It promotes sprouting 
of cholinergic neurons and modulates pain by enhancing neuropeptide expression (Wang and 
Lehky, 2012, Banner et al., 1998, Rao et al., 1993, Gadient and Patterson, 1999, Geisterfer and 
Gauldie, 1996). In endometriosis, increased expression of LIF (Tawfeek et al., 2012, Dimitriadis 
et al., 2006) may contribute to sprouting of sensory neurons that are more sensitive to stimuli. 
Increased innervation of eutopic endometrium and endometriotic lesions is implicated in pain 
generation (Tokushige et al., 2006a, Wang et al., 2009, Kobayashi et al., 2013). Moreover, 
increased LIF expression may lead to increased expression of cytokines and neuropeptides, also 
observed in women with endometriosis (Bokor et al., 2009, Scholl et al., 2009, Tokushige et al., 
2006b), thereby contributing to enhancement of peripheral sensitisation.   
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In endometriotic lesions, the upregulated pain modulating genes included gamma-aminobutyric 
acid A receptor, alpha 2 (GABRA2). This gene encodes for the member of the GABA family 
which are major inhibitors of neuronal activity (Rea et al., 2007, Jasmin et al., 2003, Lau and 
Vaughan, 2014). In chronic pain conditions, GABA receptors (GABAA and GABAB) actually 
facilitate pain transmission by increasing the threshold of neurons that inhibit neurotransmission 
and inactivating them (Enna and McCarson, 2006). Increased expression of GABA encoding 
genes in endometriotic lesions may enhance pain generation by inactivating the inhibitory 
neurons.     
 
In the secretory phase, genes involved in pain modulation were upregulated in both endometriotic 
lesions as well as the eutopic endometrium of women with endometriosis. In the endometriotic 
lesions, gene encoding for gamma-aminobutyric acid type B (GABBAB) was upregulated which 
facilitates pain by inactivating inhibitory neurons. In the eutopic endometrium serotonin receptor 
5-hydroxytryptamine (serotonin) receptor 1D (HTR1D) was one of the upregulated pain 
modulating genes. In the periphery, serotonin receptors are present on sensory nerve endings and 
following noxious stimulation, enhance or inhibit the activation of gated ion channels (Ossipov et 
al., 2010, Bardin, 2011, Lindstedt et al., 2011, Treister et al., 2011, Sommer, 2004). Serotonin 
receptors facilitate pain by sensitising peripheral sensory neurons directly (Tegeder and Lötsch, 
2009, Wei et al., 2010, Suzuki and Dickenson, 2005, Hooten et al., 2013, Oliveira et al., 2007). 
HTR1D encodes for a serotonin receptor which contributes to inflammatory pain (Ahn and 
Basbaum, 2006, Manteniotis et al., 2013, Tepper et al., 2002). In endometriosis, increased 
expression of pain modulating genes in the secretory phase may contribute to dysmenorrhea by 
modulating neuronal conductance as well as directly sensitising the peripheral sensory neurons. 
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Pain modulation in endometriosis is complex, as are the other interrelated aspects of the pain 
matrix in the disease. Indeed, generally speaking, pain generation is a complex process, involving 
interactions between the peripheral and central nervous systems (Ossipov et al., 2010). In 
endometriosis, alteration in both the peripheral and central nervous systems may contribute to pain 
symptoms (Stratton and Berkley, 2011, Triolo et al., 2013). Neuronal development and sensory 
innervation are locally increased in the eutopic endometrium and endometriotic lesions. The 
sensory nerve fibres are sensitised by the inflammatory microenvironment which leads to signal 
transduction and generation of action potential (Morotti et al., 2014b, Berkley et al., 2005, Triolo 
et al., 2013). The sensitised peripheral sensory neurons conduct action potentials via the DRG of 
the spinal cord to the CNS (Schaible, 2007, Porpora et al., 1999, Stratton and Berkley, 2011). 
Once the CNS processes the sent information, descending impulses are sent to the spinal cord to 
dampen the excitatory impulses (Bolay and Moskowitz, 2002, Kitahata, 1993, Ossipov et al., 
2010, Neziri et al., 2014, Triolo et al., 2013). However, in case of chronic pain conditions such as 
endometriosis, persistent sensitisation may lead to descending impulses to become excitatory and 
contribute to development of chronic pain (Bolay and Moskowitz, 2002, Kwon et al., 2013, 
Voscopoulos and Lema, 2010, Morotti et al., 2014b, Triolo et al., 2013, Neziri et al., 2014, 
Stratton and Berkley, 2011). 
 
5.6 Implications for pain management in endometriosis 
There is almost certainly a relationship between variable responses to pain management and 
complexity of pain mechanisms in endometriosis (Neziri et al., 2014, Evans et al., 2007, Howard, 
2009, Kobayashi et al., 2013, Triolo et al., 2013, Bloski and Pierson, 2008). The current pain 
management techniques are ineffective for a proportion of women with endometriosis and pain 
symptoms generally have high recurrence rates, in addition to treatments being associated with 
some unpleasant side effects (Huang, 2008, Bruner-Tran et al., 2013, Kennedy et al., 2005, Nasir 
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and Bope, 2004, Sutton et al., 1994, Medicine, 2014, Bloski and Pierson, 2008, Culley et al., 
2013). Hence, identifying and targeting candidate genes involved in pain generation in 
endometriosis may aid in better management of pain associated with the disease (Dun et al., 
2010).    
 
Gene therapy has been used for managing chronic pain and works by targeting candidate genes 
known to be involved in pain generation (Goins et al., 2012, Jain, 2008, Wilson and Yeomans, 
2000). Delivery of potent bioactive molecules either interrupts nociceptive signalling, or interferes 
with the plasticity in the nervous system underlying the development or persistence of chronic 
pain (Jain, 2008, Mata et al., 2008). In gene therapy, genes are delivered through vectors to 
peripheral tissues from where they are transported through natural mechanisms to the targeted 
neurons (Goins et al., 2012). A vector is a virus which infects the targeted cells and transports its 
genome to the nucleus where the candidate gene can be expressed for various desired durations 
(Wilson and Yeomans, 2000, Tavares and Martins, 2013, Jain, 2008, Goins et al., 2012). 
 
Several gene targets are being tested on animal models for their application to chronic pain 
management. For example, targeting of primary sensory neurons by modulating signal transducing 
channels such as TRPV1 alleviates pain symptoms by toxic flood of Ca
2+
 ions. This damages the 
nociceptive TPRV1 containing axons (Brederson et al., 2013), which has been successfully 
applied to animal models and is now under Phase I clinical trial on patients with advanced cancer 
pain (Smith, 2008). Delivering immune modulatory genes have demonstrated a reduction in not 
only pain, but also in the expression of pro-inflammatory mediators such as TNF-α, IL-6 and IL-1 
(Zhou et al., 2008, Ledeboer et al., 2007, Hao et al., 2007). Currently, genes for neuronal growth 
factors such as NGF and BDNF, modulators of inflammatory cytokines such as IL-2, IL-4 and IL-
10, signal transduction such as TRPV1, repolarisation of sensory neurons and inhibitory 
106 
 
 
neuromodulators such as GABA, opioids are being employed for managing pain (Yao et al., 2002, 
Yao et al., 2003, Hao et al., 2007, Hao et al., 2006, Milligan et al., 2005). 
 
Gene therapy for managing endometriosis and endometriotic lesions such as delivering negative 
oestrogen receptors to endometriotic cells for abrogating oestrogen action has been successful in 
inhibiting angiogenesis, suppressing inflammatory factors and inducing apoptosis (Othman et al., 
2007). Similarly in rodent models, the size of endometriotic lesions was significantly reduced 
along with levels of VEGF in the serum with endostatin gene therapy (Zhang et al., 2012, Ma and 
He, 2014). Delivery of genes which promote an immunogenic response to endometriotic lesions 
are being explored for treating endometriosis (Shubina et al., 2013). Application of gene therapy 
to block NGF by utilising anti-NGF antibodies which will in turn block NGF-dependent neuronal 
survival is being analysed for treating endometriosis-associated pain (Shubina et al., 2013, Howe 
et al., 2010). In the future, candidate pain related genes that are dysregulated in endometriosis, 
may be novel gene therapy targets for treatment of pain symptoms.      
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Conclusions and Future Directions 
 
Conclusions 
Pain related genes were significantly upregulated in the eutopic endometrium of women with 
endometriosis compared to women without endometriosis, and in endometriotic lesions compared 
to eutopic endometrium from women with endometriosis. In both eutopic endometrium and 
endometriotic lesions from women with endometriosis, pain related genes were also significantly 
upregulated in the secretory compared to the proliferative phase of the menstrual cycle. The 
expression levels of different pain related genes positively correlated with each other in both the 
eutopic endometrium and lesions of women with endometriosis. 
 
In conclusion, upregulation of a range of pain related genes may be associated with pain 
symptoms in endometriosis, particularly in the time leading up to menstruation (secretory phase of 
the menstrual cycle), specifically, genes involved in neuronal development, sensitisation due to 
inflammation, signal transduction, conduction and modulation. This, combined with previously 
described nociceptive, inflammatory and neuropathic pain generation mechanisms in 
endometriosis indicates the complexity of pain processes in the disease. Improved understanding 
of the molecular mechanisms underlying generation of pain in endometriosis may in future aid the 
development of therapeutic approaches. 
 
Future directions 
Molecular pain mechanisms associated with endometriosis are very complex and require further 
in-depth understanding. This study has provided some information about local gene dysregulations 
which may contribute to pain symptoms in women with endometriosis. However, a variety of 
possible further studies are of interest which may improve our current understanding of pain 
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mechanisms in endometriosis. Listed below are some of the investigations which may be 
considered a priority: 
 A range of datasets are required to be explored to identify candidate dysregulated genes 
involved in pain generation. For example, analysing differential gene expression in blood 
samples of women with and without endometriosis may provide insights about molecular 
mechanisms that make women susceptible to endometriosis.  
 Identifying differential gene expression between different lesion types (peritoneal, ovarian 
and deep) may contribute to improved understanding of pain related mechanisms.  
 Pain in endometriosis is experienced most during pre-menstrual and menstrual phases, 
hence profiling endometrial gene expression from women with endometriosis these times 
in the cycle may shed some light on pain mechanisms.  
 Improving understanding of pain in endometriosis may be accomplished by conducting 
studies focussing on how endometriosis affects the PNS and CNS, and examining these 
studies in context of mechanisms underlying other chronic pain conditions.  
 Understanding mechanisms of nerve fibre stimulation in fibres innervating the eutopic 
endometrium and endometriotic lesions may further the understanding of mechanisms 
underlying pain in endometriosis.  
Basic studies and clinical trials are required to evaluate treatment options for endometriosis pain. 
For example, application of immunomodulators and anti-inflammatory mediators in the treatment 
of endometriosis requires further investigation. Additionally, genes involved in pain generation in 
other chronic painful conditions as well as those that have been identified in endometriosis should 
be further explored to for their application in gene therapy for endometriosis-associated pain.  
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Appendix 1: Characteristics of included studies. 
Hull et al. 2008 
Methods Cross-sectional study 
Individual patient gene expression data available 
Participants Women with endometriosis (age 20-46 years) that have regular 
menstrual cycles and are not using hormonal treatment (N = 9). 
Endometriosis was confirmed by laparoscopy. 
Interventions Endometrial biopsies collected using Pipelle suction curettes; RNA 
extracted from endometrial tissue; Hybridisation with U133A 
Affymetrix cDNA arrays containing ∼23,000 probe sets in total; 
compared gene expression of eutopic and ectopic endometrial samples. 
Outcomes  Genes found to be significantly up-regulated and down-
regulated in ectopic lesions relative to eutopic endometrium 
were 292 and 390, respectively.  
 Biological processes significantly over- or under- represented 
were inflammatory response, response to wounding, cell 
adhesion, calcium-independent cell adhesion, primary 
metabolic process, and DNA metabolic process. 
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 9 
Blind assessment of 
samples by the 
pathologist 
Unclear Information not provide in the study. 
Use of established 
criteria for assessing 
menstrual cycle phase 
Yes Noyes criteria were used to confirm the cycle phase from 
all the biopsies of endometrial tissue. 
Quality check of RNA Yes RNA integrity was assessed using an Agilent-2100 
Bioanalyzer. 
Validation of 
microarray results 
Unclear Method unclear. 
Other potential sources Yes Clinical characteristics of participants not provided. 
 
Hever et al. 2007  
Methods Cross-sectional study 
Individual patient gene expression data available. 
Participants Women with endometriosis (age: missing) that have normal menstrual 
cycles and are not using hormonal treatment (N = 10). Endometriosis 
was confirmed by laparoscopy. 
Interventions Endometrial biopsies; RNA extracted from the endometrial tissue; 
hybridisation with Affymetrix Human Genome U133 Plus 2.0 gene 
array; compared gene expression of eutopic and ectopic endometrial 
samples. 
Outcomes Fifty-three up-regulated genes associated with immune responses, 
cell-to-cell signaling/interaction, and hematological system 
development/function; inflammatory diseases, immune responses, and 
cellular movement were found to be up-regulated. 
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Risk of Bias 
Item Judgement Description 
Small sample size Yes  N = 10 
Blind assessment of 
samples by the 
pathologist 
No Stage of endometriosis not assessed. 
Use of established 
criteria for assessing 
menstrual cycle phase 
Unclear Information not provided. 
Quality check of RNA Unclear Information not provided. 
Validation of 
microarray results 
Yes Quantitative PCR was used to validate the microarray 
results.  
Other potential sources Yes Clinical characteristic of patients regarding age not 
provided. 
 
Burney et al. 2007 
Methods Case-control study 
Individual patient gene expression data available. 
Participants Women with endometriosis (age 22-44 years) that have normal 
menstrual cycles and are not using hormonal treatment (N = 21). 
Endometriosis was confirmed by laparoscopy. 
Interventions Endometrial biopsies collected from Pipelle catheters or curette from 
the uterine fundus under sterile conditions; RNA extraction; 
Hybridisation with Affymetrix Human Genome U133 Plus 2.0 gene 
array; Compared gene expression of eutopic and normal endometrial 
samples. 
Outcomes Significantly differentially expressed genes in different phases of the 
menstrual cycle in endometrium of women with endometriosis 
compared to women without endometriosis.  
Risk of Bias 
Item Judgement Description 
Small sample size No N = 21 (women with endometriosis) N = 16 (women 
without endometriosis)  
Blind assessment of 
samples by the 
pathologist 
Yes Blind assessment was done by up to four independent 
histopathologists.  
Use of established 
criteria for assessing 
menstrual cycle phase 
Yes Noyes criteria were used to confirm the cycle phase 
from all the biopsies of endometrial tissue. 
Quality check of RNA Yes RNA quality was confirmed by assessing the  
A260/A280 ratio and agarose gel electrophoresis. 
Validation of microarray 
results 
Yes Quantitative PCR was used to validate the microarray 
results. 
Other potential sources No None. 
 
Khan et al. 2012 
Methods Cross-sectional study 
Individual patient gene expression data available. 
Participants Women with endometriosis (age 24-45 years) that have normal 
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menstrual cycles and are not using hormonal treatment (N = 26). 
Endometriosis was confirmed by laparoscopy. 
Interventions Endometrial biopsies collected from Pipelle suction curette from the 
uterine fundus; ; RNA extracted from the endometrial tissue; 
Hybridisation with Agilent Whole Human Genome 60-mer 4X44K; 
Compared gene expression of eutopic and ectopic endometrial 
samples. 
Outcomes  Several genes associated with immunological, neuracrine and 
endocrine functions were found to be differentially expressed. 
 Twenty-eight genes as potential markers for ovarian 
endometriosis in fertile women were discovered. 
Risk of Bias 
Item Judgement Description 
Small sample size No N = 26 
Blind assessment of 
samples by the 
pathologist 
No Severity stages were defined at the time of surgery. 
Use of established 
criteria for assessing 
menstrual cycle phase 
Yes Noyes criteria was used to confirm the cycle phase from 
all the biopsies of endometrial tissue. 
Quality check of RNA Yes RNA quality was confirmed by Agilent 2100 
Bioanalyzer, RNA 6000 Nano LabChip kit and Agilent 
2100 Expert Software. 
Validation of microarray 
results 
Yes Quantitative PCR was used to validate the microarray 
results. 
Other potential sources No None. 
 
Crispi et al. 2013 
Methods Case-control study 
Individual patient gene expression data available. 
Participants Women with endometriosis (age 22-46 years) that have normal 
menstrual cycles and are not using hormonal treatment (N = 27). 
Endometriosis was confirmed by laparoscopy. Women without 
endometriosis that have normal menstrual cycle (N = 6). 
Interventions Endometrial; RNA extraction; Hybridisation with Affymetrix 
HGU133A 2.0 arrays Arrays; Compared gene expression of eutopic, 
ectopic and healthy endometrial samples. 
Outcomes Dysregulated genes involved in gonad developmental or wound 
healing process. 
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 9 (women with endometriosis); N = 6 (women 
without endometriosis) 
Blind assessment of 
samples by the 
pathologist 
No Diagnosis was made during laparoscopy. 
Use of established 
criteria for assessing 
menstrual cycle phase 
Unclear Method not mentioned in the paper.  
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Quality check of RNA Yes RNA quality was assessed by Experion RNA StdSens 
Kit (Bio-Rad Laboratories, Hercules, CA). 
Validation of microarray 
results 
Yes Quantitative PCR was used to validate the microarray 
results . 
Other potential sources Yes Limited clinical characteristic information of control 
participants. 
 
Sohler et al. 2013  
Methods Cross-sectional study 
Individual patient gene expression data available. 
Participants Women with endometriosis (age 21-52 years) that have normal 
menstrual cycles and are not using hormonal treatment (N = 27). 
Endometriosis was confirmed by laparoscopy. 
Interventions Endometrial biopsy; RNA extraction; Hybridisation with Affymetrix 
HGU133Plus2.0 arrays which contain 54 675 probe sets; Compared 
gene expression of eutopic and ectopic endometrial samples. 
Outcomes  Gene dysregulation in ectopic endometrium compared to 
eutopic endometrium in women with endometriosis. 
 Gene expression differed in different menstrual cycle phases 
in eutopic endometrium but not in ectopic endometrium.  
Risk of Bias 
Item Judgement Description 
Small sample size No N = 27 
Blind assessment of 
samples by the 
pathologist 
Unclear Blind assessment by the pathologist was not mentioned. 
Use of established 
criteria for assessing 
menstrual cycle phase 
Yes Out of the six criteria used to determine the menstrual 
cycle phase, one was based on published histological 
criteria to identify menstrual cycle phases.  
Quality check of RNA Yes RNA quality was assessed by Agilent Bioanalyzer 2100 
and the concentration was assessed on a Nanodrop 
spectrophotometer. 
Validation of microarray 
results 
Yes Quantitative PCR was used to validate the microarray 
results. 
Other potential sources No None. 
 
Zevallous et al. 2012  
Methods Case-control study 
Individual patient gene expression data available. 
Participants Women with endometriosis (age 25-43 years) that have normal 
menstrual cycles and are not using hormonal treatment (N = 28). 
Endometriosis was confirmed by laparoscopy. 
Interventions Endometrial biopsy; RNA extraction; Hybridisation with Affymetrix 
HU Gene 1.0 ST arrays; Compared gene expression of eutopic and 
normal endometrial samples. 
Outcomes Gene dysregulation in eutopic endometrium compared to normal 
endometrium in women with and without endometriosis. 
Risk of Bias 
Item Judgement Description 
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Small sample size Yes N = 12 (women with endometriosis); N = 18 (women 
without endometriosis)  
Blind assessment of 
samples by the 
pathologist 
Yes Stage of endometriosis was blind assessed by the 
pathologist.  
Use of established 
criteria for assessing 
menstrual cycle phase 
Yes Histological dating was done by haematoxylin staining 
and eosin staining by an experienced gynaecological 
pathologist. 
Quality check of RNA Yes RNA quality was assessed by Agilent Bioanalyzer 
2100 and the concentration was assessed on a 
Nanodrop spectrophotometer. 
Validation of microarray 
results 
Yes Quantitative PCR was used to validate the microarray 
results. 
Other potential sources No None. 
 
Talibi et al. 2006  
Methods Cross-sectional study 
Individual patient gene expression data available. 
Participants Women without endometriosis (age 23-50 years) that have normal 
menstrual cycles and are not using hormonal treatment (N = 45). 
Endometriosis was confirmed by laparoscopy. 
Interventions Endometrial biopsies collected from Pipelle catheter or curetting the 
endometrium from hysterectomy specimens; RNA extraction; 
Hybridisation with Affymetrix HG U133 Plus 2.0 Arrays; profiled 
gene expression of endometrial samples. 
Outcomes Gene expression varies across different phases of the menstrual 
cycle. 
Risk of Bias 
Item Judgement Description 
Small sample size No N = 45  
Blind assessment of 
samples by the 
pathologist 
No Not required as the women did not have 
endometriosis. 
Use of established criteria 
for assessing menstrual 
cycle phase 
Yes Noyes criteria was used to confirm the cycle phase 
from all the biopsies of endometrial tissue.  
Quality check of RNA Yes RNA quality was analysed by assessing the 260/280 
absorbance ratio and gel electrophoresis. 
Validation of microarray 
results 
Yes Quantitative PCR was used to validate the microarray 
results.  
Other potential sources No None. 
 
Sherwin et al. 2008 
Methods Case-control study 
Published gene list available 
Participants Women with and without endometriosis that have regular menstrual 
cycles and are not using hormonal treatment (N = 16). Endometriosis 
presence or absence was confirmed by laparoscopy. 
Interventions Endometrial biopsies collected using Pipelle suction curettes; RNA 
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extracted from endometrial tissue; Hybridisation with custom made 
cDNA arrays containing ∼22,000 probe sets in total; compared gene 
expression of eutopic endometrial samples with and without 
endometriosis. 
Outcomes  Genes found to be significantly up-regulated and down-
regulated in eutopic endometrium from women with and 
without endometriosis were 8 and 1, respectively.  
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 16 
Blind histological 
assessment of samples  
Unclear Information not provide in the study. 
Use of established criteria 
for assessing menstrual 
cycle phase 
Yes Noyes criteria were used to confirm the cycle phase 
from all the biopsies of endometrial tissue. 
Quality check of RNA Yes RNA integrity was assessed using an Agilent-2100 
Bioanalyzer. 
Validation of microarray 
results 
Yes By RT-PCR 
Other potential sources Yes Clinical characteristics of participants not provided. 
 
Kao et al. 2003 
Methods Case-control study 
Published gene list available 
Participants Women with and without endometriosis (age 28-39 years) that have 
regular menstrual cycles and are not using hormonal treatment (N = 
20). Endometriosis presence or absence was confirmed by 
laparoscopy. 
Interventions Endometrial biopsies collected using Pipelle suction curettes; RNA 
extracted from endometrial tissue; Hybridisation with Affymetrix 
Genechip Hu95A oligonucleotide microarray containing 12686 probe 
sets in total; compared gene expression of eutopic endometrial 
samples with and without endometriosis. 
Outcomes  Genes found to be significantly up-regulated and down-
regulated in eutopic endometrium from women with and 
without endometriosis were 91 and 115, respectively.  
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 15 
Blind histological 
assessment of samples  
Unclear Information not provided in the 
study. 
Use of established criteria 
for assessing menstrual 
cycle phase 
Unclear Information not provided in the 
study 
Quality check of RNA Unclear Information not provided in the 
study 
Validation of microarray 
results 
Yes By RT-PCR and Northern blot 
analysis 
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Other potential sources Yes Clinical characteristics of 
participants not provided. 
 
Hurst et al. 2013 
Methods Case-control study 
Published gene list available 
Participants Women with and without endometriosis (age 18-40 
years) that have regular menstrual cycles and are 
not using hormonal treatment (N = 15). 
Endometriosis present or absent was confirmed by 
laparoscopy. 
Interventions Endometrial biopsies collected using Pipelle 
suction curettes; RNA extracted from endometrial 
tissue; Hybridisation with Affymetrix 8500 
oligonucleotide microarray containing 8500 probe 
sets; compared gene expression of eutopic 
endometrial samples with and without 
endometriosis. 
Outcomes  Genes found to be significantly up-
regulated and down-regulated in eutopic 
endometrium from women with and 
without endometriosis were 26 and 32, 
respectively.  
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 15 
Blind histological assessment of samples  No The surgeon 
judged the 
stage of 
endometriosis 
at the time of 
the surgery 
Use of established criteria for assessing 
menstrual cycle phase 
Unclear Information not 
provided in the 
study 
Quality check of RNA Unclear Information not 
provided in the 
study 
Validation of microarray results Yes By RT-PCR 
Other potential sources Yes Clinical 
characteristics 
of participants 
not provided. 
 
Zafrakas et al. 2008 
Methods Cross-sectional study 
Published gene list available 
Participants Women with endometriosis that have regular menstrual cycles and 
are not using hormonal treatment (N = 4). Endometriosis was 
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confirmed by laparoscopy. 
Interventions Endometrial biopsies as well as endometriotic lesions collected using 
Pipelle suction curettes; RNA extracted from endometrial tissue; 
Hybridisation with Affymetrix HG-U133 gene chip containing 40000 
probe sets; compared gene expression of eutopic endometrial and 
endometriotic lesion samples with endometriosis. 
Outcomes Genes found to be significantly up-regulated and down-regulated in 
the endometriotic lesions compared to eutopic endometrium from 
women with endometriosis were 26 and 32, respectively.  
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 4 
Blind histological 
assessment of samples  
Unclear Information not provided in the study 
Use of established criteria 
for assessing menstrual 
cycle phase 
No Information not provided in the study 
Quality check of RNA Unclear Information not provided in the study 
Validation of microarray 
results 
Yes By RT-PCR 
Other potential sources Yes Clinical characteristics of participants not provided. 
 
Gaetje et al. 2007 
Methods Cross-sectional study 
Published gene list available 
Participants Women with and without endometriosis that have regular menstrual 
cycles and are not using hormonal treatment (N = 3). Endometriosis 
was confirmed by laparoscopy. 
Interventions Endometrial biopsies as well as endometriotic lesions collected using 
Pipelle suction curettes; RNA extracted from endometrial tissue; 
Hybridisation with Affymetrix HG U133A microarray containing 
22283 probe sets; compared gene expression of eutopic endometrial 
and endometriotic lesion samples with endometriosis. 
Outcome Genes found to be significantly up-regulated and down-regulated in 
endometriotic lesions as compared to eutopic endometrium from 
women with endometriosis were 15 and 2, respectively.  
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 3 
Blind histological 
assessment of samples  
Unclear Information not provided in the study 
Use of established criteria 
for assessing menstrual 
cycle phase 
No The menstrual cycle phase was not assessed in the 
study 
Quality check of RNA Unclear Information not provided in the study 
Validation of microarray 
results 
Yes By RT-PCR and immunofluorescence  
Other potential sources Yes Clinical characteristics of participants not provided. 
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Eyster et al. 2007 
Methods Cross-sectional study 
Published gene list available 
Participants Women with endometriosis that have regular menstrual cycles and 
are not using hormonal treatment (N = 11). Endometriosis was 
confirmed by laparoscopy. 
Interventions Endometrial biopsies as well as endometriotic lesions collected using 
Hysteroscopy and dilatation and curettage; RNA extracted from 
endometrial tissue; Hybridisation with CodeLink Whole Human 
Genome Bioarrays containing 54359 probe sets; compared gene 
expression of eutopic endometrial and endometriotic lesion samples 
with endometriosis. 
Outcomes  Genes found to be significantly up-regulated or down-
regulated in endometriotic lesions as compared to eutopic 
endometrium from women with endometriosis were 717 in 
total. 
 Genes found to be significantly dysregulated in ovarian 
compared to peritoneal lesions  
  Genes found to be significantly dysregulated in mild 
endometriosis compared to all other patients in the study 
 Genes found to be significantly dysregulated in peritoneal 
endometriosis compared to all other patients in the study 
   Genes found to be significantly dysregulated in proliferative 
phase of the menstrual cycle compared to all other patients in 
the study. 
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 11 
Blind histological 
assessment of samples  
Unclear Information not provided in the study 
Use of established criteria 
for assessing menstrual 
cycle phase 
Unclear Information not provided in the study 
Quality check of RNA Yes RNA quality was assessed by RNA 6000 Nano 
LabChip kit in an Agilent Bioanalyzer 
Validation of microarray 
results 
Yes By RT-PCR  
Other potential sources Yes Clinical characteristics of participants not provided. 
 
Borghese et al. 2008 
Methods Cross-sectional study 
Published gene list available 
Participants Women with endometriosis that have regular menstrual cycles and 
are not using hormonal treatment (N = 12). Endometriosis was 
confirmed by laparoscopy. 
Interventions Endometrial biopsies as well as endometriotic lesions collected; 
RNA extracted from endometrial tissue; Hybridisation with Institut 
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Cochin HG18 60mer expression array containing 47633 probe sets; 
compared gene expression of eutopic endometrial and endometriotic 
lesion samples with endometriosis. 
Outcomes  Genes found to be significantly up-regulated or down-
regulated in endometriotic lesions as compared to eutopic 
endometrium from women with endometriosis were 2823 and 
2782, respectively. 
 27 groups were upregulated and 28 groups were 
downregulated in the endometriotic lesions compared to the 
eutopic endometrium from women with endometriosis 
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 11 
Blind histological 
assessment of samples  
Unclear Information not provided in the study 
Use of established criteria 
for assessing menstrual 
cycle phase 
No Menstrual cycle phase was not assessed in the study 
Quality check of RNA Yes RNA quality was assessed by agarose gel 
electrophoresis and spectrophotometry 
Validation of microarray 
results 
Yes By RT-PCR  
Other potential sources Yes Clinical characteristics of participants not provided. 
 
Mettler et al. 2006 
Methods Cross-sectional study 
Published gene list available 
Participants Women with endometriosis (age 22-40) that have regular menstrual 
cycles and are not using hormonal treatment (N = 5). Endometriosis 
was confirmed by laparoscopy. 
Interventions Endometrial biopsies as well as endometriotic lesions collected; RNA 
extracted from endometrial tissue; Hybridisation with Atlas Human 
1,2 array containing 1176 probe sets; compared gene expression of 
eutopic endometrial and endometriotic lesion samples with 
endometriosis. 
Outcome  Genes found to be significantly up-regulated or down-
regulated in endometriotic lesions as compared to eutopic 
endometrium from women with endometriosis were 9and 4, 
respectively. 
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 11 
Blind histological 
assessment of samples  
Unclear Information not provided in the study 
Use of established 
criteria for assessing 
menstrual cycle phase 
No Menstrual cycle phase was not assessed in the study 
Quality check of RNA Yes RNA quality was assessed by agarose gel 
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electrophoresis 
Validation of microarray 
results 
No Information not provided in the study 
Other potential sources Yes Clinical characteristics of participants not provided. 
 
Sun et al. 2014 
Methods Cross-sectional study 
Published gene list available 
Participants Women with endometriosis (age 24-45) that have regular menstrual 
cycles and are not using hormonal treatment (N = 4). Endometriosis 
was confirmed by laparoscopy. 
Interventions Endometrial biopsies as well as endometriotic lesions collected by 
curettage; RNA extracted from endometrial tissue; Hybridisation 
with SurePrint G3 Human Gene Expression 8x60K v2 array 
containing 32776 probe sets; compared gene expression of eutopic 
endometrial and endometriotic lesion samples with endometriosis. 
Outcomes  Genes found to be significantly up-regulated or down-
regulated in endometriotic lesions as compared to eutopic 
endometrium from women with endometriosis were 527and 
421, respectively. 
 Dysregulated pathways in the endometriotic lesions by Gene 
Ontology analysis 
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 4 
Blind histological 
assessment of samples  
Unclear Information not provided in the study 
Use of established criteria 
for assessing menstrual 
cycle phase 
No Menstrual cycle phase was not assessed in the study 
Quality check of RNA Yes RNA yield was assessed by NanoDrop ND-2000 
spectrophotometer (Thermo Fisher Scientific) and 
RNA quality was assessed by Agilent 2100 
bioanalyzer and RNA 6000 Nano kit (Agilent 
Technologies) 
Validation of microarray 
results 
Yes Results verified by RT-PCR 
Other potential sources No Clinical characteristics of participants provided. 
 
Vouk et al. 2011 
Methods Cross-sectional study 
Published gene list available 
Participants Women with endometriosis (age 24-50) that have regular menstrual 
cycles and are not using hormonal treatment (N = 20). Endometriosis 
was confirmed by laparoscopy. 
Interventions Endometrial biopsies as well as endometriotic lesions collected by 
hysterectomy or biopsy; RNA extracted from endometrial tissue and 
endometriotic lesions; Hybridisation with TaqMan low-density array 
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containing 172 probe sets; compared gene expression of eutopic 
endometrial and endometriotic lesion samples with endometriosis. 
Outcomes  Genes found to be significantly up-regulated or down-
regulated in endometriotic lesions as compared to eutopic 
endometrium from women with endometriosis were 60 and 
18, respectively. 
 Dysregulated pathways in the endometriotic lesions from 
women with endometriosis 
Risk of Bias 
Item Judgement Description 
Small sample size Yes N = 20 
Blind histological 
assessment of samples  
Unclear  Information not provided in the study 
Use of established criteria 
for assessing menstrual 
cycle phase 
No Menstrual cycle phase was not assessed in the study 
Quality check of RNA Yes RNA quality was assessed by Agilent bioanalyzer 
Validation of microarray 
results 
Yes Results verified by RT-PCR 
Other potential sources No Clinical characteristics of participants provided. 
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Appendix 2: Characteristics of excluded studies. 
Study Reason for exclusion 
Sha et al. (2007) Endometrial endothelial cells from eutopic 
endometrium from women with and without 
endometriosis used 
Wu et al. (2006) Epithelial cells from eutopic endometrium and 
endometriotic lesions from women with endometriosis 
were used 
Matsuzaki et al. (2005) Epithelial and stromal cells from eutopic endometrium 
and deep rectovaginal endometriotic lesions from 
women with endometriosis 
Matsuzaki et al. (2004) Epithelial and stromal cells from eutopic endometrium 
and rectovaginal endometriotic lesions from women 
with endometriosis by laser capture micro-dissection 
Arimoto et al. (2003) Epithelial cells isolated from eutopic endometrium and 
ovarian lesions from women with endometriosis 
Fassbender et al. (2012) Published gene lists with menstrual cycle phase 
adjusted data for women with endometriosis and for 
women without endometriosis 
Roth et al. (2007) Study has not been peer-reviewed as yet. Only 
individual patient gene expression data was available 
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Appendix 3: Participant characteristics for studies included in the meta-analysis with 
individual patient gene expression data available.  
Patient ID Age Menstrual phase Diagnosed 
endometriosis 
(E/NE)
++
 
Hormone 
treatment 
(Y/N) 
Hull et al. 2008: Unavailable participant characteristics  
Hever et al.2007  
01-M Missing Proliferative E N 
02-M Missing Proliferative E N 
04-M Missing Secretory E N 
05-M Missing Secretory E N 
06-M Missing Secretory E N 
02-G Missing Secretory E N 
03-G Missing Secretory E N 
05-G Missing Secretory E N 
06-G Missing Secretory E N 
08-G Missing Secretory E N 
Khan et al. 2012  
E17 29 Proliferative E N 
E20 40 Proliferative E N 
E23 33 Proliferative E N 
E26 45 Proliferative E N 
E31 24 Proliferative E N 
E32 28 Proliferative E N 
E33 28 Secretory E N 
E40 25 Proliferative E N 
E43 40 Proliferative E N 
E48 31 Proliferative E N 
E49 37 Secretory E N 
E52 30 Proliferative E N 
E56 30 Proliferative E N 
E57 37 Secretory E N 
E68 31 Secretory E N 
E70 34 Secretory E N 
E73 25 Proliferative E N 
E75 40 Proliferative E N 
Talbi et al. 2006  
598 33 Proliferative NE N 
M182 34 Proliferative NE N 
M165 31 Proliferative NE N 
M169 32 Proliferative NE N 
455
*
 39 Proliferative NE N 
562 50 Proliferative NE N 
629 46 Secretory NE N 
650 48 Secretory NE N 
664 44 Secretory NE N 
610 49 Secretory NE N 
617 42 Secretory NE N 
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Patient ID Age Menstrual phase Diagnosed 
endometriosis 
(E/NE)
++
 
Hormone 
treatment 
(Y/N) 
626 42 Secretory NE N 
M153 34 Secretory NE N 
659 46 Secretory NE N 
G98A 30 Secretory NE N 
M158 23 Secretory NE N 
M163 33 Secretory NE N 
442 43 Secretory NE N 
449 39 Secretory NE N 
462 39 Secretory NE N 
614 43 Secretory NE N 
576 41 Secretory NE N 
619 44 Secretory NE N 
Burney et al. 2007   
26A 31 Proliferative E N 
587 37 Proliferative E N 
647 39 Proliferative E N 
594 38 Proliferative E N 
651 37 Proliferative E N 
508 25 Proliferative E N 
489 39 Secretory E N 
496 37 Secretory E N 
599 35 Secretory E N 
27A 22 Secretory E N 
517 35 Secretory E N 
575 26 Secretory E N 
33A 27 Secretory E N 
7A/97A 35 Secretory E N 
73A 26 Secretory E N 
516 34 Secretory E N 
540 37 Secretory E N 
543 38 Secretory E N 
678 44 Secretory E N 
72A 31 Secretory E N 
645 39 Secretory E N 
Zevallos 2012  
PECN T-047 25 Secretory E N 
PECN T-061 29 Secretory E N 
PECN T-126 29 Proliferative E N 
PECN T-145 43 Proliferative E N 
PECN T-147 38 Proliferative E N 
PECN T-148 36 Proliferative E N 
PECN T-169 34 Secretory E N 
PECN T-174 39 Secretory E N 
PECN T-186 38 Secretory E N 
PECN T-215 37 Secretory E N 
PECN T-244 31 Secretory E N 
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Patient ID Age Menstrual phase Diagnosed 
endometriosis 
(E/NE)
++
 
Hormone 
treatment 
(Y/N) 
PECN T-271 34 Secretory E N 
PECN T-013 34 Secretory NE N 
PECN T-078 32 Secretory NE N 
PECN T-089 34 Secretory NE N 
PECN T-124 32 Proliferative NE N 
PECN T-136 33 Secretory NE N 
PECN T-139 28 Proliferative NE N 
PECN T-156 25 Proliferative NE N 
PECN T-160 34 Proliferative NE N 
PECN T-164 35 Secretory NE N 
PECN T-167 37 Secretory NE N 
PECN T-184 29 Secretory NE N 
PECN T-192 42 Proliferative NE N 
PECN T-223 40 Secretory NE N 
PECN T-231 32 Proliferative NE N 
PECN T-224 39 Secretory NE N 
PECN T-257 43 Secretory NE N 
Crispi et al. 2013: Unavailable no endometriosis participant characteristics  
1 31 Proliferative E N 
2 30 Proliferative E N 
3 32 Proliferative E N 
4 35 Proliferative E N 
5 30 Proliferative E N 
6 30 Proliferative E N 
7 22 Proliferative E N 
8 42 Proliferative E N 
Sohler et al. 2013  
1 40 Proliferative E N 
2 43 Secretory E N 
3 33 Proliferative E N 
4 23 Secretory E N 
5 29 Proliferative E N 
6 25 Secretory E N 
7 36 Secretory E N 
8 52 Secretory E N 
9 30 Proliferative E N 
10 30 Proliferative E N 
11 37 Secretory E N 
12 35 Proliferative E N 
13 35 Secretory E N 
14 38 Secretory E N 
15 29 Proliferative E N 
16 33 Secretory E N 
17 21 Proliferative E N 
18 47 Proliferative E N 
22 38 Proliferative E N 
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Patient ID Age Menstrual phase Diagnosed 
endometriosis 
(E/NE)
++
 
Hormone 
treatment 
(Y/N) 
25 36 Secretory E N 
27 33 Not known E N 
31 34 Not known E N 
32 22 Secretory E N 
35 36 Not known E N 
36 29 Proliferative E N 
37 26 Mid-cycle E N 
38 46 Secretory E N 
E: Endometriosis; NE: No endometriosis 
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Appendix 4: Steps for normalisation of individual patient gene expression data by 
GeneSpring. 
 
1. A new project was created in the start-up dialogue box. 
 
2. From under the “Project” option, “New Experiment” option was chosen to create a new 
experiment. 
 
3. The experiment was named accordingly and analysis chosen depending on the type of 
platform used. Data Import work flow was chosen.  
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4. Once the experiment was set up, the data was loaded on to the programme. 
 
5. Proceed on to the next step once data has been loaded. 
 
 
6. For preproceesing, “baseline to median of all samples” was chosen. 
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7. The programme then runs the pre-processing and normalisation. 
 
8. Once normalisation is finished the programme gives the boxplots and the entity list of the 
normalised data. The normalised entity list can be exported to another drive for further 
analysis by right clicking on the “entity list” option under the experiment and then 
choosing “export list” option.   
 
9. The information that is required to be included in the list, such as Entrez gene ID, Gene 
name, etc., can be chosen. 
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Appendix 5: Steps for the meta-analysis and analysis of dysregulated genes for published 
gene lists. 
1. Install R version 3.1.2 using standard installation procedures. 
2. Create an analysis folder in your hard drive to store the input and output ﬁles as well as the 
R analysis script. 
3. Install the RobustRankAggreg package by going to “Packages” and then to “Install 
packages”. The package containing functions for RRA analysis is downloaded from 
CRAN website and installed the system. 
4. Load the previously installed RobustRankAggreg package to use the functions deﬁned by 
it by running the command in the R console: 
library(RobustRankAggreg) 
5. Deﬁne the working directory for the analysis.  
setwd("C:/Name of the Working Directory/") 
6. To read the data from the constructed ﬁle into R, use the command    
meta <-  read.delim("up_regulated.txt", na = "") 
This command reads in the aforementioned ﬁle and assigns it to the data frame named 
“meta”. The argument na = "" deﬁnes that empty cells in the table are recognized as “not 
available” in the data frame “meta”. 
7. Convert the data to a list format as required by RobustRankAggreg  
meta <-  as.list(meta) 
8. To get rid of the “not available” positions in the list, we use custom helper function:  
for (i in 1: length(meta)){meta[[i]] <- meta[[i]] [!is.na(meta[[i]])]  
meta[[i]] <- as.character(meta[[i]])} 
9. Deﬁne the vector count , which stores the data about how many genes each study was able 
to detect:    
count <- c(x, y, z,)  
where x,y and Z denote the total number of a genes detectable by the study or the 
microarray platform being used. 
10. Construct the matrix of normalized ranks using rankMatrix command:   
rankmat <- rankMatrix(meta, N = count)  
This command uses the list consisting of dysregulated genes as an input (previously 
constructed list  meta ). The argument N is used to deﬁne the number of genes each study 
was able to proﬁle (previously deﬁned vector count) 
11. Run RRA analysis using the “aggregateRanks” command to obtain a signiﬁcance score ρ-
score 
ranks<- aggregateRanks(rmat=rankmat) 
12. Apply a multiple testing correction. Conservative Bonferroni correction is used by 
multiplying all the ρ-scores with the number of studies or the number of gene lists 
ranks$adjustedPval <-  apply(cbind(ranks$Score * max(count), 1), 1, min)   
13. Filter the results by signiﬁcance 
results <- ranks[ranks$adjustedPval < 0.05,] 
Results can be displayed by running the command results, which displays the outcome of 
the analysis 
14. Export the results table out of R with the following command:  
write.table(results, "results.txt", sep = "\t") 
This command creates a tab-delimited results ﬁle into the analysis folder. 
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Appendix 6: Top-35 upregulated genes in eutopic endometrium from women with 
endometriosis compared to from women without endometriosis.  
 
Entrez 
 ID 
Gene  
Symbol Gene name 
Fold  
Change P value 
384 ARG2 Arginase, type II 2.65 1.8X10
-24
 
4837 NNMT Nicotinamide N-methyltransferase 4.48 3X10
-23
 
23710 GABARAPL1  GABA(A) receptor-associated protein like 1 2.51 8.5X10
-23
 
9547 CXCL14  Chemokine (C-X-C motif) ligand 14 10.7 1X10
-22
 
1612 DAPK1 Death-associated protein kinase 1 2.61 1.2X10
-22
 
1942 EFNA1  Ephrin-A1 2.64 3.9X10
-22
 
6564 SLC15A1  Solute carrier family 15 member 1 4.38 7.2X10
-22
 
1910 EDNRB  Endothelin receptor type B 3.22 1.6X10
-21
 
6505 SLC1A1  Solute carrier family 1  member 1 4.71 4.9X10
-21
 
53630 BCMO1  Beta-carotene 15,15'-monooxygenase 1 2.45 6.8X10
-21
 
1604 CD55 
CD55 molecule, decay accelerating factor 
for complement (Cromer blood group) 
3.73 6.8X10
-21
 
7042 TGFB2  Transforming growth factor, beta 2 2.64 6.8X10
-21
 
347 APOD Apolipoprotein D 3.32 8.6X10
-21
 
79838 TMC5 Transmembrane channel-like 5 3.31 1.8X10
-20
 
54762 GRAMD1C GRAM domain containing 1C 3.71 6.1X10
-20
 
6539 SLC6A12  
Solute carrier family 6 (neurotransmitter 
transporter, betaine/GABA), member 12 
2.53 6.2X10
-20
 
8531 CSDA Cold shock domain protein A 1.78 9.7X10
-20
 
6696 SPP1 Secreted phosphoprotein 1 5.35 2.1X10
-19
 
1356 CP Ceruloplasmin (ferroxidase) 4.89 8.8X10
-19
 
10370 CITED2  
Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 2 
2.57 9.8X10
-19
 
3914 LAMB3  Laminin, beta 3 3.49 1.2X10
-18
 
1052 CEBPD 
CCAAT/enhancer binding protein (C/EBP), 
delta 
3.14 2 X10
-18
 
7849 PAX8 Paired box 8 2.33 2.1X10
-18
 
1647 GADD45A  Growth arrest and DNA-damage-inducible α 3.21 2.2X10-18 
5047 PAEP Progestagen-associated endometrial protein 10 2.3X10
-18
 
1803 DPP4 Dipeptidyl-peptidase 4 3.32 3X10
-18
 
79722 ANKRD55  Ankyrin repeat domain 55 2.49 4.8X10
-18
 
22996 TTC39A Tetratricopeptide repeat domain 39A 2.56 5.2X10
-18
 
1311 COMP Cartilage oligomeric matrix protein 4.58 6.9X10
-18
 
107 ADCY1 Adenylate cyclase 1 (brain) 2.59 1X10
-17
 
3026 HABP2  Hyaluronan binding protein 2 3 2.5X10
-17
 
4217 MAP3K5 
Mitogen-activated protein kinase kinase 
kinase 5 
3.15 2.9X10
-17
 
9829 DNAJC6 
DnaJ (Hsp40) homolog, subfamily C, 
member 6 
3.2 3.3X10
-17
 
6947 TCN1 Transcobalamin I 4.86 3.3X10
-17
 
1824 DSC2 Desmocollin 2 2.09 4.1X10
-17
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Appendix 7: Top-35 downregulated genes in eutopic endometrium from women with 
endometriosis compared to from women without endometriosis. 
 
Entrez 
 ID 
Gene  
Symbol Gene name 
Fold  
Change P value 
6424 SFRP4 Secreted frizzled-related protein 4 0.2 3X10
-23
 
1307 COL16A1  Collagen, type XVI, alpha 1 0.4 3.9X10
-22
 
2735 GLI1  GLI family zinc finger 1 0.6 8.3X10
-20
 
9770 RASSF2 
Ras association (RalGDS/AF-6) domain family 
member 2 
0.4 2.1X10
-19
 
891 CCNB1 Cyclin B1 0.4 4.10X10
19
 
1908 EDN3  Endothelin 3 0.3 4.8X10
-19
 
10857 PGRMC1 Progesterone receptor membrane component 1 0.4 4.8X10
-19
 
9493 KIF23  Kinesin family member 23 0.4 6.6X10
-19
 
9315 C5orf13 Chromosome 5 open reading frame 13 0.3 7.2X10
-18
 
11065 UBE2C  Ubiquitin-conjugating enzyme E2C 0.4 9.2X10
-18
 
55244 SLC47A1  Solute carrier family 47, member 1 0.3 1.2X10
-17
 
10234 LRRC17  Leucine rich repeat containing 17 0.4 1.3X10
-17
 
332 BIRC5 Baculoviral IAP repeat-containing 5 0.5 1.9X10
-17
 
9133 CCNB2 Cyclin B2 0.4 2.2X10
-17
 
7298 TYMS Thymidylate synthetase 0.4 2.8X10
-17
 
5241 PGR Progesterone receptor 0.4 3.1X10
-17
 
6240 RRM1 Ribonucleotide reductase M1 0.6 4.5X10
-17
 
26227 PHGDH  Phosphoglycerate dehydrogenase 0.5 4.5X10
-17
 
701 BUB1B  
Budding uninhibited by benzimidazoles 1 
homolog beta (yeast) 
0.4 4.7X10
-17
 
4675 NAP1L3  Nucleosome assembly protein 1-like 3 0.4 4.9X10
-17
 
5111 PCNA Proliferating cell nuclear antigen 0.5 5.4X10
-17
 
58189 WFDC1 WAP four-disulfide core domain 1 0.4 7.1X10
-17
 
140465 MYL6B  
Myosin, light chain 6B, alkali, smooth muscle and 
non-muscle 
0.6 1.6X10
-16
 
55872 PBK  PDZ binding kinase 0.3 2.7X10
-16
 
64388 GREM2 Gremlin 2 0.3 3.3X10
-16
 
8395 PIP5K1B  
Phosphatidylinositol-4-phosphate 5-kinase, type I, 
beta 
0.4 3.7X10
-16
 
7083 TK1 Thymidine kinase 1, soluble 0.5 4.6X10
-16
 
10112 KIF20A  Kinesin family member 20A 0.4 5.3X10
-16
 
4678 NASP  
Nuclear autoantigenic sperm protein (histone-
binding) 
0.6 6.6X10
-16
 
3479 IGF1  Insulin-like growth factor 1 (somatomedin C) 0.4 9.9X10
-16
 
24141 C20orf103 Chromosome 20 open reading frame 103 0.5 1X10
-15
 
3033 HADH  Hydroxyacyl-CoA dehydrogenase 0.6 1.2X10
-15
 
991 CDC20 Cell division cycle 20 homolog (S. cerevisiae) 0.5 1.4X10
-15
 
7153 TOP2A Topoisomerase (DNA) II alpha 170kDa 0.3 1.4X10
-15
 
9833 MELK  Maternal embryonic leucine zipper kinase 0.4 1.6X10
-15
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Appendix 8: Top 20 dysregulated pathways in the eutopic endometrium from women with 
endometriosis as compared to from women without endometriosis. 
 
Pathway ID Pathway name P value 
F 
score 
Overall 
GO:0045087  Innate immune response 1.9X10
-6
 16.53 
GO:0005275  Amine transmembrane transporter activity 5.7X10
-6
 14.92 
GO:0002526  Acute inflammatory response 7.4X10
-6
 14.08 
GO:0019724  B cell mediated immunity 1X10
-5
 13.44 
GO:0016064  Immunoglobulin mediated immune response 1X10
-5
 13.43 
GO:0004896  
Hematopoietin/interferon-class (D200-domain) 
cytokine receptor activity 
1.2X10
-5
 13.03 
GO:0050817  Coagulation     
GO:0007596  Blood coagulation 1.3X10
-5
 12.59 
GO:0006935  Chemotaxis 1.3X10
-5
 12.54 
GO:0042330  Taxis 1.3X10
-5
 12.54 
GO:0002253  Activation of immune response 2X10
-5
 12.12 
GO:0002460  
Adaptive immune response based on somatic 
recombination of immune receptors built from 
immunoglobulin superfamily domains 
2.1X10
-5
 11.99 
GO:0002250  Adaptive immune response 2.3X10
-5
 11.83 
GO:0007204  Elevation of cytosolic calcium ion concentration 2.3X10
-5
 11.76 
GO:0051480  Cytosolic calcium ion homeostasis 2.3X10
-5
 11.76 
GO:0050776  Regulation of immune response 2.4X10
-5
 11.49 
GO:0015171  Amino acid transmembrane transporter activity 2.9X10
-5
 11.29 
GO:0007599  Hemostasis 2.9X10
-5
 11.25 
GO:0046943 Carboxylic acid transmembrane transporter activity 3.8X10
-5
 11.01 
GO:0006959 Humoral immune response 4.4X10
-5
 10.76 
Proliferative phase 
GO:0006935  Chemotaxis 5.6X10
-4
 563.24 
GO:0042330  Taxis 5.6X10
-4
 563.24 
GO:0002684  Positive regulation of immune system process 5.6X10
-4
 472.76 
GO:0009617  Response to bacterium 5.6X10
-4
 465.51 
GO:0042379  Chemokine receptor binding 7.5X10
-4
 460.02 
GO:0046649  Lymphocyte activation 8.5X10
-4
 457.74 
GO:0008009  Chemokine activity 7.5X10
-4
 455.66 
GO:0001664  G-Protein-coupled receptor binding 1X10
-3
 438.23 
GO:0000165  MAPKKK cascade 5.6X10
-4
 438.17 
GO:0030097  Hemopoiesis 5.6X10
-4
 416.35 
GO:0048534  Hemopoietic or lymphoid organ development 5.6X10
-4
 391.78 
GO:0007626  Locomotory behaviour 1.2X10
-3
 382.76 
GO:0002521  Leukocyte differentiation 5.3X10
-5
 373.21 
GO:0042110  T cell activation 8.2X10
-4
 369.29 
GO:0045595  Regulation of cell differentiation 5.6X10
-4
 348.41 
GO:0048584  Positive regulation of response to stimulus 2.9X10
-3
 346.79 
GO:0002252  Immune effector process 3.2X10
-3
 341.76 
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Pathway ID Pathway name P value 
F 
score 
GO:0048583  Regulation of response to stimulus 1.1X10
-3
 332.09 
GO:0019882  Antigen processing and presentation 5.4X10
-3
 330.89 
GO:0051347  Positive regulation of transferase activity 2.6X10
-3
 327.04 
Secretory phase 
GO:0045087  Innate immune response 3.9X10
-12
 800.29 
GO:0002253  Activation of immune response 1.9X10
-11
 731.01 
GO:0048583  Regulation of response to stimulus 1X10
-9
 727.45 
GO:0050776  Regulation of immune response 1.6X10
-11
 727.08 
GO:0002684  Positive regulation of immune system process 9.8X10
-10
 718.7 
GO:0048584  Positive regulation of response to stimulus 4.2X10
-10
 703.8 
GO:0002526  Acute inflammatory response 2.5X10
-10
 702.86 
GO:0050778  Positive regulation of immune response 1.4X10
-10
 676.53 
GO:0019724  B cell mediated immunity 1.5X10
-10
 668.52 
GO:0006959  Humoral immune response 2.5X10
-10
 646.26 
GO:0016064 Immunoglobulin mediated immune response 2.2X10
-10
 645.13 
GO:0006935  Chemotaxis 1.3X10
-4
 617.04 
GO:0042330  Taxis 1.3X10
-4
 617.04 
GO:0002460  
Adaptive immune response based on somatic 
recombination of immune receptors built from 
immunoglobulin superfamily domains 
1X10
-9
 607.88 
GO:0002250  Adaptive immune response 1X10
-9
 600.73 
GO:0002252  Immune effector process 2X10
-8
 599.32 
GO:0002449  Lymphocyte mediated immunity 3.1X10
-10
 529.1 
GO:0002443  Leukocyte mediated immunity 9.2X10
-10
 514.51 
GO:0030155  Regulation of cell adhesion 4.9X10
-7
 502.69 
GO:0006916  Anti-apoptosis 3.8X10
-5
 449.56 
Eutopic endometrium: Proliferative Vs Secretory phase 
GO:0042035  Regulation of cytokine biosynthetic process 9.7X10
-8
 21.65 
GO:0005249  Voltage-gated potassium channel activity 9.7X10
-8
 21.2 
GO:0042107  Cytokine metabolic process 1.6X10
-7
 20.03 
GO:0030955  Potassium ion binding 1.6X10
-7
 19.78 
GO:0042089  Cytokine biosynthetic process 1.7X10
-7
 19.34 
GO:0022843  Voltage-gated cation channel activity 1.7X10
-7
 19.29 
GO:0008227  Amine receptor activity 2.7X10
-7
 18.56 
GO:0009897  External side of plasma membrane 3.5X10
-7
 18.11 
GO:0001816 Cytokine production 3.5X10
-7
 18 
GO:0001653  Peptide receptor activity 3.6X10
-7
 17.73 
GO:0008528  Peptide receptor activity, G-protein coupled 3.6X10
-7
 17.73 
GO:0031225  Anchored to membrane 4.7X10
-7
 17.33 
GO:0006968  Cellular defense response 4.7X10
-7
 17.25 
GO:0003015  Heart process 5.4X10
-7
 16.95 
GO:0060047  Heart contraction 5.4X10
-7
 16.95 
GO:0006874  Cellular calcium ion homeostasis 5.7X10
-7
 16.82 
GO:0055074  Calcium ion homeostasis 5.8X10
-7
 16.7 
GO:0016459  Myosin complex 5.8X10
-7
 16.66 
GO:0005819  Spindle 6X10
-7
 16.56 
GO:0015370  Solute:sodium symporter activity 6.1X10
-7
 16.49 
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Appendix 9: Top-35 upregulated genes in eutopic endometrium from women with 
endometriosis compared to from women without endometriosis in the proliferative phase of 
the menstrual cycle. 
 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
change 
P value  
1942 EFNA1  Ephrin-A1 1.95 0.00058 
50486 G0S2 G0/G1switch 2 2.78 0.00058 
9052 GPRC5A 
G protein-coupled receptor, family C, group 5, 
member A 
1.88 0.00058 
3034 HAL Histidine ammonia-lyase 2.66 0.00058 
3557 IL1RN  Interleukin 1 receptor antagonist 2.75 0.00058 
10221 TRIB1 Tribbles homolog 1 (Drosophila) 2.24 0.00058 
23764 MAFF  
v-Maf musculoaponeurotic fibrosarcoma oncogene 
homolog F (avian) 
2.08 0.00065 
6696 SPP1 Secreted phosphoprotein 1 3.61 0.00086 
1356 CP Ceruloplasmin (ferroxidase) 3.58 0.00116 
4791 NFKB2  
Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells 2 (p49/p100) 
1.24 0.00117 
1890 TYMP Thymidine phosphorylase 1.67 0.00135 
1364 CLDN4  Claudin 4 2.21 0.0017 
1647 GADD45A  Growth arrest and DNA-damage-inducible, alpha 1.86 0.00187 
56649 TMPRSS4 Transmembrane protease, serine 4 2.06 0.00209 
1316 KLF6  Kruppel-like factor 6 2.14 0.00219 
9258 MFHAS1  Malignant fibrous histiocytoma amplified sequence 1 1.35 0.00238 
5801 PTPRR Protein tyrosine phosphatase, receptor type, R 2 0.00242 
2114 ETS2 
v-Ets erythroblastosis virus E26 oncogene homolog 2 
(avian) 
1.4 0.00247 
8714 ABCC3 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 3 
2 0.00248 
7849 PAX8 Paired box 8 1.54 0.00259 
3914 LAMB3  Laminin, beta 3 2.62 0.00274 
124044 SPATA2L Spermatogenesis associated 2-like 1.34 0.00319 
8553 BHLHE40  Basic helix-loop-helix family, member e40 1.9 0.00329 
6928 HNF1B  HNF1 homeobox B 1.54 0.00338 
2634 GBP2  Guanylate binding protein 2, interferon-inducible 1.9 0.00348 
1051 CEBPB  CCAAT/enhancer binding protein (C/EBP), beta 1.37 0.00356 
6533 SLC6A6  
Solute carrier family 6 (neurotransmitter transporter, 
taurine), member 6 
1.47 0.00395 
604 BCL6  B-cell CLL/lymphoma 6 2.15 0.00396 
2872 MKNK2  MAP kinase interacting serine/threonine kinase 2 1.29 0.00396 
3400 ID4  
Inhibitor of DNA binding 4, dominant negative helix-
loop-helix protein 
1.48 0.00415 
8878 SQSTM1 Sequestosome 1 1.31 0.00424 
10158 PDZK1IP1  PDZK1 interacting protein 1 2.39 0.00425 
2810 SFN Stratifin 1.59 0.00455 
79838 TMC5 Transmembrane channel-like 5 1.98 0.00466 
1604 CD55 
CD55 molecule, decay accelerating factor for 
complement (Cromer blood group) 
2.57 0.00489 
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Appendix 10: Top-35 downregulated genes in eutopic endometrium from women with 
endometriosis compared to from women without endometriosis in the proliferative phase of 
the menstrual cycle. 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
change 
P value 
2200 FBN1 Fibrillin 1 0.69 0.00065 
4628 MYH10 Myosin, heavy chain 10, non-muscle 0.69 0.00219 
539 ATP5O 
ATP synthase, H+ transporting, mitochondrial F1 
complex, O subunit 
0.77 0.00263 
79712 GTDC1 Glycosyltransferase-like domain containing 1 0.79 0.00263 
5213 PFKM Phosphofructokinase, muscle 0.83 0.00343 
1289 COL5A1  Collagen, type V, alpha 1 0.62 0.00396 
56945 MRPS22 Mitochondrial ribosomal protein S22 0.86 0.00455 
6424 SFRP4  Secreted frizzled-related protein 4 0.38 0.00497 
273 AMPH Amphiphysin 0.69 0.00521 
64943 NT5DC2 5'-Nucleotidase domain containing 2 0.58 0.0059 
1036 CDO1 Cysteine dioxygenase, type I 0.71 0.00603 
54875 CNTLN  Centlein, centrosomal protein 0.74 0.0064 
4052 LTBP1 
Latent transforming growth factor beta binding 
protein 1 
0.54 0.00667 
292 SLC25A5 
Solute carrier family 25 (mitochondrial carrier; 
adenine nucleotide translocator), member 5 
0.8 0.00702 
2184 FAH Fumarylacetoacetate hydrolase (fumarylacetoacetase) 0.78 0.00708 
1009 CDH11 Cadherin 11, type 2, OB-cadherin (osteoblast) 0.69 0.00729 
10763 NES Nestin 0.69 0.00735 
3151 HMGN2 High-mobility group nucleosomal binding domain 2 0.74 0.00749 
1307 COL16A1 Collagen, type XVI, alpha 1 0.63 0.00782 
8270 LAGE3  L antigen family, member 3 0.79 0.00782 
5125 PCSK5 Proprotein convertase subtilisin/kexin type 5 0.51 0.00786 
9 NAT1 
N-Acetyltransferase 1 (arylamine N-
acetyltransferase) 
0.62 0.0079 
8975 USP13 Ubiquitin specific peptidase 13 (isopeptidase T-3) 0.76 0.0079 
2735 GLI1 GLI family zinc finger 1 0.7 0.00859 
4192 MDK Midkine (neurite growth-promoting factor 2) 0.64 0.00859 
3232 HOXD3  Homeobox D3 0.74 0.00867 
26227 PHGDH  Phosphoglycerate dehydrogenase 0.64 0.00867 
5001 ORC5 Origin recognition complex, subunit 5 0.82 0.00904 
991 CDC20 Cell division cycle 20 homolog (S. cerevisiae) 0.52 0.00911 
3202 HOXA5  Homeobox A5 0.54 0.00916 
7372 UMPS Uridine monophosphate synthetase 0.81 0.01031 
2201 FBN2 Fibrillin 2 0.46 0.01061 
10962 MLLT11  
Myeloid/lymphoid or mixed-lineage leukemia 
(trithorax homolog, Drosophila); translocated to, 11 
0.65 0.01082 
8507 ENC1 Ectodermal-neural cortex 1 (with BTB-like domain) 0.55 0.0112 
23085 ERC1 ELKS/RAB6-interacting/CAST family member 1 0.78 0.0112 
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Appendix 11: Top-35 upregulated genes in eutopic endometrium from women with 
endometriosis compared to from women without endometriosis in the secretory phase of the 
menstrual cycle. 
 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
Change 
P value  
5047 PAEP Progestagen-associated endometrial protein 16.23 6.3X10
-15
 
145741 C2CD4A C2 calcium-dependent domain containing 4A 7.07 1.1X10
-14
 
6505 SLC1A1  
Solute carrier family 1 (neuronal/epithelial high 
affinity glutamate transporter, system Xag), 
member 1 
7.43 1.1X10
-14
 
1942 EFNA1  Ephrin-A1 2.43 6.1X10
-14
 
307 ANXA4  Annexin A4 2.85 8.6X10
-14
 
1356 CP Ceruloplasmin (ferroxidase) 5.43 8.6X10
-14
 
2886 GRB7  Growth factor receptor-bound protein 7 2.08 8.6X10
-14
 
4217 MAP3K5 Mitogen-activated protein kinase kinase kinase 5 3.26 8.6X10
-14
 
3321 IGSF3  Immunoglobulin superfamily, member 3 1.71 9.7X10
-14
 
84159 ARID5B  AT rich interactive domain 5B (MRF1-like) 2.24 1.3X10
-13
 
710 SERPING1  
Serpin peptidase inhibitor, clade G (C1 inhibitor), 
member 1 
3.21 1.4X10
-13
 
2634 GBP2  Guanylate binding protein 2, interferon-inducible 3.07 2.1X10
-13
 
4233 MET Met proto-oncogene  3.36 2.9X10
-13
 
6564 SLC15A1  
Solute carrier family 15 (oligopeptide transporter), 
member 1 
4.49 2.9X10
-13
 
91404 SESTD1 SEC14 and spectrin domains 1 2.49 3.7X10
-13
 
120224 TMEM45B Transmembrane protein 45B 2.59 3.7X10
-13
 
10451 VAV3  vav 3 guanine nucleotide exchange factor 2.15 3.7X10
-13
 
8714 ABCC3 ATP-binding cassette, sub-family C, member 3 2.66 3.9X10
-13
 
85415 RHPN2 Rhophilin, Rho GTPase binding protein 2 3.6 4.1X10
-13
 
3026 HABP2  Hyaluronan binding protein 2 3.31 6.2X10
-13
 
79838 TMC5 Transmembrane channel-like 5 3.75 6.2X10
-13
 
23555 TSPAN15 Tetraspanin 15 2.26 6.2X10
-13
 
347902 AMIGO2  Adhesion molecule with Ig-like domain 2 2.77 6.8X10
-13
 
3914 LAMB3  Laminin, beta 3 3.48 6.8X10
-13
 
1604 CD55 
CD55 molecule, decay accelerating factor for 
complement (Cromer blood group) 
5 
6.9X10
-13
 
28231 SLCO4A1  
Solute carrier organic anion transporter family, 
member 4A1 
2.51 
6.9X10
-13
 
722 C4BPA Complement component 4 binding protein, alpha 5.7 8.8X10
-13
 
3620 IDO1  Indoleamine 2,3-dioxygenase 1 3.26 8.8X10
-13
 
2308 FOXO1  Forkhead box O1 1.98 1.1X10
-12
 
6990 DYNLT3  Dynein, light chain, Tctex-type 3 2.34 1.4X10
-12
 
1910 EDNRB  Endothelin receptor type B 3.21 1.8X10
-12
 
121260 SLC15A4  Solute carrier family 15, member 4 2.63 1.8X10
-12
 
64114 TMBIM1  Transmembrane BAX inhibitor motif containing 1 1.77 1.8X10
-12
 
9249 DHRS3 Dehydrogenase/reductase (SDR family) member 3 2.5 2X10
-12
 
10509 SEMA4B 
Sema domain, immunoglobulin domain (Ig), 
transmembrane domain (TM) and short 
cytoplasmic domain, (semaphorin) 4B 
1.63 2.3X10
-12
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Appendix 12: Top-35 downregulated genes in eutopic endometrium from women with 
endometriosis compared to from women without endometriosis in the secretory phase of the 
menstrual cycle. 
 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
change 
P value 
8395 PIP5K1B Phosphatidylinositol-4-phosphate 5-kinase, type I,β 0.4 1.1X10-14 
1908 EDN3  Endothelin 3 0.28 5.9X10
-14
 
10439 OLFM1  Olfactomedin 1 0.46 8.6X10
-14
 
10234 LRRC17 Leucine rich repeat containing 17 0.34 2.7X10
-13
 
744 MPPED2 Metallophosphoesterase domain containing 2 0.34 6.2X10
-13
 
79695 GALNT12  
UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase 
0.39 6.8X10
-13
 
25803 SPDEF 
SAM pointed domain containing ets transcription 
factor 
0.41 1.4X10
-12
 
79695 GALNT12  
UDP-N-acetyl-alpha-D-galactosamine:polypeptide 
N-acetylgalactosaminyltransferase  
0.42 4.6X10
-12
 
6565 SLC15A2  Solute carrier family 15 member 2 0.19 5.4X10
-12
 
3112 HLA-DOB  Major histocompatibility complex, class II, DOβ 0.39 7.4X10-12 
9770 RASSF2 
Ras association (RalGDS/AF-6) domain family 
member 2 
0.42 9.3X10
-12
 
249 ALPL Alkaline phosphatase, liver/bone/kidney 0.36 1X10
-11
 
9493 KIF23  Kinesin family member 23 0.58 1.1X10
-11
 
64388 GREM2 Gremlin 2 0.39 1.7X10
-11
 
80010 RMI1  
RMI1, RecQ mediated genome instability 1, 
homolog (S. cerevisiae) 
0.61 1.7X10
-11
 
29091 STXBP6 Syntaxin binding protein 6 (amisyn) 0.47 1.8X10
-11
 
201164 PLD6  Phospholipase D family, member 6 0.66 2.1X10
-11
 
580 BARD1  BRCA1 associated RING domain 1 0.63 2.2X10
-11
 
6424 SFRP4 Secreted frizzled-related protein 4 0.23 2.2X10
-11
 
9687 GREB1  Growth regulation by estrogen in breast cancer 1 0.47 2.6X10
-11
 
148327 CREB3L4  cAMP responsive element binding protein 3-like 4 0.51 3X10
-11
 
83690 CRISPLD1  
Cysteine-rich secretory protein LCCL domain 
containing 1 
0.43 3.1X10
-11
 
3248 HPGD Hydroxyprostaglandin dehydrogenase 15-(NAD) 0.34 3.2X10
-11
 
146456 TMED6 
Transmembrane emp24 protein transport domain 
containing 6 
0.38 3.6X10
-11
 
10512 SEMA3C 
Sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3C 
0.47 4.1X10
-11
 
10346 TRIM22  Tripartite motif-containing 22 0.57 4.4X10
-11
 
79366 HMGN5  High-mobility group nucleosome binding domain 5 0.62 5X10
-11
 
25878 MXRA5 Matrix-remodelling associated 5 0.5 5.1X10
-11
 
155066 ATP6V0E2 ATPase, H+ transporting V0 subunit e2 0.53 6.1X10
-11
 
128239 IQGAP3  IQ motif containing GTPase activating protein 3 0.7 6.1X10
-11
 
55283 MCOLN3  Mucolipin 3 0.52 7.2X10
-11
 
57447 NDRG2 NDRG family member 2 0.53 7.4X10
-11
 
359845 FAM101B Family with sequence similarity 101, member B 0.62 8.3X10
-11
 
8654 PDE5A Phosphodiesterase 5A, cGMP-specific 0.58 9X10
-11
 
84189 SLITRK6  SLIT and NTRK-like family, member 6 0.4 9.7X10
-11
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Appendix 13: Top-35 upregulated genes in eutopic endometrium from women with 
endometriosis in the proliferative vs. secretory phase of the menstrual cycle. 
 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
change 
P value 
4684 NCAM1 Neural cell adhesion molecule 1 2.79 6.5X10
-12
 
5627 PROS1 Protein S (alpha) 3.09 2.5X10
-11
 
5791 PTPRE Protein tyrosine phosphatase, receptor type, E 3.01 1.6X10
-10
 
54438 GFOD1  
Glucose-fructose oxidoreductase domain containing 
1 
3.07 2.6X10
-10
 
5271 SERPINB8  
Serpin peptidase inhibitor, clade B (ovalbumin), 
member 8 
2.43 3.5X10
-10
 
81855 SFXN3  Sideroflexin 3 2.35 4X10
-10
 
80303 EFHD1  EF-hand domain family, member D1 3.02 5X10
-10
 
4862 NPAS2 Neuronal PAS domain protein 2 2.32 9.2X10
-10
 
1890 TYMP Thymidine phosphorylase 3.28 1.8X10
-9
 
7035 TFPI 
Tissue factor pathway inhibitor (lipoprotein-
associated coagulation inhibitor) 
2.35 2.2X10
-9
 
5918 RARRES1 
Retinoic acid receptor responder (tazarotene 
induced) 1 
2.98 
2.4X10
-9
 
57214 KIAA1199  KIAA1199 4.15 2.8X10
-9
 
23476 BRD4  Bromodomain containing 4 1.97 3.9X10
-9
 
1803 DPP4 Dipeptidyl-peptidase 4 4.47 3.9X10
-9
 
3690 ITGB3  
Integrin, beta 3 (platelet glycoprotein IIIa, antigen 
CD61) 
2.15 
3.9X10
-9
 
8714 ABCC3 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 3 
3.81 
4.1X10
-9
 
9846 GAB2  GRB2-associated binding protein 2 2.45 4.1X10
-9
 
5578 PRKCA Protein kinase C, alpha 1.8 4.1X10
-9
 
710 SERPING1  
Serpin peptidase inhibitor, clade G (C1 inhibitor), 
member 1 
3.06 
4.1X10
-9
 
3855 KRT7 Keratin 7 4.52 4.2X10
-9
 
7223 TRPC4 
Transient receptor potential cation channel, 
subfamily C, member 4 
3.38 4.4X10
-9
 
415 ARSE Arylsulfatase E (chondrodysplasia punctata 1) 2.87 5.4X10
-9
 
11030 RBPMS  RNA binding protein with multiple splicing 1.93 5.7X10
-9
 
1521 CTSW Cathepsin W 3.19 5.9X10
-9
 
3026 HABP2  Hyaluronan binding protein 2 4 6.2X10
-9
 
978 CDA Cytidine deaminase 2.59 6.5X10
-9
 
7378 UPP1 Uridine phosphorylase 1 2.48 6.8X10
-9
 
579 NKX3-2  NK3 homeobox 2 2.37 7.3X10
-9
 
10855 HPSE Heparanase 3.07 8.9X10
-9
 
113146 AHNAK2  AHNAK nucleoprotein 2 3.26 1X10
-8
 
8534 CHST1 
Carbohydrate (keratan sulfate Gal-6) sulfotransferase 
1 
2.36 
1X10
-8
 
1824 DSC2 Desmocollin 2 2.63 1X10
-8
 
4524 MTHFR Methylenetetrahydrofolate reductase (NAD(P)H) 2.67 1.3X10
-8
 
11067 C10orf10 Chromosome 10 open reading frame 10 2.97 1.6X10
-8
 
3034 HAL Histidine ammonia-lyase 3.97 1X10
-8
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Appendix 14: Top-35 downregulated genes in eutopic endometrium from women with 
endometriosis in the proliferative vs. secretory phase of the menstrual cycle. 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
change 
P value 
53407 STX18 Syntaxin 18 0.32 2X10
-12
 
26275 HIBCH  3-Hydroxyisobutyryl-CoA hydrolase 0.37 4X10
-10
 
983 CDK1 Cyclin-dependent kinase 1 0.39 8.7X10
-10
 
9232 PTTG1 Pituitary tumor-transforming 1 0.37 1.3X10
-9
 
10455 PECI Peroxisomal D3,D2-enoyl-CoA isomerase 0.33 1.8X10
-9
 
5241 PGR Progesterone receptor 0.3 1.9X10
-9
 
8836 GGH  
Gamma-glutamyl hydrolase (conjugase, 
folylpolygammaglutamyl hydrolase) 
0.41 2.1X10
-9
 
3251 HPRT1 Hypoxanthine phosphoribosyltransferase 1 0.51 2.2X10
-9
 
29127 RACGAP1 Rac GTPase activating protein 1 0.48 3.6X10
-9
 
2146 EZH2  Enhancer of zeste homolog 2 (Drosophila) 0.44 3.9X10
-9
 
3655 ITGA6  Integrin, alpha 6 0.46 3.9X10
-9
 
5111 PCNA Proliferating cell nuclear antigen 0.46 3.9X10
-9
 
3838 KPNA2 
Karyopherin alpha 2 (RAG cohort 1, importin 
alpha 1) 
0.44 4.4X10
-9
 
6240 RRM1 Ribonucleotide reductase M1 0.45 5.5X10
-9
 
3148 HMGB2  High-mobility group box 2 0.35 7.7X10
-9
 
7514 XPO1 Exportin 1 (CRM1 homolog, yeast) 0.49 8.2X10
-9
 
9133 CCNB2 Cyclin B2 0.37 1.2X10
-8
 
57535 KIAA1324  KIAA1324 0.34 1.3X10
-8
 
29880 ALG5  
Asparagine-linked glycosylation 5, dolichyl-
phosphate beta-glucosyltransferase 
0.53 
1.4X10
-8
 
7298 TYMS Thymidylate synthetase 0.34 1.4X10
-8
 
3161 HMMR  
Hyaluronan-mediated motility receptor 
(RHAMM) 
0.42 
1.7X10
-8
 
54431 DNAJC10 DnaJ (Hsp40) homolog, subfamily C, member 10 0.34 1.8X10
-8
 
3479 IGF1  Insulin-like growth factor 1 (somatomedin C) 0.42 1.8X10
-8
 
4487 MSX1 Msh homeobox 1 0.39 1.8X10
-8
 
9493 KIF23  Kinesin family member 23 0.39 1.9X10
-8
 
56547 MMP26 Matrix metallopeptidase 26 0.15 1.9X10
-8
 
5955 RCN2 
Reticulocalbin 2, EF-hand calcium binding 
domain 
0.41 
1.9X10
-8
 
79084 WDR77 WD repeat domain 77 0.38 2.4X10
-8
 
9709 HERPUD1 
Homocysteine-inducible, endoplasmic reticulum 
stress-inducible, ubiquitin-like domain member 1 
0.39 2.6X10
-8
 
4678 NASP  
Nuclear autoantigenic sperm protein (histone-
binding) 
0.51 2.8X10
-8
 
8395 PIP5K1B 
Phosphatidylinositol-4-phosphate 5-kinase, type I, 
beta 
0.39 2.8X10
-8
 
9055 PRC1 Protein regulator of cytokinesis 1 0.35 3.2X10
-8
 
3015 H2AFZ H2A histone family, member Z 0.49 3.6X10
-8
 
6430 SRSF5  Serine/arginine-rich splicing factor 5 0.46 3.7X10
-8
 
515 ATP5F1  
ATP synthase, H+ transporting, mitochondrial Fo 
complex, subunit B1 
0.52 4.6X10
-8
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Appendix 15: Top-35 upregulated genes in endometriotic lesions compared to eutopic 
endometrium from women with endometriosis. 
 
Entrez 
Id 
Gene  
symbol 
Gene name 
Fold 
change 
P value 
6505 SLC1A1  
Solute carrier family 1 (neuronal/epithelial high 
affinity glutamate transporter system Xag) 
member1 
3.81 1.1X10
-17
 
7042 TGFB2  Transforming growth factor, beta 2 2.28 1.1X10
-16
 
3026 HABP2  Hyaluronan binding protein 2 3.04 1.8X10
-16
 
79838 TMC5 Transmembrane channel-like 5 2.38 2.3X10
-14
 
79820 CATSPERB Cation channel, sperm-associated, beta 2.11 2.4X10
-14
 
1604 CD55 
CD55 molecule, decay accelerating factor for 
complement (Cromer blood group) 
2.87 
2.7X10
-14
 
54762 GRAMD1C GRAM domain containing 1C 2.98 5.8X10
-14
 
6947 TCN1 Transcobalamin I (vitamin B12 binding protein) 4.93 1.8X10
-13
 
1803 DPP4 Dipeptidyl-peptidase 4 2.95 3.4X10
-13
 
3034 HAL Histidine ammonia-lyase 3.11 5.3X10
-13
 
1591 CYP24A1 
Cytochrome P450, family 24, subfamily A, 
polypeptide 1 
3.28 
5.3X10
-13
 
486 FXYD2  FXYD domain containing ion transport regulator 2 2 1.3X10
-12
 
6564 SLC15A1  
Solute carrier family 15 (oligopeptide transporter), 
member 1 
2.79 
1.5X10
-12
 
79722 ANKRD55  Ankyrin repeat domain 55 2.1 1.7X10
-12
 
6539 SLC6A12  Solute carrier family 6 member 12 2.05 2.9X10
-12
 
28231 SLCO4A1  
Solute carrier organic anion transporter family, 
member 4A1 
2.49 
4X10
-12
 
1311 COMP Cartilage oligomeric matrix protein 3.73 4.6X10
-12
 
53630 BCMO1  Beta-carotene 15,15'-monooxygenase 1 1.89 5.2X10
-12
 
5271 SERPINB8  
Serpin peptidase inhibitor, clade B (ovalbumin), 
member 8 
1.77 
6.2X10
-12
 
1577 CYP3A5 
Cytochrome P450, family 3, subfamily A, 
polypeptide 5 
2.27 7.7X10
-12
 
9829 DNAJC6 DnaJ (Hsp40) homolog, subfamily C, member 6 2.51 2.9X10
-11
 
10045 SH2D3A SH2 domain containing 3A 1.63 3.4X10
-11
 
6097 RORC RAR-related orphan receptor C 1.6 3.8X10
-11
 
6542 SLC7A2  Solute carrier family 7 member 2 2.07 3.9X10
-11
 
1942 EFNA1  Ephrin-A1 1.83 3.9X10
-11
 
22996 TTC39A Tetratricopeptide repeat domain 39A 2.19 4.6X10
-11
 
54463 FAM134B Family with sequence similarity 134, member B 1.88 4.7X10
-11
 
722 C4BPA Complement component 4 binding protein, alpha 3.57 4.8X10
-11
 
22904 SBNO2  Strawberry notch homolog 2 (Drosophila) 1.93 4.9X10
-11
 
8714 ABCC3 
ATP-binding cassette, sub-family C (CFTR/MRP), 
member 3 
2.38 5.3X10
-11
 
9001 HAP1 Huntingtin-associated protein 1 1.65 6.6X10
-11
 
1910 EDNRB  Endothelin receptor type B 2.05 7X10
-11
 
6690 SPINK1  Serine peptidase inhibitor, Kazal type 1 2.17 1.7X10
-10
 
1824 DSC2 Desmocollin 2 1.79 2.6X10
-10
 
11138 TBC1D8  TBC1 domain family, member 8  1.63 2.8X10
-10
 
143 
 
 
Appendix 16: Top-35 downregulated genes in endometriotic lesions compared to eutopic 
endometrium from women with endometriosis. 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
change 
P value 
3151 HMGN2  
High-mobility group nucleosomal binding domain 
2 
0.61 1.8X10
-13
 
51596 CUTA CutA divalent cation tolerance homolog (E. coli) 0.53 1.6X10
-11
 
27018 NGFRAP1  
Nerve growth factor receptor (TNFRSF16) 
associated protein 1 
0.6 1.4X10
-10
 
9791 PTDSS1 Phosphatidylserine synthase 1 0.6 1.6X10
-10
 
9770 RASSF2 
Ras association (RalGDS/AF-6) domain family 
member 2 
0.52 2.1X10
-10
 
9500 MAGED1  Melanoma antigen family D, 1 0.45 2.7X10
-10
 
26227 PHGDH  Phosphoglycerate dehydrogenase 0.65 5.2X10
-10
 
10857 PGRMC1 Progesterone receptor membrane component 1 0.59 9.2X10
-10
 
57570 TRMT5 TRM5 tRNA methyltransferase 5 homolog 0.64 1.9X10
-9
 
140465 MYL6B  
Myosin, light chain 6B, alkali, smooth muscle and 
non-muscle 
0.67 4.2X10
-9
 
1628 DBP  
D site of albumin promoter (albumin D-box) 
binding protein 
0.63 
6.3X10
-9
 
5955 RCN2 Reticulocalbin 2, EF-hand calcium binding domain 0.6 7.2X10
-9
 
9324 HMGN3  
High mobility group nucleosomal binding domain 
3 
0.63 1.1X10
-8
 
23475 QPRT Quinolinate phosphoribosyltransferase 0.59 1.3X10
-8
 
5501 PPP1CC 
Protein phosphatase 1, catalytic subunit, gamma 
isozyme 
0.64 
1.7X10
-8
 
64710 NUCKS1  
Nuclear casein kinase and cyclin-dependent kinase 
substrate 1 
0.63 
5.3X10
-8
 
201254 STRA13 Stimulated by retinoic acid 13 homolog (mouse) 0.76 6.3X10
-8
 
10234 LRRC17 Leucine rich repeat containing 17 0.5 7X10
-8
 
1278 COL1A2  Collagen, type I, alpha 2 0.62 7.5X10
-8
 
64110 MAGEF1  Melanoma antigen family F, 1 0.78 8.1X10
-8
 
6424 SFRP4 Secreted frizzled-related protein 4 0.41 1.1X10
-7
 
3945 LDHB Lactate dehydrogenase B 0.56 1.2X10
-7
 
1163 CKS1B CDC28 protein kinase regulatory subunit 1B 0.72 1.4X10
-7
 
9315 C5orf13 Chromosome 5 open reading frame 13 0.54 1.6X10
-7
 
55830 GLT8D1  Glycosyltransferase 8 domain containing 1 0.69 1.8X10
-7
 
8270 LAGE3  L antigen family, member 3 0.62 1.9X10
-7
 
4192 MDK Midkine (neurite growth-promoting factor 2) 0.63 2X10
-7
 
3033 HADH  Hydroxyacyl-CoA dehydrogenase 0.65 2.2X10
-7
 
6297 SALL2  Sal-like 2 (Drosophila) 0.71 2.2X10
-7
 
11331 PHB2  Prohibitin 2 0.71 2.4X10
-7
 
5985 RFC5 Replication factor C (activator 1) 5, 36.5kDa 0.75 2.4X10
-7
 
6117 RPA1 Replication protein A1, 70kDa 0.62 2.5X10
-7
 
10575 CCT4 Chaperonin containing TCP1, subunit 4 (delta) 0.72 2.7X10
-7
 
10455 PECI Peroxisomal D3,D2-enoyl-CoA isomerase 0.63 2.7X10
-7
 
79017 GGCT Gamma-glutamylcyclotransferase 0.59 3X10
-7
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Appendix 17: Top 20 dysregulated pathways in the endometriotic lesions compared eutopic 
endometrium from women with endometriosis. 
 
Pathway ID Pathway name P value F score 
Overall  
  
GO:0045087  Innate immune response 1.9X10
-6
 16.53 
GO:0005275  Amine transmembrane transporter activity 5.7X10
-6
 14.92 
GO:0002526  Acute inflammatory response 7.4X10
-6
 14.08 
GO:0019724  B cell mediated immunity 1X10
-5
 13.44 
GO:0016064  Immunoglobulin mediated immune response 1X10
-5
 13.43 
GO:0004896  
Hematopoietin/interferon-class (D200-domain) cytokine 
receptor activity 
1.2X10
-5
 
13.03 
GO:0050817  Coagulation 1.3X10
-5
 12.6 
GO:0007596  Blood coagulation 1.3X10
-5
 12.59 
GO:0006935  Chemotaxis 1.3X10
-5
 12.54 
GO:0042330  Taxis 1.3X10
-5
 12.54 
GO:0002253  Activation of immune response 2X10
-5
 12.12 
GO:0002460  
Adaptive immune response based on somatic 
recombination of immune receptors built from 
immunoglobulin superfamily domain 
2.1X10
-5
 
11.99 
GO:0002250  Adaptive immune response 2.3X10
-5
 11.83 
GO:0007204  Elevation of cytosolic calcium ion concentration 2.3X10
-5
 11.76 
GO:0051480  Cytosolic calcium ion homeostasis 2.3X10
-5
 11.76 
GO:0050776  Regulation of immune response 2.4X10
-5
 11.49 
GO:0015171  Amino acid transmembrane transporter activity 2.9X10
-5
 11.29 
GO:0007599 Hemostasis 2.9X10
-5
 11.25 
GO:0046943  Carboxylic acid transmembrane transporter activity 3.8X10
-5
 11.01 
GO:0006959  Humoral immune response 4.4X10
-5
 10.76 
Proliferative phase 
GO:0009617  Response to bacterium 1.4X10
-5
 11.05 
GO:0002521  Leukocyte differentiation 1.4X10
-5
 11.06 
GO:0019955  Cytokine binding 1.4X10
-5
 10.43 
GO:0006935  Chemotaxis 2X10
-5
 9.85 
GO:0042330  Taxis 2X10
-5
 9.23 
GO:0030098  Lymphocyte differentiation 2.8X10
-5
 9.37 
GO:0006968  Cellular defence response 4.1X10
-5
 8.58 
GO:0042742  Defence response to bacterium 4.1X10
-5
 7.67 
GO:0019882  Antigen processing and presentation 5.5X10
-5
 7.23 
GO:0002696  Positive regulation of leukocyte activation 5.5X10
-5
 6.64 
GO:0050867  Positive regulation of cell activation 5.5X10
-5
 6.02 
GO:0004896 Hematopoietin/interferon-class (D200-domain) cytokine 
receptor activity 
5.5X10
-5
 5.92 
GO:0007626  Locomotory behaviour 7.3X10
-5
 5.06 
GO:0045087  Innate immune response 8X10
-5
 4.82 
GO:0042110  T cell activation 8X10
-5
 4.32 
GO:0051251  Positive regulation of lymphocyte activation 1.1X10
-4
 3.89 
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Pathway ID Pathway name P value F score 
GO:0002684  Positive regulation of immune system process 1.2X10
-4
 3.53 
GO:0030155  Regulation of cell adhesion 1.2X10
-4
 3.32 
GO:0042035  Regulation of cytokine biosynthetic process 1.9X10
-4
 2.89 
GO:0031401  Positive regulation of protein modification process 3X10
-4
 2.5 
Secretory phase: No significant pathways 
Endometriotic lesions: Proliferative Vs Secretory phase 
GO:0006816 Calcium ion transport 1.5X10
-7
 26.05 
GO:0044456 Synapse part 1.5X10
-7
 25.41 
GO:0045211 Postsynaptic membrane 1.7X10
-7
 24.57 
GO:0015276 Ligand-gated ion channel activity 2X10
-7
 23.45 
GO:0022834 Ligand-gated channel activity 2X10
-7
 23.45 
GO:0006836 Neurotransmitter transport 2.7X10
-7
 22.64 
GO:0015674 Di-, tri-valent inorganic cation transport 8.1X10
-7
 20.52 
GO:0005230 Extracellular ligand-gated ion channel activity 8.1X10
-7
 20.48 
GO:0005262  Calcium channel activity 1.1X10
-6
 19.82 
GO:0001505 Regulation of neurotransmitter levels 1.4X10
-6
 19.32 
GO:0030594  Neurotransmitter receptor activity 2X10
-6
 18.6 
GO:0042165 Neurotransmitter binding 2X10
-6
 18.52 
GO:0030136 Clathrin-coated vesicle 2.4X10
-6
 18.19 
GO:0007187 
G-Protein signaling, coupled to cyclic nucleotide second 
messenger 
2.9X10
-6
 
17.79 
GO:0008509  Anion transmembrane transporter activity 3.6X10
-6
 17.37 
GO:0022843 Voltage-gated cation channel activity 3.6X10
-6
 17.26 
GO:0006813 Potassium ion transport 3.6X10
-6
 17.22 
GO:0030135  Coated vesicle 3.9X10
-6
 17.03 
GO:0005267  Potassium channel activity 4X10
-6
 16.85 
GO:0060249 Anatomical structure homeostasis 4X10
-6
 16.85 
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Appendix 18: Top-35 upregulated genes in the proliferative phase endometriotic lesions 
compared to eutopic endometrium from women with endometriosis.  
 
Entrez 
ID 
Gene 
symbol 
Gene name 
Fold 
change 
P value 
4783 NFIL3  Nuclear factor, interleukin 3 regulated 1.95 3.9X10
-6
 
3775 KCNK1 Potassium channel, subfamily K, member 1 1.5 9.4X10
-6
 
23764 MAFF  
v-Maf musculoaponeurotic fibrosarcoma oncogene 
homolog F (avian) 
2.11 1.1X10
-5
 
9473 C1orf38 Chromosome 1 open reading frame 38 1.58 1.3X10
-5
 
10221 TRIB1  Tribbles homolog 1 (Drosophila) 1.91 1.7X10
-5
 
7127 TNFAIP2  Tumor necrosis factor, alpha-induced protein 2 1.39 3X10
-5
 
3976 LIF 
Leukemia inhibitory factor (cholinergic 
differentiation factor) 
2.35 
3.8X10
-5
 
28984 C13orf15 Chromosome 13 open reading frame 15 1.81 4.1X10
-5
 
4973 OLR1  
Oxidized low density lipoprotein (lectin-like) 
receptor 1 
1.71 
4.3X10
-5
 
64092 SAMSN1 
SAM domain, SH3 domain and nuclear localization 
signals 1 
1.68 6.7X10
-5
 
728 C5AR1 Complement component 5a receptor 1 2.18 1.1X10
-4
 
1051 CEBPB  CCAAT/enhancer binding protein (C/EBP), beta 1.46 1.2X10
-4
 
3914 LAMB3  Laminin, beta 3 2.31 1.2X10
-4
 
79838 TMC5 Transmembrane channel-like 5 2.12 1.4X10
-4
 
597 BCL2A1  BCL2-related protein A1 2.59 1.5X10
-4
 
9766 KIAA0247  KIAA0247 1.34 1.5X10
-4
 
1316 KLF6  Kruppel-like factor 6 1.87 1.5X10
-4
 
5791 PTPRE Protein tyrosine phosphatase, receptor type, E 1.51 1.5X10
-4
 
6781 STC1 Stanniocalcin 1 2.05 1.5X10
-4
 
10123 ARL4C  ADP-ribosylation factor-like 4C 1.84 1.6X10
-4
 
55765 C1orf106 Chromosome 1 open reading frame 106 1.85 1.6X10
-4
 
3553 IL1B Interleukin 1, beta 2.31 1.7X10
-4
 
6774 STAT3 
Signal transducer and activator of transcription 3 
(acute-phase response factor) 
1.29 
1.7X10
-4
 
3576 IL8  Interleukin 8 3.92 2X10
-4
 
5055 SERPINB2  
Serpin peptidase inhibitor, clade B (ovalbumin), 
member 2 
1.63 
2.1X10
-4
 
1992 SERPINB1  
Serpin peptidase inhibitor, clade B (ovalbumin), 
member 1 
1.37 
2.6X10
-4
 
6692 SPINT1  Serine peptidase inhibitor, Kunitz type 1 1.76 2.6X10
-4
 
9123 SLC16A3  
Solute carrier family 16, member 3 (monocarboxylic 
acid transporter 4) 
1.48 
3.1X10
-4
 
2114 ETS2 
v-Ets erythroblastosis virus E26 oncogene homolog 2 
(avian) 
1.43 
3.2X10
-4
 
1326 MAP3K8 Mitogen-activated protein kinase kinase kinase 8 1.64 3.2X10
-4
 
6364 CCL20 Chemokine (C-C motif) ligand 20 3.3 3.3X10
-4
 
9518 GDF15 Growth differentiation factor 15 2.41 3.4X10
-4
 
29909 GPR171 G protein-coupled receptor 171 1.34 3.4X10
-4
 
3383 ICAM1  Intercellular adhesion molecule 1 1.68 3.5X10
-4
 
10135 NAMPT Nicotinamide phosphoribosyltransferase 1.57 3.5X10
-4
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Appendix 19: Top-35 downregulated genes in the proliferative phase endometriotic lesions 
compared to eutopic endometrium from women with endometriosis. 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
change 
P value  
40 ACCN1 Amiloride-sensitive cation channel 1, neuronal 0.68 2.1X10
-3
 
8309 ACOX2 Acyl-CoA oxidase 2, branched chain 0.71 2.8X10
-4
 
118 ADD1  Adducin 1 (alpha) 0.84 2.7X10
-3
 
501 ALDH7A1  Aldehyde dehydrogenase 7 family, member A1 0.83 3.6X10
-3
 
11041 B3GNT1  
UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 1 
0.71 5.4X10
-5
 
576 BAI2  Brain-specific angiogenesis inhibitor 2 0.76 3.6X10
-3
 
8815 BANF1  Barrier to autointegration factor 1 0.82 6.1X10
-3
 
54987 C1orf123 Chromosome 1 open reading frame 123 0.83 2.7X10
-3
 
79000 C1orf135 Chromosome 1 open reading frame 135 0.77 2.1X10
-3
 
92342 C1orf156 Chromosome 1 open reading frame 156 0.74 1.7X10
-3
 
51161 C3orf18 Chromosome 3 open reading frame 18 0.79 5.6X10
-3
 
55319 C4orf43 Chromosome 4 open reading frame 43 0.77 2.2X10
-3
 
63920 C5orf54 Chromosome 5 open reading frame 54 0.7 1.6X10
-3
 
729515 C6orf35 Chromosome 6 open reading frame 35 0.84 1.3X10
-4
 
65265 C8orf33 Chromosome 8 open reading frame 33 0.82 5.9X10
-3
 
23066 CAND2 
Cullin-associated and neddylation-dissociated 2 
(putative) 
0.69 2.1X10
-3
 
9994 CASP8AP2 Caspase 8 associated protein 2 0.73 6.8X10
-3
 
869 CBLN1  Cerebellin 1 precursor 0.55 3.7X10
-3
 
10574 CCT7 Chaperonin containing TCP1, subunit 7 (eta) 0.84 5.5X10
-3
 
51293 CD320 CD320 molecule 0.76 3.4X10
-4
 
1031 CDKN2C 
Cyclin-dependent kinase inhibitor 2C (p18, inhibits 
CDK4) 
0.67 
2X10
-3
 
1307 COL16A1  Collagen, type XVI, alpha 1 0.62 1.2X10
-3
 
22894 DIS3  DIS3 mitotic control homolog (S. cerevisiae) 0.84 7X10
-3
 
56986 DTWD1 DTW domain containing 1 0.78 5.5X10
-3
 
8665 EIF3F  Eukaryotic translation initiation factor 3, subunit F 0.9 7X10
-3
 
2135 EXTL2  Exostoses (multiple)-like 2 0.73 3.1X10
-3
 
83989 FAM172A  Family with sequence similarity 172, member A 0.82 2.7X10
-3
 
91775 FAM55C Family with sequence similarity 55, member C 0.74 6.5X10
-3
 
80204 FBXO11  F-box protein 11 0.82 6.8X10
-3
 
2318 FLNC  Filamin C, gamma 0.73 6.7X10
-4
 
79068 FTO  Fat mass and obesity associated 0.85 6.2X10
-4
 
5348 FXYD1  FXYD domain containing ion transport regulator 1 0.64 6.7X10
-5
 
51659 GINS2 GINS complex subunit 2 (Psf2 homolog) 0.71 6.8X10
-3
 
2736 GLI2  GLI family zinc finger 2 0.7 5.9X10
-3
 
9737 GPRASP1 
G protein-coupled receptor associated sorting 
protein 1 
0.68 
3.2X10
-3
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Appendix 20: Significantly dysregulated genes in the secretory phase endometriotic lesions 
compared to eutopic endometrium from women with endometriosis. 
 
Entrez 
ID 
Gene 
symbol 
Gene name 
Fold 
change 
P value 
Upregulated genes 
71 JUND Jun D proto-oncogene 1.7 0.00078 
165 SRSF3  Serine/arginine-rich splicing factor 3 1.37 0.00078 
83692 CYB5R3  Cytochrome b5 reductase 3 1.41 0.00132 
1307 UBC  Ubiquitin C 1.51 0.00557 
1277 CD99L2  CD99 molecule-like 2 1.28 0.00931 
1291 PTRF Polymerase I and transcript release factor 1.57 0.01020 
1293 HNRNPM  Heterogeneous nuclear ribonucleoprotein M 1.35 0.01231 
1385 LAMP1  Lysosomal-associated membrane protein 1 1.47 0.02249 
1434 COL1A1  Collagen, type I, alpha 1 1.69 0.02337 
6387 RPS12 Ribosomal protein S12 1.46 0.02580 
1727 EEF1D  
Eukaryotic translation elongation factor 1 delta 
(guanine nucleotide exchange protein) 
1.34 0.03132 
1634 COL16A1  Collagen, type XVI, alpha 1 2 0.03189 
10395 FMOD  Fibromodulin 1.65 0.03240 
3301 SRSF3  Serine/arginine-rich splicing factor 3 1.34 0.03281  
29940 U2AF1  U2 small nuclear RNA auxiliary factor 1 1.3 0.03322  
1843 FBLN1  Fibulin 1 1.87 0.03614 
1936 AEBP1  AE binding protein 1 1.57 0.03614  
1938 NR4A1 
Nuclear receptor subfamily 4, group A, member 
1 
2.35 0.03746 
30845 NDUFAF3  
NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex, assembly factor 3 
1.25 0.04246  
10209 COL6A1  Collagen, type VI, alpha 1 2.01 0.04956 
Downregulated genes 
55898 UNC45A Unc-45 homolog A (C. elegans) 0.82 0.00572 
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Appendix 21: Top-35 upregulated genes in the secretory phase endometriotic lesions 
compared to proliferative phase endometriotic lesions from women with endometriosis. 
 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
change 
P value 
7705 ZNF146  Zinc finger protein 146 2.57 0.0004 
22794 CASC3 Cancer susceptibility candidate 3 2.77 0.00046 
1387 CREBBP  CREB binding protein 2.77 0.00046 
342096 GOLGA6A  Golgin A6 family, member A 4.65 0.00046 
7166 TPH1 Tryptophan hydroxylase 1 4.33 0.00046 
253959 RALGAPA1  
Ral GTPase activating protein, alpha subunit 1 
(catalytic) 
2.78 0.00046 
84162 KIAA1109  KIAA1109 4.11 0.00046 
23230 VPS13A 
Vacuolar protein sorting 13 homolog A (S. 
cerevisiae) 
2.89 0.00046 
55888 ZNF167  Zinc finger protein 167 3 0.00046 
4684 NCAM1 Neural cell adhesion molecule 1 4.77 0.00046 
9825 SPATA2 Spermatogenesis associated 2 2.64 0.00046 
9668 ZNF615  Zinc finger protein 615 3.55 0.00046 
56154 TEX15 Testis expressed 15 4.22 0.00046 
54806 AHI1  Abelson helper integration site 1 2.37 0.00064 
1859 DYRK1A  
Dual-specificity tyrosine-(Y)-phosphorylation 
regulated kinase 1A 
4.47 0.00064 
374354 NHLRC2  NHL repeat containing 2 2.92 0.00064 
23648 SSBP3 Single stranded DNA binding protein 3 2.4 0.00064 
4598 MVK Mevalonate kinase 2.06 0.00064 
55291 PPP6R3 Protein phosphatase 6, regulatory subunit 3 3.03 0.00064 
9373 PLAA  Phospholipase A2-activating protein 2.31 0.00064 
254394 MCM9 
Minichromosome maintenance complex 
component 9 
2.19 0.00064 
10472 ZNF238  Zinc finger protein 238 2.77 0.00067 
5098 PCDHGA8 Protocadherin gamma subfamily A, 8 2.67 0.00067 
157922 CAMSAP1 Calmodulin regulated spectrin-associated protein 1 2.48 0.00069 
9611 NCOR1 Nuclear receptor corepressor 1 2.46 0.00069 
3980 LIG3  Ligase III, DNA, ATP-dependent 3.39 0.00069 
9831 ZNF623  Zinc finger protein 623 2.69 0.00069 
8675 STX16 Syntaxin 16 2.49 0.0007 
8708 B3GALT1  
UDP-Gal:betaGlcNAc beta 1,3-
galactosyltransferase, polypeptide 1 
2.89 0.00073 
80184 CEP290 Centrosomal protein 290kDa 2.56 0.00073 
9362 CPNE6 Copine VI (neuronal) 2.51 0.00073 
27332 ZNF638  Zinc finger protein 638 2.64 0.00073 
152006 RNF38  Ring finger protein 38 2.69 0.00073 
9569 GTF2IRD1  GTF2I repeat domain containing 1 2.33 0.00073 
23390 ZDHHC17 Zinc finger, DHHC-type containing 17 3.25 0.00073 
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Appendix 22: Top-35 downregulated genes in the secretory phase endometriotic lesions 
compared to proliferative phase endometriotic lesions from women with endometriosis. 
 
Entrez 
Id 
Gene 
symbol 
Gene name 
Fold 
change 
P value 
397 ARHGDIB  Rho GDP dissociation inhibitor (GDI) beta 0.38 0.0005 
1622 DBI 
Diazepam binding inhibitor (GABA receptor 
modulator, acyl-CoA binding protein) 
0.28 0.0005 
2512 FTL Ferritin, light polypeptide 0.26 0.0005 
4792 NFKBIA  
Nuclear factor of kappa light polypeptide gene 
enhancer in B-cells inhibitor, alpha 
0.23 0.0005 
9144 SYNGR2 Synaptogyrin 2 0.24 0.0005 
301 ANXA1  Annexin A1 0.31 0.0006 
55615 PRR5 Proline rich 5 (renal) 0.29 0.0006 
7905 REEP5  Receptor accessory protein 5 0.32 0.0006 
8407 TAGLN2  Transgelin 2 0.37 0.0006 
837 CASP4 Caspase 4, apoptosis-related cysteine peptidase 0.28 0.0007 
1729 DIAPH1  Diaphanous homolog 1 (Drosophila) 0.34 0.0007 
50848 F11R F11 receptor 0.37 0.0007 
4836 NMT1 N-myristoyltransferase 1 0.33 0.0007 
8673 VAMP8 Vesicle-associated membrane protein 8 (endobrevin) 0.25 0.0007 
6574 SLC20A1  
Solute carrier family 20 (phosphate transporter), 
member 1 
0.33 0.0008 
6720 SREBF1  
Sterol regulatory element binding transcription factor 
1 
0.33 0.0008 
6890 TAP1 
Transporter 1, ATP-binding cassette, sub-family B 
(MDR/TAP) 
0.37 0.0008 
26472 PPP1R14B 
Protein phosphatase 1, regulatory (inhibitor) subunit 
14B 
0.41 0.0008 
9709 HERPUD1 
Homocysteine-inducible, endoplasmic reticulum 
stress-inducible, ubiquitin-like domain member 1 
0.32 0.0008 
9592 IER2  Immediate early response 2 0.18 0.0008 
3936 LCP1 Lymphocyte cytosolic protein 1 (L-plastin) 0.37 0.0008 
10899 JTB Jumping translocation breakpoint 0.4 0.0008 
10490 VTI1B  
Vesicle transport through interaction with t-SNAREs 
homolog 1B (yeast) 
0.41 0.0008 
10577 NPC2 Niemann-Pick disease, type C2 0.26 0.0009 
527 ATP6V0C 
ATPase, H+ transporting, lysosomal 16kDa, V0 
subunit c 
0.31 0.0009 
2896 GRN Granulin 0.24 0.0009 
3059 HCLS1  Hematopoietic cell-specific Lyn substrate 1 0.32 0.0009 
3106 HLA-B Major histocompatibility complex, class I, B 0.35 0.0009 
8519 IFITM1  Interferon induced transmembrane protein 1 (9-27) 0.26 0.0009 
10410 IFITM3  Interferon induced transmembrane protein 3 (1-8U) 0.32 0.0009 
6888 TALDO1  Transaldolase 1 0.32 0.0009 
23585 TMEM50A Transmembrane protein 50A 0.4 0.0009 
840 CASP7 Caspase 7, apoptosis-related cysteine peptidase 0.49 0.0009 
7184 HSP90B1 Heat shock protein 90kDa beta (Grp94), member 1 0.25 0.0009 
57136 C20orf3 Chromosome 20 open reading frame 3 0.36 0.0009 
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Appendix 23: Upregulated genes in the eutopic endometrium from women with compared to 
women without endometriosis. 
Entrez ID Gene name P value 
TGFB3 Transforming growth factor β-3 0.000018 
PTPRR Protein tyrosine phosphatase, receptor type, R 0.00045 
CASP5 Cysteine protease 0.000709 
PCDH17 Protocadherin 17 0.0009 
ATP1A2 ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide 0.001059 
BAIAP2 BAI1-associated protein 2 0.00135 
ART3 Putative mono-ADP-ribosyltransferase 0.001419 
FN1 Fibronectin 1 0.0018 
JUNB Jun B proto-oncogene 0.002117 
CELF1 RNA-binding protein CUG-BP/hNab50 (NAB50) 0.002128 
SNCG Synuclein, gamma 0.002249 
CPE Carboxypeptidase E 0.002699 
abcb11 Bile salt export pump 0.002837 
CYP2J2 Cytochrome P450, Family 2, Subfamily J, polypeptide 2 0.003149 
DPT Dermatopontin 0.003175 
ZIC2 ZIC2 protein 0.003546 
IL6ST Interleukin-6 signal transducer 0.003599 
ASCL1 Achaete-scute complex homolog 1 (Drosophila) 0.004233 
CA1 Carbonic anhydrase XII 0.004255 
PMS2L2 PMS7 mRNA (yeast mismatch repair gene PMS1 homologue) 0.004963 
PDE9A Phosphodiesterase 9A 0.005291 
PRIM2 DNA primase (subunit p58) 0.005672 
DDX58 DEAD (Asp-Glu-Ala-Asp) box polypeptide 58 0.006348 
IFNA21 Leukocyte (α) interferon 0.00638 
SCQ2 Secretogranin II gene 0.007797 
TSPAN15 Tetraspanin 15 0.008463 
Vhl von Hippel-Lindau tumor suppressor (VHL) gene 0.008505 
efnb1 ELK receptor tyrosine kinase ligand 0.009213 
PLEKHB1 Pleckstrin homology domain containing, family B (evectins) member 1 0.009519 
MEKK1 MEK kinase 1 0.009921 
GPR56 G-protein-coupled receptor 56 0.010576 
MG2 Mucin 0.010629 
CD1E CD1 R2 gene for MHC-related antigen 0.011337 
FOS V-fos FBJ murine osteosarcoma viral oncogene homolog 0.011632 
ANK2 Ankyrin, Brank-2 protein 0.012044 
ITGA2 Integrin α-2 subunit 0.012752 
POU3F4 Brain 4 mRNA 0.013459 
CCL21 Chemokine (C–C motif) ligand 21 0.013744 
ATF6B G13 protein 0.014167 
PGF 
Placental growth factor, vascular endothelial growth factor-related 
protein 
0.014799 
DNAJB4 Heat shock protein hsp40 homolog 0.014874 
KLK1 Kallikrein 0.015581 
C11orf9 Chromosome 11 open reading frame 9 0.015854 
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Appendix 24: Downregulated genes in the eutopic endometrium from women with compared 
to women without endometriosis. 
 
Entrez ID Gene name P value 
OGN Osteoglycin 0.00045 
APC2 APCL protein 0.000709 
HSPBP1 Hsp70 binding protein HspBP1 0.001419 
LGTN Ligatin 0.002117 
NPHP1 Nephrocystin 0.002128 
LAT 36-kDa Phosphothyrosine protein 0.002837 
KIT V-kit Hardy–Zuckerman 4 feline sarcoma viral oncogene homolog 0.003175 
IFP35 Interferon-induced leucine zipper protein 0.003546 
CALR Calreticulin 0.004233 
IER3 IEX-1: radiation-inducible immediate-early gene 0.004255 
ICAM2 Cell adhesion ligand for LFA-1 0.004963 
SNUPN Snurportin 1 0.005291 
SOD2 Manganese superoxide dismutase 0.005672 
PDCD4 Programmed cell death 4 (neoplastic transformation inhibitor) 0.006348 
WASP Wiskott-Aldrich syndrome protein 0.00638 
IL15 IL-15 precursor 0.007089 
AP2 Cytoplasmic antiproteinase 2 0.007406 
GABBR2 GABA-B receptor mRNA 0.007797 
ALDH7A1 Aldehyde dehydrogenase 7 family, member A1 0.008463 
PP14 Human placental protein 14 0.008505 
 
FBLN2 Fibulin-2 0.009213 
DMD Dystrophin (muscular dystrophy, Duchenne and Becker types) 0.009519 
VCAN Chondroitin sulphate proteoglycan versican, V1 splice-variant 0.009921 
EPHX2 Epoxide hydrolase 2, cytoplasmic 0.010576 
PLA2G16 HREV107-like protein 0.010629 
PNP Purine nucleoside phosphorylase 0.011337 
LOC388796 Small nucleolar RNA, H/ACA box 71C 0.011632 
DHRS3 Retinal short-chain dehydrogenase/reductase retSDR1 mRNA 0.012044 
PFN2 Profilin 2 0.012688 
CLDN10 Claudin-10 0.012752 
PIM1 pim-1 Oncogene 0.013459 
GPSM2 G-protein signaling modulator 2 (AGS3-like, C. elegans) 0.013744 
G0S2 G0S2 protein 0.014167 
RAD17 Rad17-like protein 0.014874 
PAEP Pregnancy-associated endometrial α2-globulin 0.015581 
FGF13 Fibroblast growth factor 13 0.015854 
MITF A-type microphthalmia associated transcription factor 0.016288 
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Appendix 25: Top 20 up- and down-regulated pathways in endometriosis. 
 
Pathway ID Pathway name P value 
Eutopic endometrium from women with and without endometriosis  
GO:0042221 Response to chemical  6.8X10
-6
 
GO:0010033 Response to organic substance  9.9X10
-6
 
GO:0050896 Response to stimulus  1.2X10
-5
 
GO:0009605 Response to external stimulus  1.2X10
-5
 
GO:0048856 Anatomical structure development  3.8X10
-5
 
GO:0051716 Cellular response to stimulus  5.7X10
-5
 
GO:0044767 Single-organism developmental process  5.8X10
-5
 
GO:0032502 Developmental process  7.1X10
-5
 
GO:0009612 Response to mechanical stimulus  7.4X10
-5
 
GO:0044763 Single-organism cellular process  8.6X10
-5
 
GO:0007275 Multicellular organismal development  1.6X10
-4
 
GO:0048869 Cellular developmental process  1.8X10
-4
 
GO:0014070 Response to organic cyclic compound  2.7X10
-4
 
GO:0007165 Signal transduction  3.7X10
-4
 
GO:0044700 Single organism signaling  3.9X10
-4
 
GO:0023052 Signaling  3.9X10
-4
 
GO:0044707 Single-multicellular organism process  3.9X10
-4
 
GO:0008150 Biological process  4.610
-4
 
GO:0030154 Cell differentiation  4.7X10
-4
 
Endometriotic lesions vs. Eutopic endometrium from women with endometriosis 
GO:0008584 Male gonad development  4.1X10
-8
 
GO:0046546 Development of primary male sexual characteristics  4.1X10
-8
 
GO:0046661 Male sex differentiation  1.7X10
-7
 
GO:0008406 Gonad development  1.1X10
-6
 
GO:0045137 Development of primary sexual characteristics  1.2X10
-6
 
GO:0007548 Sex differentiation  6.5X10
-6
 
GO:0048608 Reproductive structure development  1.6X10
-4
 
GO:0061458 Reproductive system development  1.7X10
-4
 
GO:0060008 Sertoli cell differentiation  2.8X10
-4
 
GO:0007530 Sex determination  4.3X10
-4
 
GO:0030325 Adrenal gland development  6.3X10
-4
 
GO:0048856 Anatomical structure development  9.7X10
-4
 
GO:0030154 Cell differentiation  1.2X10
-3
 
GO:0044707 Single-multicellular organism process  1.2X10
-3
 
GO:0044767 Single-organism developmental process  1.2X10
-3
 
GO:0032502 Developmental process  1.4X10
-3
 
GO:0003006 Developmental process involved in reproduction  1.7X10
-3
 
GO:0048869 Cellular developmental process  1.9X10
-3
 
GO:0032501 Multicellular organismal process  2.1X10
-3
 
GO:0048731 System development  3.3X10
-3
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Appendix 26: Upregulated genes in the endometriotic lesions compared to eutopic 
endometrium from women with endometriosis. 
 
Entrez ID Gene name P value 
C7 Complement factor 7 5.1X10
-9
 
CLDN11 Claudin 11 2.4X10
-8
 
VIT Vitirin 4.5X10
-8
 
MYH11 Myosin heavy chain 11, smooth muscle 5.5X10
-8
 
PNOC Prepronociceptin 3.1X10
-6
 
RARRES1 Retinoic acid receptor responder 1 4.5X10
-6
 
DLK1 Delta-like 1 homolog (Drosophila) 6.5X10
-6
 
PLA2G2A Phospholipase A2, group IIA (platelets, synovial fluid) 1.1X10
-5
 
IGKC Immunoglobulin κ constant 1.6X10-5 
KLHDC8A Kelch domain containing 8A 2X10
-5
 
GATA4 GATA binding protein 4 2.3X10
-5
 
SCN7A Sodium channel, voltage-gated, type VII, alpha subunit 2.7X10
-5
 
TCF21 Transcription factor 21 3.1X10
-5
 
SPRR2A Small proline-rich protein 2A 5.6X10
-5
 
GSTA1 Glutathione S-transferase A1 5.8X10
-5
 
WISP2 WNT1 inducible signaling pathway protein 2 6.1X10
-5
 
PLA2G5 Phospholipase A2, group V 6.8X10
-5
 
HSD11B1 Hydroxysteroid (11-beta) dehydrogenase 1 8.7X10
-5
 
IGJ Immunoglobulin J polypeptide, linker for alpha and mu 9.2X10
-5
 
HOXC9 Homeobox C9 (HOXC9) 0.000301 
SYNPO2 Synaptopodin 2 0.000514 
LTBP2 Latent transforming growth factor beta binding protein 2 0.000676 
CYP17A1 Cytochrome P450, family 17, subfamily A, polypeptide 1 0.001029 
CPVL Carboxypeptidase, vitellogenic-like 0.001065 
SFRP2 Secreted frizzled-related protein 2 0.001803 
INSL3 Insulin-like 3 (Leydig cell) 0.002057 
SMR3B Submaxillary gland androgen regulated protein 3B 0.002199 
MGC27165 Hypothetical protein MGC27165 0.00245 
FABP4 Fatty acid-binding protein 4 0.002704 
ITLN1 Intelectin 1 (galactofuranose binding) 0.002989 
FLJ38894 FLJ38894 0.003086 
TAGLN Transgelin 0.003674 
NELL1 NEL-like 1 (chicken) 0.004397 
THBS1 Thrombospondin 1 0.004506 
NR0B1 Nuclear receptor subfamily 0, group B, member 1 0.005978 
NR5A1 Nuclear receptor subfamily 5, group A, member 1 0.00617 
HP Haptoglobin 0.006307 
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Appendix 27: Downregulated genes in the endometriotic lesions compared to eutopic 
endometrium from women with endometriosis. 
 
Entrez ID Gene name P value 
MMP26 Matrix metalloproteinase 26 2.8X10
-7
 
C9orf152 Chromosome 9 open reading frame 152 7.8X10
-6
 
SCGB2A1 Secretoglobin, family 2A, member 1 1.1X10
-5
 
FOXA2 Forkhead box A2 1.3X10
-5
 
DLX6 Distal-less homeobox 6 3.6X10
-5
 
KIAA1324 KIAA1324 5.8X10
-5
 
SCGB1D4 Secretoglobin, family 1D, member 4 6.2X10
-5
 
SCGB1D2 Secretoglobin, family 1D, member 2 6.6X10
-5
 
CKS2 CDC28 protein kinase regulatory subunit 2 0.000197 
FEN1 Flap structure-specific endonuclease 1 0.000446 
TYMS Thymidylate synthetase 0.000494 
CCNB1 Cyclin B1 0.000847 
MCCC2 Methylcrotonoyl-coenzyme A carboxylase 2 (beta) 0.000901 
MSX1 Msh homeobox homolog 1 0.000926 
TOP2A Topoisomerase (DNA) II alpha 0.001124 
ASPM Asp (abnormal spindle)-like, microcephaly associated (Drosophila) 0.001225 
CDC2 Cell division cycle 2, G1 to S and G2 to M 0.00149 
MSX2 Msh homeobox homolog 2 0.001559 
SPDEF SAM pointed domain containing ets transcription factor 0.001577 
ENPP3 Ectonucleotide pyrophosphatase/phosphodiesterase 3 0.001665 
UGT8 UDP glycosyltransferase 8 0.001757 
CRB3 Crumbs homolog 3 (CRB3) 0.001803 
CLDN3 Claudin 3 0.001869 
PRSS8 Protease, serine, 8 (prostasin) 0.001927 
IHH Indian hedgehog homolog 0.001946 
GABRP Gamma-aminobutyric acid (GABA) A receptor, pi 0.001966 
TRH Thyrotropin releasing hormone 0.001985 
PKHD1L1 Polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 0.002057 
EHF ets homologous factor 0.002065 
AIPL1 Aryl hydrocarbon receptor interacting protein-like 1 0.002199 
GJD3 Gap junction protein, chi 1(connexin 31.9) 0.002704 
RBM35A RNA binding motif protein 35A 0.003086 
PCDH19 Protocadherin 19 0.003605 
DLG7 Discs, large homolog 7 (Drosophila) 0.003674 
FLJ21511 FLJ21511 0.004114 
RPL12L2 Ribosomal protein L12 pseudogene 11 0.004397 
TPD52 Tumor protein D52 0.004506 
HSD17B2 Hydroxysteroid (17-beta) dehydrogenase 2 0.005142 
ELMO3 Engulfment and cell motility 3 (ced-12 homolog) 0.005407 
SCGB1D1 Secretoglobin, family 1D, member 1 0.005978 
KIAA0101 KIAA0101 0.006123 
SH3YL1 SH3 domain containing, Ysc84-like 1 0.006307 
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